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ABSTRACT
Patrick Roberts: Targeting Ras and Rho Family GTPases for the Treatment of Cancer
Through Inhibition of CAAX-Signaled Modifications and the ERK MAPK Pathway.
(Under the direction of Dr. Channing Der)
Ras and Rho family GTPases share many structural and biochemical similarities
while regulating distinct cellular functions.  One such similarity is the carboxyl-terminal
CAAX motif (C = cysteine, A = aliphatic amino acid, and X = terminal amino acid), which
signals a series of post-translational modifications important for proper subcellular
localization. These modifications are catalyzed by prenyltransferase enzymes,
farnesyltransferase (FTase) or geranylgeranyltransferase I (GGTase-I), and subsequently by
the endoprotease Ras converting enzyme 1 (Rce1) and by isoprenylcysteine-O-carboxyl
methyltransferase (Icmt).  Fully processed proteins are thus prenylated, clipped and
methylated.  Prenylation is known to be absolutely required for correct subcellular
localization and biological function of small GTPases.  The importance of the post-prenyl
processing steps has not been as well validated.
The overwhelming evidence that aberrant Ras signaling is critical in oncogenesis, and
emerging data supporting similar importance for Rho, has resulted in intense efforts to
develop inhibitors of these proteins.  Two main approaches are currently underway.  The first
approach exploits the requirement for CAAX processing, resulting in the development of
FTase and GGTase inhibitors now in the clinic.  The second approach is to block
iii
downstream effector pathways, such as the MAPK pathways.  We evaluated these two
approaches in Ras-mutant non-small cell lung cancer (NSCLC).
Efforts to develop anti-Ras therapies have revealed great complexity in Ras effector
utilization, and some therapies (FTase inhibitors, FTIs) have been met with unexpected
resistance.  Therefore, we examined the requirement for downstream ERK MAPK signaling
in Ras-mutant NSCLC and determined that this pathway is critical for Ras-mutant NSCLC.
In addition, using genetic and pharmacologic approaches we validated that Icmt methylation
is also required, further supporting it as a novel target for drug development.  While FTIs do
not block Ras, they have shown some success in clinical trials, yet their mechanism is
unknown.  We have identified several Rho proteins as potential targets of FTase inhibition,
which should aid in the future development of these compounds.  Finally, we show here that
Rho family localization is also exquisitely dependent on Rce1 and Icmt, indicating that Rce1
and Icmt are promising targets to block aberrant Rho signaling in cancer.
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And if you feel that you can't go on.
And your will's sinkin' low.
Just believe and you can't go wrong.
In the light you will find the road.
Led Zeppelin
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Chapter 1
 Introduction:  Targeting Ras family signaling for cancer treatment
2Overview of thesis – Mutational activation of the Ras oncogenes is found in 30%
of all human cancers.  Hyperactivation of Ras by aberrant upstream signaling by receptor
tyrosine kinases (RTKs) is also commonly seen in human cancers.  In particular,
overexpression or mutational activation of the epidermal growth factor receptor (EGFR)
is associated with many cancers.  Aberrant Ras and EGFR signaling is associated with a
high percentage of non-small cell line cancers (NSCLCs).  Because of my strong interest
in lung cancer therapeutics, I have chosen to focus my research on the identification and
validation of approaches to develop anti-Ras inhibitors for lung cancer treatment.
Currently, two major directions considered for the development of anti-Ras drugs.  First,
Ras activation of cytoplasmic signaling networks is critical for Ras-mediated
oncogenesis.  Therefore, inhibitors of Ras signaling have been considered, with much of
the current focus on the Raf-MEK-ERK mitogen-activated protein kinase (MAPK)
cascade.  Second, inhibitors of the enzymes that catalyze Ras posttranslational
modifications that promote Ras association with the plasma membrane have also been
pursued.  My research studies have concentrated on inhibitors of the ERK MAPK
cascade and on validating specific enzymes involved in CAAX-signaled posttranslational
modification of Ras and Ras family proteins.  In this introduction, I summarize the state-
of-the art in current efforts to target these two aspects of Ras function.
A. The Raf-MEK-ERK mitogen-activated protein kinase cascade.
In 2005 the American Cancer Society reported that cancer has surpassed heart
disease as the leading cause of death in the United States in people under the age of 85
(Jemal et al., 2005). Non-small cell lung cancer (NSCLC) is a particularly troublesome
3disease, with few successful treatment options.  While we have made great strides in
unraveling the mysteries of cancer genetics and biology, the important task now facing
researchers and clinicians is to translate these discoveries into novel therapeutics that will
improve patient outcomes. Since many of the genetic alterations found in cancers involve
genes whose products are regulators of signal transduction (Hanahan and Weinberg,
2000), much of the focus in the development of novel therapeutics has involved inhibitors
of signal transduction molecules, in particular protein kinases (Arslan et al., 2006; Davies
et al., 2006; Sebolt-Leopold and English, 2006). The human kinome is comprised of over
518 protein kinases (http://kinase.com), with disease associations reported for over 150
kinases (http://www.cellsignal.com/reference/kinase_disease.asp). Presently, the Food
and Drug Administration (FDA) has approved 10 protein kinase inhibitors and over 100
kinase-targeted agents are currently undergoing clinical evaluation.
Target-based therapies are widely considered to be the future of cancer treatment
and much attention has been focused on developing inhibitors of the Raf-MEK-ERK
mitogen-activated protein kinase (MAPK) signaling pathway and its upstream activators
(Sebolt-Leopold and Herrera, 2004). Evidence that ERK MAPK signaling promotes cell
proliferation, cell survival, and metastasis, along with the overwhelming frequency in
which this pathway is aberrantly activated in cancer, in particular by upstream activation
by the epidermal growth factor receptor (EGFR) and the Ras small GTPases (Figure 1),
support current efforts to identify approaches to inhibit this pathway.
Mammalian cells possess four well-characterized and widely studied mitogen-
activated protein kinase cascades (MAPKs) (Figure 2). These cascades are comprised of
three protein kinases that act as a signaling relay controlled, in part, by protein
4phosphorylation: a MAPK kinase kinase (MAPKKK), a MAPK kinase (MAPKK), and a
MAPK (Johnson and Lapadat, 2002). The terminal serine/threonine kinases (MAPKs) are
the extracellular signal-regulated kinases (ERK1/2), the c-Jun amino terminal kinases
(JNK12/3; also called SAPKs), p38 kinases (p38α/β/γ/δ) and ERK5. Generally, the ERK
pathway is activated by growth factor-stimulated cell surface receptors, whereas the JNK,
p38 and ERK5 pathways are activated by stress and growth factors.
MAPK cascades function downstream of cell surface receptors and other
cytoplasmic signaling proteins whose functions are deregulated in cancer and other
human pathologic disorders. In light of the recent success in the clinical development of
small molecule inhibitors of protein kinases, components of MAPK cascades have been
the subject of intense research and drug discovery efforts. Of these, the p44 ERK1 and
p42 ERK2 MAPKs have attracted intense research interest because of their critical
involvement in the regulation of cell proliferation and survival. In particular, the
mutational activation and/or overexpression of upstream signaling components that
activate the ERK MAPKs (Figure 1), together with the substantial body of experimental
observations demonstrating the necessity of this pathway in oncogene function, has
“validated” this pathway for drug discovery (Benson et al., 2006). This has stimulated
intensive efforts by the research community and pharmaceutical industry to develop
inhibitors of ERK signaling for cancer treatment. The validated involvement of the
related JNK and p38 MAPK signaling cascades in cancer is less clearly established, and
consequently, the status of inhibitor development for these MAPK cascades will be
discussed only briefly.  However, it should be noted that members of the Rho family,
which are candidate anticancer targets described below, have been shown utilize these
5Figure 1.  Oncogene activation of the ERK MAPK cascade. Mutationally activated B-
Raf, Ras and mutationally activated [by missense mutations in the cytoplasmic kinase
domain in NSCLC or by extracellular domain truncations (e.g., VIII) in glioblastomas]
and/or overexpressed EGFR cause persistent activation of the ERK MAPK cascade in
human cancers. Activated ERKs translocate to the nucleus, where they phosphorylate and
regulate various transcription factors leading to changes in gene expression.  In particular,
ERK-mediated transcription can result in the up-regulation of EGFR ligands, such as
TGFα , thus creating an autocrine feedback loop that is critical for Ras-mediated
transformation and Raf-mediated gene expression changes.
6Figure 2.  Mammalian MAPK cascades. There are four major mammalian MAPKKK-
MAPKK-MAPK protein kinase cascades. Whereas the ERK pathway is commonly
activated by growth factors, the JNK, p38 and ERK5 pathways are activated by
environmental stress, including osmotic shock, ionizing radiation. Many of the substrates
for MAPKs are nuclear transcription factors.  Interactions and substrates were compiled
from information from STKE (http://stke.sciencemag.org/index.dtl).
7pathways to mediate oncogenesis, thus providing additional support for the development
of inhibitors of these pathways as novel anticancer agents.
Quite an extensive array of potent and specific inhibitors of p38 are being
evaluated in phase I and II clinical trials (Dominguez et al., 2005; Hynes and Leftheri,
2005; O'Neill, 2006) (Table 1). They have been developed primarily for the treatment of
chronic inflammatory diseases (e.g., rheumatoid arthritis, Crohn’s disease), although
some trials are also evaluating possible applications in cancer. One consequence of p38
inhibitors is blockage of p38-induced transcriptional expression of genes that encode pro-
inflammatory cytokines.  While Ras has been shown to cause activation of p38, for
example by activation of the Rac and Cdc42 Rho family GTPases, whether p38 inhibitors
will be useful for blocking Ras-mediated oncogenesis is uncertain.  For example, our
laboratory showed previously that inhibition of p38 enhanced, rather than blocked, Ras
transformation (Pruitt et al., 2002).  Therefore, p38 inhibitors are not currently considered
for anti-Ras therapy
In contrast to p38 inhibitors, only a handful of JNK inhibitors have been
developed, and are being considered for the treatment of cancer, as well as inflammatory,
vascular, neurodegenerative and metabolic disorders (Manning and Davis, 2003). Unlike
the considerable volume of preclinical studies that utilized highly specific inhibitors of
MEK1/2 (PD98059, U0126 and CI-1040/PD184352) or p38 (SB203580 and SB 202190)
(Davies et al., 2000), the preclinical observations made with the SP600125 JNK inhibitor
are likely to be less informative regarding the biological roles of JNK, due to the
considerable off-target activity of this compound (Bain et al., 2003). One JNK inhibitor,
CC-401, is currently in phase II evaluation in acute myelogenous leukemia, and has also
8been considered for the treatment of respiratory diseases (Table 1).   Currently, there is
limited evidence for a therapeutic value in blocking JNK to block Ras-mediated
oncogenesis.  Like p38, JNK has been shown to be activated by Ras and there is evidence
that JNK activation is necessary for Ras transformation (Westwick et al., 1994).
However, the critical role of JNK activation in Ras-mediated growth transformation is
unresolved, and consequently, the validation of JNK as an important target for anti-Ras
development remains to be done.
The MAPKKK component of the ERK cascade is comprised of the Raf
serine/threonine kinases (c-Raf-1, A-Raf and B-Raf) (Schreck and Rapp, 2006;
Wellbrock et al., 2004). Raf kinases phosphorylate and activate the MEK1 and MEK2
dual specificity protein kinases. Although Raf has been reported to phosphorylate other
proteins, to date, the only validated physiologically relevant substrates remain the two
closely related MEK1 and MEK2 proteins. MEK1/2 (MAPKK) then phosphorylates and
activates the ERK1 and ERK2 MAPKs. Activated ERKs phosphorylate and regulate the
activities of an ever-growing roster of substrates that are estimated to comprise over 160
proteins (Yoon and Seger, 2006). The majority of ERK substrates are nuclear proteins,
but others are found in the cytoplasm and other organelles. Activated ERKs can
translocate to the nucleus, where they phosphorylate and regulate various transcription
factors, such as Ets family transcription factors (e.g., Elk-1), ultimately leading to
changes in gene expression (Schulze et al., 2004; Zuber et al., 2000).
There is substantial evidence validating the importance of Raf and MEK in cancer
progression and in promoting cancer growth (Shields et al., 2000). The importance of this
pathway in oncogenesis was first suggested by the initial identification of Raf kinases as
9potent retrovirus oncogenes (Schreck and Rapp, 2006). Subsequently, laboratory-
generated constitutively activated mutants of Raf and MEK were shown to potently
transform rodent fibroblasts and other cell types. Furthermore, studies using genetic or
pharmacologic approaches have shown that MEK and ERK are required for the
transforming activities of Ras and other oncogenes. More recently, mutationally activated
B-Raf has been identified in a variety of human cancers (Davies et al., 2002) and the
finding that mutationally activated Ras and Raf occur in a non-overlapping occurrence in
melanomas, colorectal carcinomas (CRC), papillary thyroid carcinomas, serous ovarian
carcinomas, and lung cancers suggests that Ras function is facilitated primarily by
activation of Raf (Mercer and Pritchard, 2003; Rajagopalan et al., 2002; Sieben et al.,
2004; Singer et al., 2003; Vos et al., 2003). Interfering RNA suppression of mutant B-
Raf demonstrated the importance of continued B-Raf activity for the transformed and
tumorigenic growth of melanomas (Hingorani et al., 2003; Hoeflich et al., 2006; Sharma
et al., 2005; Sumimoto et al., 2006).
Recently, germline de novo mutational activation of H-Ras, K-Ras, B-Raf, as well
as MEK1 and MEK2, has been found in patients whose diseases comprise a group of
related developmental disorders (Costello, cardio-facio-cutaneous and Noonan
syndromes) (Table 2), suggesting that aberrant ERK activation contributes to other
human disorders as well as cancer (Aoki et al., 2005; Niihori et al., 2006; Rodriguez-
Viciana et al., 2006; Schubbert et al., 2006). These syndromes are associated with similar
consequences that include facial dysmorphia and cardiomyopathy, as well as increased
incidence of cancer (Duesbery and Vande Woude, 2006). Interestingly, the mutational
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spectrum seen in these syndromes differs from those seen in cancer, and generally leads
to weakly activated proteins. This reflects the likelihood that the more potent activating
mutations found in cancer cannot be tolerated during development. Taken together, these
observations provided strong support for the therapeutic value of blocking ERK signaling
in cancer and developmental disorders.
Although the Raf-MEK-ERK cascade is typically drawn as a simple linear,
unidirectional cascade of protein kinases, the more appropriate depiction of this cascade
is that it is a key core element of a complex signaling network, with many other
interactions (Figure 3) (Kolch, 2005). This complexity is best represented at the level of
Raf, where multiple signals converge to regulate Raf activation. As described below, the
Ras small GTPases are major activators of Raf kinases. However, Raf activation is
complex, with Ras facilitating the plasma membrane association of normally cytosolic
Raf, where additional signaling activities, including phosphorylation (e.g., by PAK
serine/threonine and Src family tyrosine kinases) and dephosphorylation (by protein
phosphatase 2A) events are required to fully activate the kinase function. Raf function is
also regulated by interaction with other proteins, including 14-3-3 proteins and heat
shock protein 90 (Hsp90). Hence, inhibitors of Raf and MEK are not likely to cause
similar consequences or to show equivalent clinical responses. These regulatory events
also suggest other approaches for antagonizing Raf-MEK-ERK signaling.
Another layer of regulation of the Raf-MEK-ERK cascade involves scaffolding
proteins, which help to regulate the activity, specificity and spatial regulation of
MEK/ERK signaling in mammalian cells.  These include KSR (kinase suppressor of
Ras1), MP1 (MEK partner-1), β-arrestins, IQGAP1 and others (Kolch, 2005). Of these,
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Figure 3.  The Raf-MEK-ERK cascade is a core signaling componenet of a complex
signaling network.  The ERK MAPK cascade is regulated by a complex array of
functionally diverse proteins.  In particular, Raf function is regulated by both positive and
negative signal inputs.  In particular, scaffold proteins (e.g., KSR, Sef, MP1 and
IQGAP1) bind to distinct subsets of components of this cascade to create unique ERK
MAPK signaling complexes at specific and distinct subcellular locations that result in
preferential utilization of only some of the many possible ERK substrates.  This
arrangement channels the unique input signals that activate the pathway into the specific
output signaling in distinct spatio-temporal patterns.  ERKs then phosphorylate multiple
targets, including nuclear, cytosolic, membrane-associated and cytoskeletal substrates.
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KSR has been one of the best studied, and KSR function has been shown to be critical for
Ras activation of Raf. Mouse embryo fibroblasts deficient in KSR1 function showed
impaired sensitivity to Ras transformation (Kortum and Lewis, 2004). Furthermore, anti-
sense suppression of KSR1 expression was found to impair the growth of Ras mutation
positive human tumor cells, supporting KSR as a possible therapeutic target for blocking
Ras  (Xing et al., 2003).
B. Ras family small GTPases are key upstream activators of Raf
Ras proteins (H-, K- and N-Ras) function as a GDP/GTP-regulated switch.
GDP/GTP cycling is regulated by guanine nucleotide exchange factors (RasGEFs; e.g.,
Sos) that promote formation of active Ras-GTP, whereas GTPase activating proteins
(GAPs; e.g., NF1 neurofibromin) stimulate GTP hydrolysis and formation of inactive
Ras-GDP (Mitin et al., 2005). In normal quiescent cells, Ras is GDP-bound and inactive.
Extracellular stimuli (e.g., EGF) cause transient formation of the active, GTP-bound form
of Ras. Activated Ras-GTP binds to a spectrum of downstream effector targets, of which
the Raf kinases are the best characterized. Ras is mutationally activated in 30% of all
cancers, with pancreas (90%), colon (50%), thyroid (50%), lung (30%) and melanoma
(25%) having the highest prevalence (Malumbres and Barbacid, 2003). The mutant ras
genes in human cancers encode mutated proteins that harbor single amino acid
substitutions primarily at residues G12 or Q61. Mutant Ras proteins are GAP-insensitive,
rendering the proteins constitutively GTP-bound and activated, leading to stimulus-
independent, persistent activation of downstream effectors, in particular, of the Raf-
MEK-ERK cascade (Figure 1).
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Although there is considerable experimental evidence that the Raf-MEK-ERK
cascade is a critical mediator of Ras-induced oncogenesis, recent studies have also clearly
demonstrated that Ras utilizes additional effectors to promote tumorigenesis (Repasky et
al., 2004) (Figure 4). Currently, at least four other effector classes have demonstrated
roles in Ras transformation: the p110 catalytic subunits (p110α, β, γ and δ) of class I
phosphatidylinositol 3-kinases (PI3K), the Tiam1 Rac small GTPase-specific GEF, the
Ral small GTPase-specific GEFs (RalGDS, Rgl, Rgl2 and Rgl3), and phospholipase C
epsilon. The evidence for their involvement and roles in Ras-mediated oncogenesis has
been summarized in recent reviews (Repasky et al., 2004; Shaw and Cantley, 2006). The
existence of non-Raf mechanisms of Ras-mediated oncogenesis prompts the question of
whether blocking the Raf-MEK-ERK pathway alone will be sufficient to effectively
block oncogenic Ras function, or will concurrent inhibition of multiple effector pathways
be required?  Alternatively, since this protein kinase pathway is central to many signaling
networks beyond Ras, will blocking the Raf-MEK-ERK pathway be too deleterious and
result in significant normal cell toxicity?  Instead, will blocking a subset of downstream
functions of the ERK pathway be a more effective approach? My studies in Chapter 4
have focused on defining the importance of the Raf-MEK-ERK pathway in NSCLC, a
disease in which Ras mutations are frequent events.
C. The epidermal growth factor receptor (EGFR): upstream activation of Ras
and the ERK cascade and a component of a Ras-mediated autocrine growth loop.
In addition to activating mutations of the Ras oncogene, the ERK MAPK
signaling pathway can also be activated by perturbation of components upstream of Ras.
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Figure 4. Ras stimulates diverse cytoplasmic signaling networks. Ras-GTP binds
preferentially to more than 20 classes of effector proteins. Those with
demonstrated roles in Ras-mediated oncogenesis are indicated.
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For example, aberrant overexpression or mutational activation of receptor tyrosine
kinases (RTKs; e.g., EGFR and HER2) can cause hyperactivation of Ras leading to
upregulated MAPK signaling (Hynes and Lane, 2005; Lynch et al., 2004; Stephens et al.,
2004). In particular, the EGFR is overexpressed or mutationally activated in many human
cancers (Grandis and Sok, 2004). The regularity with which this signaling cascade is
activated suggests that it may be critical in oncogenesis and makes it an appealing
pathway for drug development. Another linkage between Ras and the EGFR receptor is
mediated by the upregulation of expression of EGFR ligands by Ras signaling (Figure 1).
One important gene target of Ras activation involves transcriptional activation of the
gene for transforming growth factor alpha (TGFα), a ligand for the EGFR. Increased
TGFα gene expression and secretion of TGFα in turn causes persistent stimulation of the
EGFR. The upregulated expression and secretion of TGFα and other EGFR ligands (e.g.,
heparin-binding EGF (HB-EGF), amphiregulin) has been observed in a wide variety of
Ras- or Raf-transformed cell types (Gangarosa et al., 1997; McCarthy et al., 1995;
Schulze et al., 2001). The importance of this autocrine signaling loop for Ras
transformation has been demonstrated by the ability of inhibitors of EGFR to block
oncogenic Ras transformation. Additionally, the majority of Raf-induced changes in gene
expression were found to be dependent on EGFR function (Schulze et al., 2004). Hence,
EGFR can function both upstream, as well as downstream, of Ras and the ERK MAPK
cascade.  In addition to activating Ras, EGFR utilizes Rho signaling pathways through its
binding and activation of RhoGEFs, such as Vav2 (Pandey et al., 2000; Schiller, 2006).
D. Inhibitors of the Raf-MEK-ERK cascade
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Currently, inhibitors of the kinase function of Raf and MEK represent the most
studied and advanced approaches for blocking ERK signaling, with several inhibitors
under evaluation in clinical trials and additional inhibitors in preclinical analyses (Table
1). To date, no inhibitors of ERK1 or ERK2 have been described.
Raf inhibitors
The three Raf kinases exhibit the same substrate specificity, with MEK1 and
MEK2 the only known substrates. However, these highly related isoforms do exhibit
differences in regulation and biological function (Schreck and Rapp, 2006; Wellbrock et
al., 2004). Furthermore, functions independent of MEK activation have been described
although these activities remain poorly characterized. Several structurally distinct classes
of compounds have been developed as potential Raf kinase inhibitors (Smith et al.,
2006)). In addition to small molecule inhibitors of Raf kinase, other anti-Raf efforts
include the development of antisense inhibitors of Raf expression, particularly ISIS-5132,
a 20-base phosphorothioate DNA oligonucleotide that inhibits c-Raf-1 protein
expression. ISIS-5132 showed anti-tumor activity in preclinical xenograft models and
early clinical trials (Cripps et al., 2002; Monia et al., 1996; Oza et al., 2003; Tolcher et
al., 2002). However, no patient response or anti-tumor efficacy was seen in phase II
clinical trials (Cripps et al., 2002; Oza et al., 2003; Tolcher et al., 2002)  and it has been
withdrawn from further clinical evaluation. A related approach, using liposome-
encapsulated antisense c-raf-1 oligonucleotide (Gokhale et al., 2002), showed anti-tumor
activity in xenograft analyses (Mewani et al., 2004). Liposome entrapment serves to
protect the oligonucleotide from degradation and to improve delivery. LErafAON has
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completed initial Phase I clinical trials where it was evaluated as monotherapy and in
combination with radiation or chemotherapy (Dritschilo et al., 2006; Rudin et al., 2004).
Further clinical development of LErafAON is ongoing.
Small molecule inhibitors of Ras-Raf interaction (MCP1 and derivatives) have
been described and shown to have anti-tumor activity in cell culture studies (Kato-
Stankiewicz et al., 2002). MCP1 was identified as an inhibitor of Ras interaction with
Raf in a yeast two-hybrid based screen. The exact mechanism by which MCP1 functions
is currently unclear and this information will be important for further clinical
development of this novel class of Raf inhibitors. Currently, preclinical evaluation of
MCP continues in human tumor xenograft mouse models in combination with other
chemotherapeutic agents (Skobeleva, 2007).
Hsp90 functions as a chaperone that is required for the stability and function of
Raf and other oncogene proteins, including HER2 and the Met RTK, as well as steroid
hormone receptors that include the androgen and estrogen receptors (Neckers, 2006). The
anti-tumor activity of the antibiotic benzoquinone ansamycin geldanamycin is due to
binding to and promoting Hsp90 degradation, and hence, indirectly inhibiting the
function of Raf and other client proteins by promoting their proteosomal degradation.
Interestingly, a recent study found that Hsp90 is required for wild type c-Raf-1 and A-
Raf, but not B-Raf, stability (Grbovic et al., 2006). However, mutant B-Raf showed
dependency on Hsp90 for function. Treatment of melanoma cells with the geldanamycin
analog 17-allylamino-17-demethoxygeldanamycin (17-AAG) caused degradation of
mutant B-Raf and inhibition of ERK, and showed anti-tumor activity. Another study also
found preferential sensitivity of mutant B-Raf to 17-AAG treatment (da Rocha Dias et
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al., 2005).  17-AAG is currently in phase II clinical trials (Sharp and Workman, 2006).
Although 17-AAG has shown promising activities in preclinical and clinical trials, the
further clinical development may be limited by problems with solubility, stability, and
hepatotoxicity. Hsp90 inhibitors are relatively unique anti-tumor agents in that they
simultaneously inhibit multiple, functionally diverse, signaling components that promote
oncogenesis. Hence, the precise biomarker for defining and monitoring anti-tumor
response may be complicated.
To date, the most successful anti-Raf inhibitor has been sorafenib (tosylate salt of
BAY 43-9006; Nexavar®), an orally available compound that received FDA approval in
2005 for the use in advanced renal cell carcinoma (RCC). Sorafenib is a bi-aryl urea
compound (Smith et al., 2006) that was originally developed as an inhibitor of Raf-1
(Lyons et al., 2001). Subsequent analysis revealed that sorafenib was a potent inhibitor of
both wild type and mutant (e.g., V600E, the most frequent mutation found in human
cancers) B-Raf kinases in vitro. Crystallographic analyses of sorafenib complexed with
the kinase domain of B-Raf showed that the inhibitor bound to the ATP-binding pocket
and prevented kinase activation, thus preventing substrate binding and phosphorylation
(Wan et al., 2004).
Shortly after clinical analyses begin, it was revealed that sorafenib also showed
very potent activity for other protein kinases in vitro and in vivo, in particular, for the pro-
angiogenic RTKs such as VEGFR-2, VEGFR-3, PDGFR-β, Flt-3, c-Kit and FGFR-1
(Wilhelm et al., 2004). While sorafenib demonstrated multi-kinase inhibition, it was also
found to maintain some specificity, as it did not inhibit other protein kinases such as
MEK1, ERK1, EGFR, HER2 and others.
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In cell culture and mouse models representing a wide range of tumor cell types,
sorafenib exhibited broad anti-tumor activity and was associated with reduced MEK and
ERK activation, supporting the possibility that its anti-tumor activity involves, in part,
inhibition of Raf (Wilhelm et al., 2004). However, despite its association with reduced
ERK activation, sorafenib anti-tumor activity must also be a consequence of its ability to
inhibit angiogenesis-related kinases as well as other non-Raf kinases. This possibility is
supported by the potent anti-tumor activity that was independent of Ras or B-Raf
mutation status that was seen with sorafenib in xenograft studies.
Phase I clinical trials established sorafenib as a safe and well-tolerated oral agent
with skin rash and diarrhea as the most common adverse effects (Awada et al., 2005)
(Moore et al., 2005a). Results from phase I clinical trials suggested clinical activity in
several patients with RCC, resulting in subsequent clinical trials focused on RCC.
Ultimately this effort led to a large phase III clinical trial that enrolled more than 900
patients with advanced RCC who previously failed prior systemic therapy. The primary
endpoint of this study was improved survival. This trial met its surrogate endpoint of
significantly longer progression-free survival in the sorafenib arm compared to the
placebo arm of the study. In addition, sorafenib treatment doubled the disease
progression-free survival from 12 to 24 months when compared to the placebo-control
arm (Escudier et al., 2005); Nexavar website has updated survival data]. In addition to
RCC, several single agent and combination clinical studies are ongoing in hepatocelluar
carcinoma, non-small cell lung cancer (NSCLC), prostate cancer, breast cancer, ovarian
cancer, pancreatic cancer, melanoma and hematological malignancies (Hahn and Stadler,
2006); (Rini, 2006).
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 The results of clinical trial analyses of sorafenib have not provided sufficient
information to conclude that inhibition of Raf provides a clinical value. Since B-Raf
mutations are not seen in RCC, and since sorafenib is not a potent Raf inhibitor, the anti-
tumor activity seen may be attributed to the anti-angiogenic, rather than anti-Raf, activity
of sorafenib. Although preclinical cell culture and mouse model analyses showed that
continued expression of mutant B-Raf is critical for melanoma growth and
tumorigenicity, phase II clinical trial analyses with sorafenib observed little or no
antitumor activity when evaluated as monotherapy for advanced melanomas (Eisen et al.,
2006). Some clinical efficacy had been seen for melanomas when sorafenib was used in
combination, with clinical trials ongoing for advanced melanomas with sorafenib
combination with bevacizumab or carboplatin and paclitaxel. However, a recently
completed phase III trial administering sorafenib or placebo tablets in combination with
carboplatin and paclitaxel in patients with advanced melanoma found no difference in the
primary endpoint of improving progression-free survival.
RAF265 (formerly CHIR-265) is another orally bioavailable Raf inhibitor
currently being investigated in phase I clinical trials in locally advanced or metastatic
melanoma (http://www.clinicaltrials.gov/ct/show/NCT00304525). RAF265 inhibits all
three Raf isoforms as well as mutated B-Raf. Like sorafenib, RAF265 may also have
anti-angiogenic activity through inhibition of VEGFR2. PLX4032 is a potent and
selective inhibitor of mutant B-Raf that is currently in phase I clinical evaluation. Other
Raf inhibitors are also in preclinical evaluation and should be entering clinical evaluation
in the near future.
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The clinical success of sorafenib and another approved multi-kinase inhibitor
(sunitinib) has prompted a debate regarding the advantages and disadvantages of highly
specific versus broad specificity inhibitors (Sebolt-Leopold and English, 2006). Since
cancer is a multi-step process, requiring multiple alterations, it is expected that effective
cancer treatment requires concurrent activities that target different defects (Hanahan and
Weinberg, 2000). The greater success of combination chemotherapy is consistent with
this premise. The ability to optimize the pharmacokinetics and pharmacodynamic
properties of a single agent with multiple activities is also a great advantage for the
successful clinical development of a drug. In the development of sorafenib, the intention
was the identification of a Raf inhibitor, with the activity against other protein kinases
fortuitous and unplanned. Hence, this has complicated a full understanding of the
mechanism of action of sorafenib and the importance of its anti-Raf activities for its
clinical efficacy.  Therefore, whether blocking Raf will be a clinically effective approach
will require future clinical evaluation of more specific and potent Raf kinase inhibitors.
The clinical success of highly selective protein kinase inhibitors, in particular mAb-based
drugs (e.g., trastuzumab, bevacizumab), demonstrates that there is clinical value for both
highly selective and multi-targeted inhibitors.
MEK inhibitors
MEK1 and MEK2 are closely related dual-specificity kinases, capable of
phosphorylating both serine/threonine and tyrosine residues of their substrates ERK1 and
ERK2. They are the only known catalytic substrates of Raf kinases. The fact that ERK is
the only known substrate of MEK, when coupled with the observation that ERK is
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commonly activated in both tumor cell lines and patient tumors, has fueled strong interest
in developing pharmacological inhibitors of MEK as a means to block ERK activation
(Hoshino et al., 1999).
In contrast to sorafenib, small molecule inhibitors of MEK1/2 are highly specific
protein kinase inhibitors. While the first two MEK inhibitors, PD98059 and U0126, were
highly specific (Davies et al., 2000) they lacked the pharmaceutical properties needed to
be successful clinical candidates. Nonetheless, these compounds have been invaluable
academic research tools for dissecting the MEK-ERK pathway and have provided
enormous insight into the importance of ERK MAPK signaling in cancer (Cox and Der,
2002b; Sebolt-Leopold and Herrera, 2004).
The first MEK inhibitor to enter clinical trials was CI-1040 (PD184352), an orally
active, highly potent and selective inhibitor of MEK1 and MEK2 (Sebolt-Leopold et al.,
1999). Preclinical evaluation found that CI-1040 inhibited the growth of human colon
cancer cells and human melanoma cells in athymic nude mice (Collisson et al., 2003;
Sebolt-Leopold et al., 1999). Subsequent phase I and II clinical trials reported the most
common toxicities were mild skin rash, diarrhea, and fatigue (Lorusso et al., 2005)
(Rinehart et al., 2004). During the phase I trial, a partial response was seen in one patient
with pancreatic cancer and 25% of patients with a variety of tumors had stable disease for
greater than three months (Lorusso et al., 2005). Tumor tissues from treated patients
showed significant reduction in activated phosphorylated ERK, indicating that the target
was inhibited. These encouraging results prompted a phase II study in patients with
advanced NSCLC, breast cancer, CRC, and pancreatic cancer. Unfortunately the results
of this trial were negative and CI-1040 was determined to have poor pharmacokinetic
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properties (Rinehart et al., 2004). However, when considered together with the
significant body of positive preclinical data as well as early indications from the phase I
trial, it is still believed that MEK is a valid therapeutic target for the treatment of cancer.
Thus, two second-generation MEK1/2-specific inhibitors (PD325901 and ADZ6244)
believed to have superior pharmacological and biopharmaceutical properties have been
developed and are currently in clinical trials (Table 1).
In contrast to the majority of protein kinase inhibitors, MEK inhibitors are non-
ATP competitive inhibitors, which may account for their highly selective properties.
Structural studies with an analog of CI-1040 in complex with MEK1 or MEK2 showed
inhibitor binding did not perturb ATP binding, and instead, bound to a unique inhibitor
binding pocket adjacent to the ATP binding site (Ohren et al., 2004). Inhibitor binding
locked MEK in a catalytically-inactive conformation. This recognition of MEK
sequences that are not shared with other protein kinases, and their association with an
inactivate conformation, account for MEK inhibitor target selectively.
 PD0325901 is a derivative of CI-1040 where several slight modifications to the
chemical structure have resulted in more than a 50-fold increase in potency against
MEK1/2, improved bioavailability, and longer duration of target suppression compared to
CI-1040 (Sebolt-Leopold and Herrera, 2004). Anti-tumor activity for PD0325901 was
demonstrated for a variety of tumor xenografts and this inhibitor is now being evaluated
in phase I/II clinical trials with a focus on tumors expected to have activated ERK MAPK
signaling (Solit et al., 2006; Thompson and Lyons, 2005).
AZD6244 (ARRY-142886) is an orally bioavailable benzimidazole derivative
known to potently inhibit MEK1/2 in vitro and in cell-based assays (Lyssikatos et al.,
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2004; Yeh et al., 2004). Like other MEK inhibitors, AZD6244 is ATP-non-competitive.
Preclinical evaluation of AZD6244 showed anti-tumor activity in several human
xenograft models including colon, pancreas, breast, NSCLC and melanoma (Lee et al.,
2004). Additionally, AZD6244 anti-tumor activity was found to correlate with
suppression of ERK activation, which further validates that its mechanism of action is
MEK-dependent. Results from preclinical analysis have been extremely promising and
thus AZD6244 has moved into clinical development. Recently, initial results of a first in
human dose-ranging study to assess the pharmacokinetics, pharmacodynamics, and
toxicities of AZD6244 in patients with advanced solid tumors concluded that AZD6244
is well tolerated, and the most common treatment-related adverse events were rash,
diarrhea, nausea, fatigue, peripheral edema, and vomiting. The best clinical response seen
in the 57 patients was stable disease (19 patients at the end of cycle two; 9 of whom
achieved stable disease for 5 months or greater). The pharmacokinetic and
pharmacodynamic analyses showed good systemic exposure, which correlated with high
levels of ERK inhibition in peripheral blood mononuclear cells (PBMCs)
(http://www.arraybiopharma.com). AZD6244 is now being evaluated in multiple phase II
trials in a variety of solid tumors.
Rosen and colleagues recently reported that B-Raf mutant tumors are exquisitely
sensitive to MEK inhibition (Solit et al., 2006). In this study the authors used genetic and
pharmacological (CI-1040 and PD0325901) approaches to evaluate MEK-dependence in
a variety of tumor types and found that human tumor cell lines possessing mutant B-Raf
were much more sensitive to MEK inhibition than cells with wild-type B-Raf or mutant
K-Ras. In their xenograft models they found B-Raf mutation positive tumor xenografts
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had completely abrogated tumor growth whereas xenografts of Ras mutation positive
tumor cells were only partially inhibited, perhaps reflecting the fact that Ras also utilizes
non-Raf effector pathways to promote oncogenesis. Whether Ras or B-Raf mutation
status will accurately identify the patients who will respond to MEK inhibitor treatment,
and whether suppression of ERK activity is an accurate measure of drug inhibition of
MEK, are issues that remain to be determined.
In addition to small molecule inhibitors of MEK kinase activation, bacterial toxins
have been identified that inhibit MEK function by unique biochemical mechanisms.
Anthrax lethal factor (LF) is a protease and a component of Bacillus anthracis exotoxin,
the Gram-positive bacterium responsible for the disease anthrax. LF, together with a
second exotoxin component (protective antigen), comprise lethal toxin (LeTx). LeTx
inactivates multiple MAPKKs, including MEK1 and MEK2 by proteolytic cleavage and
inactivation of kinase function (Bodart et al., 2002). LeTx was shown to block the
transformed and tumorigenic growth of Ras-transformed rodent fibroblasts (Duesbery et
al., 2001). LeTx also showed preferential inhibition of growth of melanoma cell lines that
harbored mutated B-Raf and elevated ERK activity (Abi-Habib et al., 2005). Yersinia
outer protein J (YopJ) is another bacterial toxin that inhibits MEK function. The bacterial
pathogen Yersinia pestis, the causative agent for the plague (Black Death), uses a type III
secretion system to inject YopJ and other virulence factors into target cells. YopJ was
shown to bind directly to MEK1, MEK2 and other MAPKKs and to block their
phosphorylation and activation (Orth et al., 1999). YopJ functions as an acetyltransferase,
using acetyl-coenzyme A (CoA) to modify the critical serine and threonine residues in
the activation loop of MEKs and thereby blocking MAPKKK phosphorylation and
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activation (Mukherjee et al., 2006). YopJ also causes acetylation of a threonine residue in
the activation loop of IκB kinase β, preventing its phosphorylation and inactivation of
IκB, thus preventing nuclear translocation and activation of the NF-κB transcription
factor. Since inhibition of NF-κB also has an anti-tumor consequences (Karin, 2006),
YopJ can inhibit concurrently at least two important pathways that promote oncogenesis.
The unique biochemical activities of these bacterial proteins may identify novel
approaches for blocking MEK-ERK signaling.
E. Inhibitors of EGFR signaling
Another approach that has been considered for anti-Ras therapy involves targeting
the EGFR.  The rationale for targeting this RTK for blocking Ras is based on two issues.
First, a common consequence of mutated Ras function is upregulated expression of the
gene for transforming growth factor alpha (TGFα) and other EGFR ligands, resulting in
increased protein expression and secretion. This results in the induction of an autocrine
growth factor loop where Ras mutation positive tumor cells secrete growth factors that
stimulate a receptor expressed on the same cell, leading to uncontrolled cellular
proliferation(Gangarosa et al., 1997; McCarthy et al., 1995; Schulze et al., 2001).
Inhibition of TGFα stimulation of the EGFR impairs Ras transformation, demonstrating
the critical role of this autocrine loop in Ras-mediated growth transformation.   Second,
as described above, a key consequence of EGFR signaling is activation of Ras and ERK
MAPK pathway (Schulze et al., 2004).  Therefore, targeting EGFR signaling may be an
effective approach for blocking Ras in cancer treatment.
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The EGFR family consists of four transmembrane receptors: EGFR (HER1/ErbB-
1), HER2 (ErbB-2/Neu), HER3 (ErbB-3) and HER4 (ErbB-4) (Mendelsohn and Baselga,
2006; Scaltriti and Baselga, 2006). Multiple ligands bind to and activate EGFR, HER3
and HER4. Ligands for EGFR include EGF, TGF_, HB-EGF, betacellulin and epiregulin.
Ligand binding results in the formation of receptor homodimers and heterdimers leading
to subsequent receptor activation and ultimately the activation of downstream signal
transduction pathways  (Wiley, 2003; Yarden, 2001).
The best-characterized cytoplasmic signaling pathway activated by the EGFR is
the ERK MAPK pathway, and ERK activation has been utilized as a biomarker for EGFR
inhibitor action. Additional EGFR-activated pathways include the phosphatidylinositol 3-
kinase (PI3K) and AKT serine/threonine kinase, signal transducer and activator of
transcription (STAT), as well as protein kinase C and phospholipase D pathways (Citri et
al., 2003). EGFR activation of these pathways results in enhanced proliferation,
angiogenesis, invasion and metastasis, as well as inhibition of apoptosis (Jimeno and
Hidalgo 2006). Aberrant activation of the EGFR signaling commonly occurs in cancer
(NSCLC, CRC, breast cancer, gastric cancer, and others) and multiple mechanisms
describing its activation have been reported including EGFR overexpression, EGFR gene
amplification, acquisition of activating mutations and overexpression of EGFR ligands
(Baselga and Arteaga, 2005).
Two strategies to inhibit EGFR signaling have been successfully developed and
include monoclonal antibodies (mAbs) directed against the extracellular domain of EGFR
(Table 3) and small molecule tyrosine kinase inhibitors (TKIs) of the intracellular
tyrosine kinase domain (Table 4). By blocking ligand-receptor interactions, mAbs inhibit
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receptor homo- and heterodimerization resulting in receptor internalization and inhibition
of EGFR signaling pathways. Additionally, the clinical activity of some EGFR mAbs
may also be attributed to their ability to stimulate an immune response. Alternatively,
EGFR receptor tyrosine kinase inhibitors (TKIs) bind to the intracellular tyrosine kinase
domain preventing ATP-binding and receptor activation, thus blocking EGFR activation
of ERK and other signaling pathways. Mab and small molecule inhibitors of EGFR
possess shared and distinct features that distinguish their mechanistic and clinical
activities (Table 5). Hence, it is believed that their use in combination may act
synergistically and improve anti-EGFR therapy.
As with other signal transduction inhibitors, EGFR inhibitors lack the severe
myelosuppressive toxicities seen with conventional cytotoxic drugs. Toxicities are most
evident in tissues that are dependent on EGFR function, in particular the skin (Lacouture,
2006). This includes a papulopustular rash that affects the face and upper trunk,
abnormalities in hair growth, and dry and itchy skin. There is incomplete evidence that
the strength of skin rash may be a good indication of drug activity and possibly favorable
patient response and survival (Perez-Soler and Saltz, 2005).
Several EGFR mAbs have been developed that recognize the extracellular domain
of the EGFR (Figure 5). However, since they recognize distinct sequences and vary in
binding affinities and composition (Figure 5), they also vary in their biological activities.
The first FDA-approved EGFR mAb was cetuximab, a chimeric monoclonal IgG1
antibody initially approved for use in combination with irinotecan for the treatment of
EGFR-detectable metastatic CRC refractory to irinotecan, as well as monotherapy for the
treatment of EGFR-detectable metastatic CRC in patients intolerant to irinotecan
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(Cunningham et al., 2004). More recently, cetuximab has received additional approval
for use in combination with radiation to treat inoperable squamous cell cancer of the head
and neck (Bonner et al., 2006). Finally, although EGFR expression was an initial basis
for patient selection, patient response has not correlated with the degree of
overexpression. Thus, a reliable biomarker for defining patient response remains elusive.
While cetuximab has proven to be an effective treatment in the aforementioned
indications and continues to be investigated for use in other tumor types, one of its major
drawbacks is the associated risk of anaphylactic reactions during cetuximab infusion
(Bonner et al., 2006; Cunningham et al., 2004). This has led to the development of two
humanized EGFR (matuzumab and nimotuzumab) and two fully human (panitum umab
and zalutumumab) mAbs.
Panitumumab (Vectibix, Amgen, Inc) was approved in 2006 for the treatment of patients
with EGFR-expressing, metastatic CRC with disease progression on or following
fluoropyrimidine-, oxaliplatin-, and irinotecan-containing chemotherapy regimens.
Panitumumab is a fully humanized mAb that is similar to cetuximab except that
panitumumab is an IgG2 antibody that does not elicit antibody-dependent cell mediated
cytotoxicity (ADCC) (Yang et al., 1999). In the pivotal phase III trial that led to its
approval, panitumumab treatment significantly improved progression free survival and
resulted in an 8% overall response rate (Gibson et al., 2006). The most common toxicities
seen include rash, fatigue, hypomagnesemia, abdominal pain and diarrhea. As expected
with a fully humanized mAb, no grade 3/4 infusion-related reactions were seen in this
trial.
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Figure 5. EGFR monoclonal antibodies. Nomenclature of monoclonal antibodies
(mAbs) has been devised for assigning generic or nonproprietary names. All monoclonal
antibodies end with the suffix –mab, while different infixes are used to differentiate the
agents depending on the structure and function of the therapeutic agent. The infix
immediately preceding the -mab suffix denotes the animal origin of the antibody (o =
mouse; xi = chimera; zu = humanized; u = human).  The first mAbs were produced in
mice and are recognized as foreign by the human immune system (e.g., 225), which can
lead to increased clearance and allergic/anaphylactic reactions. Therefore, sequences that
comprise the constant regions of the antibody, which are not involved in epitope
recognition, may be replaced with human sequences, to create mAbs that are chimeric
mouse-human proteins (e.g., IMC-C225 was derived from 225) or humanized mAbs.
Recently, the use of transgenic mice with human immunoglobulin heavy and light chain
coding sequences (e.g., XenoMouse), has facilitated the generation of fully human mAbs.
The infix preceding the source of the antibodies refers to the disease condition the agent
is used to treat. Most of these consist of a consonant, vowel, and another consonant. To
simplify the naming scheme the final consonant is commonly dropped if the following
infix begins with a consonant (such as -zu- or -xi-). For mAbs used for the treatment of
cancer “-tu(m)-” is used as the infix to designate tumor.  (* designates EGFR mAbs that
are FDA approved)
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Matuzumab is a humanized IgG1 anti-EGFR mAb. As a humanized mAb
matuzumab, like panitumumab, is expected to have reduced infusion-related anaphylactic
reactions. Furthermore, as an IgG1 antibody matuzumab induced potent ADCC against
tumor cells in vivo, which distinguishes matuzumab from the recently approved
panitumumab (Bier et al., 1998). While results from several phase II trials are expected
within the next year, initial phase I trials have shown matuzumab is well-tolerated, with
rash and diarrhea the most common toxicities. In these trials, evaluation of both tumor
tissue and skin biopsies determined that matuzumab inhibited phosphorylation of EGFR,
ERK, and AKT (Doi et al., 2005; Salazar et al., 2004; Tabernero et al., 2003; Vanhoefer
et al., 2004). In phase I trials, activity has been evaluated in colorectal, cervical, and
esophageal cancers and in squamous cell cancer of the head and neck. Current therapeutic
targets in phase II trials include cervical and gastric cancers, and NSCLC.
Pertuzumab is a novel mAb with a unique mechanism of action designed to
inhibit the heterodimerization of HER2 with EGFR and other HERs. Similar to other
EGFR mAb, the most common toxicities include rash and diarrhea (Agus et al., 2005).
To date several phase II trials evaluating pertuzumab have been completed. Initial results
evaluating pertuzumab as monotherapy in metastatic breast cancer and hormone-
refractory prostate cancer were not promising as there was limited evidence of activity in
breast cancer patients and no prostate-specific antigen responses in the prostate cancer
(Cortes et al., 2005; de Bono et al., 2005). However, more promising results in refractory
or recurrent ovarian cancer have been seen in which clinical activity was seen in 15% of
patients (Gordon et al., 2005). While single-agent use of pertuzumab has shown limited
clinical activity, our experience with targeted-therapies along with preclinical xenograft
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data suggest that pertuzumab may have greater clinical benefit when used in combination
with other therapies (Friess et al., 2005). Thus, current phase II trials of pertuzumab are
focused on combination therapy, including a study of pertuzumab in combination with
erlotinib in patients with locally advanced or metastatic NSCLC.
Two EGFR small molecule kinase inhibitors have received approval for use in
NSCLC (Table 4). The first was gefitinib, which received accelerated approval as third-
line monotherapy in NSCLC based on its 12% response rate and 43% rate of tumor
control. However, gefitinib was subsequently evaluated in a large phase III trial
comparing gefitinib to placebo in NSCLC patients who had failed previous treatment
regimens, and results from this trial showed no improvement in survival compared to
placebo resulting in a FDA-mandated labeling change. Currently, gefitinib is approved
only for the treatment of cancer patients who have previously received and benefited
from treatment.  Ongoing clinical trials are evaluating the use of gefitinib for the
treatment of other cancers.
As opposed to gefitinib, erlotinib has demonstrated improved survival in a
randomized phase III placebo-controlled trial. Although the overall response rate was
only 9% in the erlotinib arm, erlotinib prolonged overall survival (6.7 versus 4.7 months)
and increased one-year survival (31% versus 22%). These results led to FDA approval in
2004. More recently, erlotinib has also gained FDA approval for use in combination with
gemcitabine for the first-line treatment of patients with locally advanced, unresectable or
metastatic pancreatic cancer (Moore et al., 2005b).
As is seen with some recent mAb-based EGFR strategies (e.g., zatumumab),
newer generation TKIs are now being developed to inhibit multiple RTKs (Table 4). In
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particular, laptinib (Tykerb) is a dual EGFR and HER2 tyrosine kinase inhibitor that has
been extensively evaluated in multiple solid tumors including breast, NSCLC, CRC, head
and neck cancer, hepatocellular carcinoma and billary carcinoma (Nelson and Dolder,
2006). Initial evaluation of this compound revealed diarrhea and skin rash as the most
common toxicities (Nelson and Dolder, 2006). While the clinical activity of this agent
has been evaluated in multiple tumor types, the main focus has been in the treatment of
breast cancer, a disease known to rely on both HER-2 and EGFR signaling. Numerous
phase I and II clinical trials have been reported, including several looking at the use of
lapatinib in refractory metastatic breast cancer and in first line treatment of  advanced
breast cancer (Moy and Goss, 2006). An international, multi-center, randomized, open
label phase III trial in patients with documented HER2 overexpressing refractory
advanced or metastatic breast cancer treated with lapatinib in combination with
capecitabine versus capecitabine alone was stopped after the interim analysis. Of the 321
evaluable patients, 161 were treated in the combination arm and 160 in the monotherapy
arm. Median time to progression in the combination arm was 8.5 months, compared with
4.5 months in the capecitabine alone arm (Tykerb at ASCO 2006,
http://www.gsk.com/investors/presentations_webcasts.html). While these data need to
mature so that an overall survival advantage can be determined, this compound is likely
to become part of the standard of care in breast cancer and possibly other tumor types as
well. The results of this phase III trial are so promising that it has been made available
through an Expanded Access Protocol of lapatinib combined with capecitabine in
metastatic breast cancer in a non-randomized, open label, uncontrolled trial.
In addition to lapatinib, EKB-569 and PKI-166 are two additional dual
39
EGFR/HER2 inhibitors in clinical trials (Table 4). Furthermore, canertinib (CI-1033),
BMS-599626 and HKI-272 are pan-HER inhibitors, while several EGFR inhibitors also
inhibit RTKs involved in tumor angiogenesis. While targeting multiple protein kinases
may enhance anti-tumor activity, it may also result in greater normal cell toxicity.
F. Rho family small GTPases: key downstream components of Ras signaling
Although the Raf-MEK-ERK cascade remains the most targeted Ras signaling
pathway for the development of anti-Ras inhibitors, there is growing evidence that other
Ras effector pathways also promote Ras mediated oncogenesis, and consequently, may
also represent important signaling pathways for anti-Ras drug discovery.  In particular, a
number of Ras effector pathways lead to activation of Rho family small GTPases (Figure
6).  For example, Tiam1 is a guanine nucleotide exchange factor and activator of Rac, a
Rho family GTPase.  Ras binds to and activates Tiam1, which in turn activates Rac, and
Rac activation has been shown to be required for Ras transformation (Lambert et al.,
2002; Minard et al., 2004; van Leeuwen et al., 1995).  Mice deficient in Tiam1
expression are viable, indicating Tiam1 is dispensable for normal mouse development
(Malliri et al., 2002).  However, Tiam1-deficient mice show a reduced incidence of H-
Ras-induced tumor formation.  PI3K regulates formation of phosphoinositides, which
promote the activation of diverse cytoplasmic signaling proteins, in particular, the Akt
serine/threonine kinases are the best studied.  Additionally, phosphoinositides have also
been shown to activate RhoGEFs (e.g., P-rex1), causing activation of Rho GTPases
(Welch et al., 2002).  The RalGEF-Ral pathway may also regulate Rho GTPase function.
A key downstream effector of the Ral small GTPases (RalA and RalB) is RalBP1, a
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Figure 6. Human Rho GTPase Family. Based on sequence and/or functional
similarities, the 20 human Rho family GTPases can be subdivided into RhoA-related
subfamily (RhoA, RhoB and RhoC), the Rac1-related subfamily (Rac1, Rac1b, Rac2 and
Rac3), the Cdc42-related subfamily (Cdc42, TC10, TCL, Wrch-1 and Chp/Wrch-2), the
Rnd subfamily (Rnd1, Rnd2 and Rnd3/RhoE) and the RhoBTB subfamily (RhoBTB1 and
RhoBTB2/DBC2).  The RhoD, Rif and RhoH/TTF proteins do not fall into any of these
subfamilies.  Generally, members of a subfamily will be regulated by common RhoGEFs
and RhoGAPs, and will utilize overlapping effectors.
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RhoGAP.  Current evidence suggests that activation of the RalGEF-Ral pathway causes
inactivation of RalBP1, leading to activation of the Rac and Cdc42 Rho GTPases (Cantor
et al., 1995).  Another link between Ras and Rho GTPases is demonstrated by the
observations that the Rnd3/RhoE Rho GTPase is transcriptionally upregulated by Ras
activation of the Raf-MEK-ERK cascade (Hansen et al., 2000; Shields et al., 2007).
Ectopic expression of Rnd3 proteins cause cell rounding, disruption of actin stress fibers,
reduced cell adhesion and increased cell migration.  These functions of Rnd3 are
mediated, in part, by inhibition of RhoA function.  Since these cellular alterations are
associated with Ras transformation, it is speculated that Rnd3 upregulation may
contribute to these Ras-induced cellular changes.  The importance of Rho GTPases in Ras
transformation is supported by studies showing that genetic or biochemical inhibition of
RhoA, Rac1 or Cdc42 inhibits Ras-mediated growth transformation of rodent
fibroblasts(Khosravi-Far et al., 1995; Qiu et al., 1997; Qiu et al., 1995a; Qiu et al.,
1995b; Roux et al., 1997).  Finally, in addition to the functional signaling links that
connect Ras with Rho GTPases, Ras and Rho GTPases undergo a similar set of
posttranslational modifications by lipids that promote their membrane association.
Hence, the anti-Ras approaches that are designed to block Ras membrane association
may also block Rho GTPase membrane association and function.
Rho proteins are members of the Ras superfamily of small GTPases and, like Ras,
function as GDP/GTP-regulated switches (Colicelli, 2004; Wennerberg et al., 2005) .
Much of our current understanding of the biochemistry and biology of the Rho family has
come from the extensive evaluation of three classical members, RhoA, Rac1, and Cdc42
(Wennerberg and Der, 2004).  Similar to Ras, Rho GDP/GTP cycling is regulated by two
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main classes of regulatory proteins. Guanine nucleotide exchange factors promote the
formation of the active GTP-bound form (Schmidt and Hall, 2002) and GTPase-
activating proteins catalyze the intrinsic GTPase activity and promote the formation of
inactive GTP-bound Rho (Bernards and Settleman, 2004). Distinctly, Rho family
members are also regulated by a third class of proteins, the Rho guanosine nucleotide
dissociation inhibitors (RhoGDIs).  This class of proteins regulates Rho localization and
effector activation by sequestering Rho in the cytoplasm (Gosser et al Nature 1997;
Hoffman et al, Cell 2000).  To accomplish this level of regulation, RhoGDIs complex
with Rho GTPases by providing a hydrophobic pocket to mask the c-terminal
isoprenylated cysteine critical for membrane targeting.
Active, GTP-bound Rho GTPases bind preferentially to downstream effectors,
stimulating diverse cytoplasmic signaling cascades that control actin reorganization and
regulate cell polarity, cell motility, cell shape, cell adhesion, and membrane trafficking.
(Etienne-Manneville and Hall, 2002).  As such, it is thought that Rho proteins contribute
to cancer progression by influencing the cell’s ability to migrate and thus invade and
metastasize.  In addition to these alterations in cellular function, aberrant activation of
Rho proteins have also been shown to contribute to other cancer phenotypes such as cell
growth, proliferation, survival, and angiogenesis (Ridley, 2004).  Therefore, defining
pharmacologic approaches for inhibition of Rho GTPase function represents an important
direction for target-based anti-cancer drug discovery, specifically inhibitors of post-
translational CAAX processing.
Similar to Ras, most Rho family members (16 of 20) terminate with a C-terminal
CAAX motif, which for the canonical Rho proteins has been shown to be critical for
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proper subcellular localization and biological function. Recognition of the C-terminal
CAAX tetrapeptide motif (C = cysteine, A = aliphatic, X = any amino acid) initiates the
same series of post-translational modifications as has been well described for Ras
proteins and ultimately leads to proper membrane targeting.   In brief, this includes the
addition of a farnesyl or geranylgeranyl isoprenoid lipid to the cysteine residue of the
CAAX sequence, the subsequent cleavage of the AAX peptide from the carboxyl-
terminus and finally the addition of a methyl group to the prenylated cysteine residue
(Sebti and Der, 2003; Winter-Vann and Casey, 2005). These steps are described more
completely in section G below.  Where studied, mutation of the cysteine residue of the
CAAX motif, which prevents all three modifications, renders Rho GTPases cytosolic and
inactive, suggesting that pharmacological inhibition of such modifications would also
interfere with Rho GTPase function.
Because Rho GTPases have such diverse biological activities and because of the
growing evidence of their role in cancer, it is imperative that we understand the global
impact of inhibiting posttranslational modifications on Rho function.  While there is
extensive evidence detailing the importance CAAX-signaled modifications for the
canonical Rho proteins, RhoA, Rac1, and Cdc42, less is known about the other Rho
members. In addition, most of the existing evidence implicating Rho function in
tumorigenesis has resulted from the study of these three members.  However, recent
reports have begun to show that other members are also important players in oncogenesis.
We have summarized here what is currently known about the role of many of the non-
classical Rho GTPases in cancer.
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Noncanonical members of the Rho Subfamily (RhoA, RhoB and RhoC)
RhoB is a small GTPase involved in actin organization and vesicle transport.
Initially, analysis of breast cancer specimens revealed that RhoB was overexpressed
compared to matched normal tissue, and this overexpression was correlated with tumor
grade and proliferation index, suggesting that RhoB may have pro-oncogenic properties
(Fritz et al., 2002).  However, subsequent analysis suggests that RhoB is actually a tumor
suppressor and during times of stress can elicit an apoptotic response (Prendergast, 2001).
In support of these findings, RhoB -/- mice were more susceptible to 7,12-
dimethylbenz[a]anthracene (DMBA)-induced skin carcinogenesis and intraperitoneal
tumor formation by transformed RhoB -/- cells (Liu et al., 2001).  Multiple studies
examining the expression of RhoB in human tumors have now shown a recurring theme
that RhoB expression is commonly lost, not gained, during cancer progression.  These
observations have been seen in head and neck squamous cell carcinoma (HNSCC), lung
cancer, and bladder cancer (Adnane et al., 2002; Kamai et al., 2003; Mazieres et al.,
2004).   Additionally, the histone deacetylase 1 (HDAC1), Erb-B1 (EGFR), Erb-B2, and
Ras oncogenes can all repress RhoB expression in NSCLC, pancreatic and cervical
cancer cell lines (Jiang et al., 2004; Wang et al., 2003).
RhoC is the third member of the RhoA/B/C class of proteins and unlike RhoB
there is extensive evidence that it is a mediator of tumor progression and metastasis.
Inflammatory breast cancer (IBC) is an extremely aggressive and metastatic form of
breast cancer that is associated with very poor prognosis (Dawood and Cristofanilli,
2007).  RhoC is overexpressed in up to 90% of IBC tumors as opposed to only 38% of
non-inflammatory breast tumors, suggesting that it may be critical in driving a more
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aggressive phenotype (van Golen et al., 1999).  To confirm this association between
RhoC expression and breast cancer aggressiveness, human mammary epithelial cells
stably expressing RhoC have been generated. Overexpression of RhoC resulted in actin
stress fiber and focal adhesion contact formation.  In addition, these cells display multiple
hallmarks of an aggressive phenotype such as the ability to grow in anchorage-
independent conditions, increased motility, increased invasion, and tumor formation (van
Golen et al., 2000b).  Additional studies in melanoma, pancreatic cancer, NSCLC,
colorectal cancer, hepatocellular carcinoma, ovarian cancer, bladder cancer, gastric
cancer, and HNSCC have all found an association between RhoC expression and tumor
aggressiveness, disease progression, or metastasis (Bellovin et al., 2006; Cai et al., 2006;
Clark et al., 2000; Kamai et al., 2003; Kleer et al., 2006; Liu et al., 2007; Shikada et al.,
2003; Suwa et al., 1998; Wang et al., 2007).
Mechanistic studies using cell-based models have revealed that expression of
RhoC results in increased secretion of angiogenic factors (VEGF, bFGF, IL-6, IL-8) and
induces expression of genes involved in invasion and metastasis (van Golen et al., 2000a;
Wu et al., 2004).  In support of these findings, an orthotopic lung model has been used to
show that RhoC leads to increased cell motility and upregulation of matrix-
metalloproteases (MMPs) ultimately leading to a more metastatic phenotype. Finally,
RhoC has been shown to promote invasion in part via activation of the PI3K-Akt
pathway, in a manner independent of ROCK signaling (Ruth et al., 2006).    
The Rac Subfamily (Rac1, Rac1b, Rac2, Rac3, and RhoG)
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Rac1b is a splice variant of the canonical Rho family member Rac1. The initial
study that identified Rac1b found that its expression was elevated in colorectal tumors
compared to normal tissue and in a subsequent report similar findings were seen in breast
cancer (Schnelzer et al., 2000).   The splice variation results in the insertion of a 19
amino acid sequence following the switch II region, creating a potentially novel effector
binding site (Jordan et al., 1999).  GTP binding and hydrolysis assays identified Rac1b as
a fast cycling GTPase (Schnelzer et al., 2000).  Consistent with this finding, Rac1b
promotes transformation of NIH3T3 cells similar to the constitutively-activated
Rac1(Q61L) mutant (Singh et al., 2004). Furthermore, Rac1b signals to promote
activation of the AKT serine/threonine kinase but does not activate the NF-kappaB
transcription factor or stimulate cyclin D1 expression, which are commonly activated by
Rac1 (Singh et al., 2004).  In addition to these mechanistic studies, exposure of mouse
mammary epithelial cells to MMP-3 has been shown to induce the expression of Rac1b
leading to increased cellular reactive oxygen species (ROS). The resultant exposure to
ROS results in epithelial-mesenchymal transition (EMT), increased oxidative damage to
DNA and genomic instability (Radisky et al., 2005).  Lastly, in colorectal cancer cells,
Rac1b induces tumor progression through the enhancement of Disheveled-3 (Dvl-3)
mediated Wnt signaling and induction of Wnt target genes (Esufali et al., 2007).
Rac2 expression is restricted to cells of hematopoietic lineages, as opposed to the
widely expressed Rac1 and Rac3.  Much of what is known about Rac2 has come from the
generation of Rac2-deficient mice which demonstrate cellular defects in multiple
hematopoietic lineages, including stem and progenitor cells, neutrophils, mast cells, T
cells, and B cells (Croker et al., 2002; Li et al., 2000; Roberts et al., 1999; Yang et al.,
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2001; Yang et al., 2000). From this analysis Rac2 function was found to be critical in
actin cytoskeletal rearrangements, as well as activating multiple signaling cascades.   In
all, Rac2 is important for cytokine- or chemokine-induced activation of mitogen-
activated protein kinases p42/p44 and p38, growth factor induced phosphatidylinositol 3-
kinase (PI3K) activation of Akt, and cell survival (Kim and Dinauer, 2001; Roberts et al.,
1999; Yang et al., 2000).  There are currently only two direct observations linking Rac2
to cancer.  First, expression of KIT(D814V) in primary hematopoietic stem/progenitor
cells (HSC/Ps) and mast cell progenitors (MCPs) results in constitutive KIT
autophosphorylation leading to ligand-independent hyperproliferation (Abraham et al.,
2001). Both genetic disruption and pharmacologic inhibition, using a Rac inhibitor
(NC23766) or the mTOR inhibitor rapamycin, showed a dose-dependent suppression in
ligand-independent growth, indicating that Rac2 and its downstream effector PI3K are
critical for KIT-induced acute myeloid leukemia (Abraham et al., 2001).  Additionally,
and somewhat surprisingly, Rac2 was found overexpressed in HNSCC when compared to
normal tissue (Abraham et al., 2001).   Although this finding needs to be confirmed, this
would not be the first time that a tissue-specific protein was abnormally expressed in a
cancer from originating from a different tissue type.
Rac3 was first linked to cancer through studies that determined it is highly active
in breast cancer cell lines and tumor tissues (Mira et al., 2000). In these studies, Rac3
activation utilized both the p21-activated kinase (Pak) and c-Jun N-terminal kinase (JNK)
MAPK signaling pathways to promote tumor growth (Mira et al., 2000). In subsequent
evaluation, Rac3 expression was able to induce transformation and membrane ruffling,
both of which were reversed following treatment with a GGTase inhibitor (Joyce and
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Cox, 2003).  Additionally Rac3 has been shown to be a downstream effector of Bcr/Abl-
mediated hematologic malignancies (Cho et al., 2005).  In a Bcr/Abl driven mouse model
of lymphoma, Vav1, a hematopoiesis-specific exchange factor for Rac, was found to be
constitutively tyrosine phosphorylated.  In addition, activated Rac3 but not Rac1 or Rac2
was detected in the malignant precursor B-lineage lymphoblasts (Cho et al., 2005).
Finally, shRNA knockdown of Rac3 in glioblastoma and breast cancer cells has been
shown to block invasion (Chan et al., 2005).  These data are supported by findings that
Rac3 is overexpressed in brain tumors and involved in the invasive and metastatic
phenotype of human breast cancer cells (Baugher et al., 2005; Hwang et al., 2005).
RhoG is the least studied of the Rac subfamily proteins in regards to its role in
oncogenesis.  However, in a study of 120 breast cancer tissues RhoG expression was
found to be elevated compared to normal tissue (Jiang et al., 2003). Node-positive tumors
exhibited significantly higher levels of RhoG compared to node-negative tumors and
higher levels of RhoG were seen in patients who died of breast cancer than in those who
remained disease-free. Although this is only one report, it suggests that the expression of
RhoG in breast cancer results in a more aggressive phenotype and poor outcomes. One
possible way that RhoG may enhance breast cancer progression and survival is by
protecting cells from anoikis caused by the loss of anchorage, through a PI3K-dependent
mechanism (Yamaki et al., 2007).
The Rnd Subfamily (Rnd1, Rnd2, Rnd3)
The Rnd proteins, Rnd1/Rho6, Rnd2, and Rnd3/Rho8/RhoE, comprise a distinct
branch of Rho-family G-proteins that lack intrinsic GTPase activity and consequently
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remain constitutively active.  While there are limited correlative or mechanistic data to
support a role of Rnd proteins in cancer, these proteins are likely to be important
mediators of oncogenesis.  Rnd1 overexpression has been observed in the same screen of
120 breast cancer tissues that identified RhoG (Jiang et al., 2003). In this study, Rnd1
expression was found to be higher in patients with recurrent disease or metastasis or who
died of breast cancer.  Rnd2 (Rho7) has not been linked to cancer; however the fact that it
can activate RhoA, which has been extensively shown to be an important signaling
molecule in cancer, suggests that its function may also be important in oncogenesis and
that it may represent another mechanism to block RhoA activity (Tanaka et al., 2006).
Finally, Rnd3 is overexpressed in NSCLC and is associated with worse overall survival
(Cuiyan et al., 2007; Zhang et al., 2007).
The Cdc42 Subfamily (pCdc42, bCdc42, TC10, and TCL)
Alternative gene splicing results in the expression of two 191 amino acid Cdc42
isoforms (Marks and Kwiatkowski, 1996):  the most commonly studied ubiquitous
Cdc42p (CDC42Hs) isoform isolated originally from placenta (Shinjo et al., 1990) and
the brain-specific Cdc42b (G25K) isoform (Munemitsu et al., 1990). Cdc42p and Cdc42b
proteins are identical between residues 1–181, except for a conservative arginine to lysine
substitution at residue 163. The carboxyl-terminal 10 amino acids (181–191) are
completely different (Cdc42p: PKKSRRCVLL; Cdc42b: TQPKRKCCIF), except for the
Cys residue at 188 that is part of the CAAX motif.  To date no functional differences
have been observed between the two isoforms. Thus while most of the effort to unravel
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the role of Cdc42 in cancer has centered on Cdc42p, it is believed that Cdc42b will also
be an important target in cancer.
Although there is no evidence directly implicating TC10 in cancer, constitutively
active TC10 has been shown to synergize with activated Raf to transform NIH3T3 cells
and wild-type TC10 function is required for H-Ras transformation (Murphy et al., 1999).
These results suggest that while TC10 itself may not be aberrantly activated in cancer, its
function may be important in tumors dependent on activated Ras or Raf.  There are few
reports of the function of the closely related TCL (TC10-like) Rho family member, and
no reports that it is involved in oncogenesis. However, with its role in early endosome
trafficking and receptor internalization, it is plausible that dysregulation of TCL function
may be important for receptor tyrosine kinase-mediated oncogenesis (de Toledo et al.,
2003).  In support of this idea, there is extensive evidence that RTKs, such as EGFR, are
commonly mutated or aberrantly expressed in cancer, and emerging evidence suggests
their signaling through Rho proteins is critical for their function (Pandey et al., 2000;
Schiller, 2006).
Atypical Rho Family Members (RhoD, Rif, RhoH)
Even less is known about the role of RhoD, Rif/RhoF, and RhoH/TTF in cancer.  RhoD
has been shown to be an important downstream effector of PAR-1 receptor signaling
through Gα in cellular invasion (Nguyen et al., 2002).  Rif, a poorly characterized Rho
member known to induce filopodia formation, has been shown to have relatively higher
expression in lymphomas, although no functional role has been determined (Gouw et al.,
2005).  Lastly, the hematopoietic cell-specific RhoH is linked to lymphoma and multiple
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myeloma (Preudhomme et al., 2000).  The exact role of RhoH in this setting is unknown.
RhoH is known to form a fusion protein with LAZ3; however whether RhoH contributes
to the oncogenic function of this chimera remains unknown.  Suppression of RhoH using
shRNA increases cell proliferation, migration and survival of hematopoietic progenitor
cells, suggesting that RhoH is a tumor suppressor and leading to speculation that the
LAZ3 fusion protein abrogates RhoH function (Gu et al., 2005).
Rho GEFs and GAPs.
While aberrant Rho activation commonly occurs as detailed above, mutational
activation is an extremely rare event. Instead alterations in Rho protein levels through
changes in gene expression, as well as alterations of Rho GEFs and GAPs that control
Rho activation, have been observed. For example, activating point mutations in Dbl,
LARG, and Tiam1 have been described (Bi et al., 2001; Chikumi et al., 2004; van
Leeuwen et al., 1995).   Similar to Rho proteins, expression of these regulatory proteins
can also be misregulated.  Overexpression of the Rac GEF Vav-1 occurs in pancreatic
cancer and neuroblastoma, while β-PIX, another Rac GEF, is overexpressed in breast
cancer (Ahn et al., 2003; Fernandez-Zapico et al., 2005; Husain and Bamezai, 1989).
Additionally, Tiam1 has been shown to correlate with the metastatic potential of breast
cancer cell lines and Tiam -/- mice are resistant to Ras-induced skin tumors ultimately
leading to identification of Tiam1 as a downstream effector of Ras (Lambert et al., 2002;
Malliri et al., 2002; Minard et al., 2004).  As mentioned, a third mechanism of
dysregulated Rho GEF activity is by the aberrant activation of RTKs (Schiller, 2006).
Finally, loss of expression of Rho GAPs have begun to be described and it is likely that
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this will represent another critical mechanism of aberrant Rho signaling (Ching et al.,
2003; Wolf et al., 2003; Wong et al., 2003).
G. Targeting CAAX-signaled modifications: FTase/GGTase, Rce1 and Icmt.
There are a large number of proteins that terminate in a carboxyl-terminal CAAX
motif important for signaling a series of post-translational modifications, which are
important for membrane localization as well as other postulated functions (Figure 7)
(Basso et al., 2006).  This series of modifications is initiated by enzymes that recognize
the carboxyl-terminal CAAX tetrapeptide (C = cysteine, A = aliphatic amino acid, and X
= terminal amino acid) motif, as mentioned above. The first step is catalyzed by one of
the cytosolic prenyltransferase enzymes, farnesyltransferase (FTase) or
geranylgeranyltransferase I (GGTase), and results in the covalent addition of a farnesyl or
geranylgeranyl isoprenoid lipid to the cysteine residue of the CAAX sequence.  Next, the
AAX peptide is cleaved by the Ras converting enzyme 1 (Rce1) endoprotease. Finally,
isoprenylcysteine-O-carboxyl methyltransferase (Icmt) covalently attaches a methyl
group to the farnesylated cysteine residue (Sebti and Der, 2003; Winter-Vann and Casey,
2005). Both Rce1 and Icmt are associated with the endoplasmic reticulum. With the
overwhelming evidence involving Ras and Rho proteins in cancer, coupled with the fact
that they possess a CAAX motif, great effort has been put forth to understand the
importance of these modifications for their function in hopes that it may be translated into
effective anti-cancer treatments.
Using Ras as the prototype substrate for these evaluations, it has been determined
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Figure 7. Post-translational processing of Ras GTPases. Normal Ras processing -
Under normal physiological conditions Ras undergoes three CAAX-motif signaled post-
translational modifications catalyzed by the cytosolic farnesyltransferase (FTase), which
catalyzes covalent addition of the C15 farnesyl isoprenoid.  This modification is followed
by reactions catalyzed by the endoplasmic reticulum (ER)-associated Ras converting
enzyme 1 (Rce1) endoprotease and isoprenylcysteine-O-carboxyl methyltransferase
(Icmt). The CAAX modifications, together with a second membrane-targeting signal
upstream of the CAAX motif (palmitoylated cysteines, for H-Ras, N-Ras and K-Ras4A;
lysine-rich sequence, for K-Ras4B) cooperate to target GTPases to the membrane.
Alternative K/N-Ras processing - When FTase activity is blocked by farnesyltransferase
inhibitors (FTIs), N-Ras and K-Ras (the Ras isoforms most commonly mutated in cancer)
undergo alternative prenylation by the related enzyme geranylgeranyltransferase I
(GGTase-I), which adds the more hydrophobic C20 geranylgeranyl isoprenoid to the
cysteine residue of the CAAX motif.  Since alternatively prenylated Ras retains normal
membrane association and function, FTIs fail to block the function of these Ras isoforms.
H-Ras does not undergo alternative prenylation, and consequently, its function is
effectively blocked by FTI treatment.
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 that each modification is important for increasing Ras affinity for membranes, and
inhibition of the initial CAAX-signaled processing step (farnesylation) has been shown to
inhibit all subsequent steps. With this knowledge, drug discovery efforts have focused on
the development of FTase inhibitors (FTIs) in hopes that they would render Ras
completely cytosolic and inactive. While FTIs have shown some success in treating
hematologic cancers, their use as Ras inhibitors has been complicated by the fact that K-
Ras and N-Ras (the Ras isoforms commonly mutated in cancer) undergo alternative
prenylation by the related enzyme, geranylgeranyltransferase I (GGTase-I), when FTase
activity is inhibited by FTIs (Figure 5) (Rowinsky, 2006; Sebti and Der, 2003). Hence, in
contrast to popular perception, FTIs are not effective inhibitors of Ras function.
Nevertheless, while FTIs are no longer considered Ras inhibitors (except for H-Ras), they
have continued to progress through preclinical and clinical development, and preclinical
studies are focused on identifying the true targets that contribute to the anti-tumor
activities of FTIs, such as the Rho family proteins described above. To date, many potent
and specific FTIs have been developed, with SCH-66336 (lonafarnib; Sarasar) and
R115777 (tipifarnib; Zarnestra) the most advanced and currently in phase II/III clinical
trials for hematologic and other cancers (Lancet et al., 2006).
Currently, the physiologically important downstream targets of FTIs remain
unidentified.  However, several of the Rho family members are potential targets for these
compounds.  Previous characterization of the canonical Rho proteins has shown they are
substrates for GGTase-I and not FTase (Michaelson et al., 2005).  As discussed in
Chapter 3, we have determined the prenyltransferase specificity of many of the non-
classical Rho proteins.  This analysis has revealed that many of the Rho family members
55
are potential candidate targets of FTI inhibition.   This is an exciting observation, in light
of the fact that Rho proteins are critical mediators of oncogenesis in solid tumors, as
mentioned above, coupled with the fact that preclinical analysis showed that FTIs were
effective in multiple solid tumor models (Basso et al., 2006).  The identification of the
FTI target(s) in these models may allow us to revisit the use of FTIs in solid tumors by
allowing us to selectively enrich our patient population with patients whose tumors show
dependence on the target.  Additionally, studies to evaluate the expression and activation
of Rho proteins in patient samples from the phase II/III clinical trials may be useful in
identifying Rho proteins as markers of response in the subset of patients that received
benefit.
With a growing list of GGTase substrates and evidence for their involvement in
cancer invasion, metastasis, and angiogenesis (i.e. RhoA, Rac1, and Cdc42), GGTase
inhibitors are now being developed (Bryan and D'Amore, 2007; Philips and Cox, 2007;
Ridley, 2004).  Preclinical evaluation of these compounds has shown their ability to
block tumor growth in vivo and has shown that they exhibit growth arrest and apoptotic
properties not seen with FTIs.  Similar to the development of FTIs, the critically
important downstream target(s) of GGTIs have not been identified.  Based on our
experience with the development of FTIs and our knowledge of tumor heterogeneity
between and within patients, it is likely that only a subset of patients will benefit from
GGTI inhibitors.  As such, the identification of the true GGTI target(s) will be critical for
their successful development and highlights the importance of our efforts to understand
prenyl and post-prenyl processing of Rho proteins.
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In addition to prenyltransferase inhibitors, Rce1- and Icmt-mediated post-prenyl
processing is under evaluation for their importance as novel therapeutic targets.  One key
area of investigation is the determination of whether these modifications are required for
proper localization and function of CAAX-terminating proteins such as the Ras and Rho
family GTPases.  To address this need and further our understanding, we have used
genetic and pharmacologic approaches to determine the requirement of Rce1 and Icmt for
Ras and Rho proteins, as detailed in Chapters 2 and 3.
Initial evaluation of the importance of each of the three post-translational
modifications of Ras concluded that inhibition of AAX proteolysis or carboxyl
methylation was not sufficient to fully block Ras transformation and thus attention was
focused on developing inhibitors of FTase (Cox and Der, 2002a). However, with the
realization that FTIs are not effective anti-Ras drugs, coupled with their limited success
in treating solid tumors, attention has shifted back to evaluating Rce1 and Icmt as targets
for inhibiting Ras membrane association and localization (Clarke and Tamanoi, 2004;
Winter-Vann and Casey, 2005).
Studies by Young, Casey and colleagues found that conditional deletion of either
Rce1 or Icmt in fibroblasts derived from Rce1- or Icmt-deficient mouse embryos (MEFs)
impaired their sensitivity to K-Ras-mediated transformation. Although knockout of Rce1
or Icmt function was critical for mouse development, lack of Rce1 or Icmt expression
was not essential for the growth of adult tissue or for MEFs in cell culture (Bergo et al.,
2000; Kim et al., 1999). When mutated K-Ras(12V) was expressed ectopically in
fibroblasts isolated from Rce1- or Icmt-deficient mouse embryos, K-Ras membrane
association was partially impaired, Ras activation of ERK was reduced, and Ras-
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mediated growth transformation was impaired (Bergo et al., 2002; Bergo et al., 2004;
Bergo et al., 2001).
Further evidence for the importance of Icmt in Ras transformation came from
studies by Casey and colleagues, who found that the anti-neoplastic drug methotrexate,
an inhibitor of DNA synthesis, may also act, in part, by inhibition of Icmt to block Ras
transformation (Winter-Vann et al., 2003). Furthermore, this group recently reported the
identification of a selective small-molecule inhibitor of Icmt, 2-[5-(3-methylphenyl)-1-
octyl-1H-indol-3-yl]acetamide (cysmethynil) (Winter-Vann and Casey, 2005). Early
preclinical evaluation indicated that cysmethynil treatment inhibited cell growth in an
Icmt-dependent fashion, resulted in cytosolic mislocalization of Ras proteins in MDCK
cells and blocked EGFR-mediated signaling. In addition, cysmethynil treatment was
shown to inhibit anchorage-independent growth of DKOB8 cells (Winter-Vann and
Casey, 2005).   While these results are intriguing, further validation of Icmt as a drug
target and characterization of cysmethynil in a more relevant model system is needed.
To address this need we have used genetic and pharmacologic approaches to disrupt Icmt
function in K-Ras-mutant NSCLC cells (see Chapter 2).
An obvious concern with Rce1 and Icmt inhibitors is the fact that the number of
substrates for these enzymes is extensive, with several hundred CAAX-terminating
proteins that are known or putative substrates for FTase or GGTase-I (Reid et al., 2004).
However, the fact that a number of these CAAX-terminating proteins also display
functions in oncogenesis (e.g., Rheb, Ral, RhoC, Rac1b) suggests that their multi-
targeted actions may also be advantageous for cancer treatment. However, it is possible
that Icmt-mediated methylation may be critical only for the function of farnesylated
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proteins, thus greatly reducing the number of potential targets for Icmt inhibitors
(Michaelson et al., 2005).  Finally, Icmt-mediated methylation is also needed for the
function of a subset of Rab family small GTPases, regulators of vesicular trafficking
(Leung et al., 2006), thus expanding the candidate targets for Icmt inhibitors beyond
CAAX-terminating proteins. Some Rab proteins have also been implicated in
oncogenesis (Cheng et al., 2005).   The requirement for these modifications in the proper
localization and function of these proteins is currently poorly understood, thus stressing
the need for our studies to further understand the role of Icmt methylation so that we can
determine potential targets and identify potential mechanisms of toxicity.
H Biomarkers: verifying target inhibition and predicting patient response
The important issues that MAPK drug discovery faces are those that have
accompanied the new era of target-based anti-cancer drug discovery. Historically,
oncology drug development has focused on determining the maximum tolerated dose
(MTD), safety profile, and efficacy of a compound, while mechanistic studies and efforts
to pre-select responders were almost never undertaken. In fact the mechanisms of action
that account for the anti-tumor activity of many of our commonly used chemotherapeutic
agents used today are still poorly understood. However, with an ever-growing
understanding of cancer biology, new targeted-based or mechanism-based therapies are
making their way into the clinic. These compounds differ greatly from the majority of the
conventional cytotoxic anti-neoplastic drugs in that they are rationally designed to
mechanistically inhibit a particular protein target that is hypothesized to be critical for
cancer growth and progression. While these novel agents offer great promise for
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significant improvements in cancer chemotherapy, they have also brought researchers
and clinicians several new challenges and issues for drug discovery. First, the
identification of useful and predictive biomarkers has become an important endeavor.
The development of methodology to accurately verify that a targeted-therapy is actually
blocking the function of its target is crucial for effective clinical evaluation. If the
compound efficiently inhibits the target but has no clinical response, then it allows
researchers to conclude that the target is not important for that particular cancer. For
example, will a reduction in ERK activation be a reliable marker for monitoring the
effectiveness of inhibitors of Raf or MEK to block target function?  Will ERK inhibition
correlate with patient response?
A related issue involves the tissue source for monitoring drug action. The most
direct and relevant measure of target inhibition is to use pre- and post-treatment tumor
samples to measure the biomarker of interest. The obvious limitation of this approach is
that tumor tissue is not readily accessible in many types of cancer and putting patients
through multiple biopsies is not reasonable. Therefore, other methods to measure target
inhibition have been devised and include the use of surrogate tissues such as peripheral
blood mononuclear cells (PBMCs), skin, and buccal mucosa (Parulekar and Eisenhauer,
2004). However, while feasible, whether drug inhibition in the surrogate tissue accurately
reflects drug activity in the tumor remains an important unresolved issue.
A second crucial issue is the identification of genetic or biochemical markers that
define the patient population that will respond to inhibitor treatment. Despite their target-
based development, patient response to signal transduction inhibitors remains
disappointingly poor and modest. For example, EGFR is overexpressed in 50-80% of
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NSCLCs, yet initial clinical trials evaluating EGFR TKIs found only a 10% response
rate. Furthermore, early correlative studies were unable to establish a positive correlation
between phospho-EGFR immunohistochemistry and response, thus complicating our
ability to predict which patients will respond. Eventually, retrospective analysis revealed
the presence of EGFR mutations in the majority of responders, thus identifying a
molecular marker with a high predictive value of response (Lynch et al., 2004). However,
more recent analyses have found that EGFR mutation status may not be as strongly
associated with patient response as initially believed 17045403 (Jimeno and Hidalgo,
2006).  Additionally, repeated studies have shown that patients with K-Ras mutations are
resistant to EGFR inhibition in both single agent and combined therapy regimens
(Eberhard et al., 2005; Pao et al., 2005). To further complicate patient selection, recent
correlative analysis suggests that in addition to EGFR/K-Ras mutational analysis, EGFR
gene amplification and protein expression may also serve as important molecular markers
(Cappuzzo et al., 2005). Specifically, EGFR mutations may be predictive of response
while EGFR gene amplification and protein expression may be better markers of
survival. An important direction in this area of research is the determination of gene array
profiles that may be more effective at predicting patient response to a particular drug.  In
light of these issues we have employed the use of tissue microarray of 169 NSCLC
patients to identify the clinicopathologic features associated with ERK activation in order
to identify patients most likely to respond to Raf and MEK inhibitors (Chapter 4).
Finally, since the successful application of Raf or MEK inhibitors will almost
certainly require their use in combination with other drugs, what other signaling
inhibitors or conventional cytotoxic drugs should be used?  Since the potential
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combinations are daunting, effective preclinical analyses are needed to better focus
clinical trial design. Will our current preclinical cell culture or mouse models allow
reliable determination of the best combination approaches?  Although still the standard of
the pharmaceutical industry, the value of human tumor xenograft mouse models in
predicting drug activity in the patient remains a hotly debated issue (Sausville and
Burger, 2006). While the new generation of genetically-engineered mouse models is
optimistically believed to provide more accurate systems for anti-cancer agent evaluation,
this remains to be validated (Sharpless and Depinho, 2006). With limited patient
populations for phase I/II clinical trials, and limited research and development budgets,
this remains an important limitation in anti-cancer drug discovery.
I.  Scope of current work.
Ras and Rho GTPases are critical mediators of oncogenesis and warrant
considerable effort to develop novel inhibitors to abrogate their aberrant signaling.  Two
approaches under consideration are to block the CAAX-signaled modifications important
for their subcellular localization or alternatively to develop inhibitors of their downstream
effectors such as the ERK MAPK pathway.  In the present work we have extended
previous analysis and validated the requirement of Icmt function in Ras-mediated
NSCLC.  Furthermore, with the mounting evidence that the non-classical Rho proteins
are involved in cancer, we have evaluated the importance of the three CAAX-signaled
modifications for Rho family localization and discovered that FTase, Rce1, and Icmt are
all potential candidate targets with which to block Rho function. Finally, in light of
extensive evidence that Ras utilizes different effector pathways in a tumor type specific
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fashion, we have determined that the Raf-MEK-ERK pathway is critical for
transformation in Ras-mutant NSCLC.
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Chapter 2
Targeting isoprenylcysteine-O-carboxyl methyltransferase
for the treatment of non-small cell lung cancer.
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A. Abstract
The Ras signaling pathway is activated in over 50% of all non-small cell lung
carcinomas (NSCLCs), making it an attractive candidate for target-based anti-cancer drug
development. One promising approach has been to disrupt the Ras C-terminal CAAX
tetrapeptide-signaled posttranslational modifications that are essential for Ras membrane
localization and oncogenesis.  Specifically, farnesyltransferase inhibitors (FTIs) that block
the CAAX-signaled lipid addition essential for Ras plasma membrane association and
transforming ability have been developed and have entered clinical trials.  While FTIs have
shown some success in treating cancer, their use as Ras inhibitors has been plagued by the
fact that K-Ras and N-Ras (the most common Ras isoforms mutated in cancer) undergo
alternative prenylation by geranylgeranyltransferase I when in the presence of FTIs.
Therefore, attention has shifted to the development of inhibitors of two other enzymes
involved in promoting Ras membrane association, Rce1 and Icmt, as promising targets for
inhibiting Ras-mediated oncogenesis.  In this study, we used genetic and pharmacologic
approaches to determine the consequence of impaired Icmt function on Ras-mediated
oncogenesis in NSCLC.  We found that Icmt function is more critical for Ras membrane
localization and transforming activity in epithelial cells compared to fibroblasts. In addition,
we found that stable expression of Icmt shRNA inhibited NSCLC anchorage independent
growth and led to reduced tumor volume in mouse xenografts. Finally, treatment with
cysmethynil, a novel Icmt small-molecule inhibitor, greatly impaired anchorage independent
growth of NSCLC cell lines.  Together these results further validate Icmt as a novel target for
the treatment of NSCLC.
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B. Introduction
Mutational activation of the K-Ras proto-oncogene occurs in approximately 20-30%
of all non-small cell lung carcinomas (NSCLC). The Ras signaling pathway can also be
activated by perturbation of components upstream or downstream of Ras itself. In addition to
aberrant overexpression, mutational activation of the epidermal growth factor receptor
(EGFR) tyrosine kinase is found in 10% of NSCLCs (Lynch et al., 2004). One key
cytoplasmic signaling pathway stimulated by the EGFR receptor is activation of Ras.
Mutational activation of the Ras effector BRAF, a serine/threonine kinase, is also seen in 3%
of NSCLC (Davies et al., 2002).  BRAF activates MEK and MEK activates the ERK
mitogen-activated protein kinases (MAPK).  Taken together, the combined frequency of
mutations in the EGFR-Ras-Raf-MEK-ERK pathway accounts for approximately 40% of all
NSCLCs.
The frequent mutational activation of the Ras signaling cascade in NSCLC, together
with frequent development of lung tumors in a K-Ras activation mouse model (Johnson et
al., 2001), validates this pathway for targeted therapy of NSCLC.  However, despite intense
efforts to develop anti-Ras inhibitors (Cox and Der, 2002; Downward, 2003), currently no
effective approaches have successfully made it to the clinic.  One approach that has been
explored intensively involves the development of inhibitors of Ras membrane association
(Basso et al., 2006); (Rowinsky, 2006).  For proper signaling, Ras proteins must be localized
to the inner surface of the plasma membrane where they interact with upstream activators
(receptor tyrosine kinases) and downstream effectors. Ras proteins are synthesized as
inactive, cytosolic proteins that quickly undergo a series of post-translational modifications,
which targets Ras to the plasma membrane. This series of modifications is initiated by
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enzymes that recognize the Ras carboxyl-terminal CAAX tetrapeptide (C = cysteine, A =
aliphatic amino acid, and X = terminal amino acid) motif. The first step is catalyzed by the
cytosolic farnesyltransferase (FTase) enzyme and results in the covalent addition of a
farnesyl isoprenoid lipid to the cysteine residue of the CAAX sequence. Next, the AAX
peptide is cleaved by the Ras converting enzyme 1 (Rce1) endoprotease. Finally,
isoprenylcysteine-O-carboxyl methyltransferase (Icmt) catalyzes covalently attachment of a
methyl group to the farnesylated cysteine residue (Sebti and Der, 2003). Both Rce1 and Icmt
are associated with the endoplasmic reticulum.
Each CAAX-signaled modification is important for increasing Ras affinity for
membranes and inhibition of the initial CAAX-signaled processing step (farnesylation) has
been shown to inhibit all subsequent steps. Therefore, much of the previous research has
focused on the development of FTase inhibitors (FTIs). While FTIs have shown some
success in treating hematologic cancers, their use as Ras inhibitors has been complicated by
the fact that K-Ras and N-Ras (the Ras isoforms commonly mutated in cancer) undergo
alternative prenylation by a related enzyme, geranylgeranyltransferase I (GGTaseI), when
FTase activity is inhibited by FTIs (Rowinsky, 2006; Sebti and Der, 2003).  Hence, FTIs
are not effective inhibitors of K-Ras function.
Inhibitors of the other CAAX-signaled modifications have also been considered for
anti-Ras inhibitors (Clarke and Tamanoi, 2004); (Winter-Vann and Casey, 2005).  However,
initial evaluation of the importance of each of the three post-translational modifications of
Ras concluded that inhibition of AAX proteolysis or carboxyl methylation was not sufficient
to fully block Ras transformation (Kato et al., 1992).  However, recent studies support further
merit in considering Rce1 and Icmt as targets for inhibiting Ras membrane association and
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localization. When mutated K-Ras(12V) was expressed ectopically in fibroblasts derived
from Rce1- or Icmt-deficient mouse embryos, K-Ras membrane association was partially
impaired, Ras activation of ERK was reduced, and Ras-mediated growth transformation was
impaired  (Bergo et al., 2001); (Bergo et al., 2002); (Bergo et al., 2004).
Further evidence for the importance of Icmt in Ras transformation came from studies
by Casey and colleagues, who found that the anti-neoplastic drug methotrexate, an inhibitor
of DNA synthesis, may also act, in part, by inhibition of Icmt to block Ras transformation
(Winter-Vann et al., 2003). Furthermore, this group reported the identification of a selective
small-molecule inhibitor of Icmt, 2-[5-(3-methylphenyl)-1-octyl-1H-indol-3-yl]acetamide
(cysmethynil) (Winter-Vann and Casey, 2005). Early preclinical evaluation indicated that
cysmethynil treatment inhibited cell growth in an Icmt-dependent fashion, resulted in
cytosolic mislocalization of ectopically-expressed green fluorescent protein tagged K-Ras
proteins in MDCK cells and blocked EGFR-mediated signaling. In addition, cysmethynil
treatment was shown to inhibit anchorage-independent growth of the K-Ras mutation
positive DLD-1 human colorectal carcinoma cell line (Winter-Vann and Casey, 2005).
While recent observations provide promising support for Rce1 and Icmt as possible
targets for anti-Ras drug discovery, the current biological studies have been limited primarily
to ectopic expression of mutated K-Ras in rodent fibroblasts. Recent studies have shown that
Ras exhibits species and cell type differences in mechanisms of transformation (Repasky et
al., 2004). In particular, differences in Ras transformation of rodent versus human cells, and
in fibroblast versus epithelial cells, have been observed. Furthermore, the consequences of
ectopic versus endogenous expression of activated K-Ras have been found to be different.
Hence, to critically evaluate the therapeutic value of targeting Icmt for NSCLC treatment, we
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have utilized genetic and pharmacologic approaches to assess the importance of Icmt
function in the growth of K-Ras mutation positive NSCLCs.  First, we determined that a
mutant of K-Ras(12V) deficient in both the Rce1 and Icmt modifications showed a more
drastic impairment in transforming activity when evaluated in RIE-1 epithelial cells.  Second,
interfering RNA suppression of Icmt expression impaired the transformed and tumorigenic
growth of K-Ras mutation positive A549 NSCLC cell line.  Finally, we found that the
anchorage-independent growth of NSCLC cell lines was highly sensitive to cysmethynil
treatment. Taken together, these observations support the therapeutic value of Icmt inhibitors
for the treatment of NSCLCs.
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C. Materials and Methods
Retrovirus expression and interfering RNA vectors.  pZIP-NeoSV(x)1 retrovirus
expression vectors encoding mutationally activated K-Ras4B(12V) proteins were described
previously (Kato et al., 1992). Using the OligoEngine RNA design software program three
distinct sequences for ICMT were identified, which by BLAST analysis should not interfere
with other genes. The following shRNA forward primers targeting Icmt mRNA sequences
start ing at  posit ions 353 (#3),  552 (#5) and 668 (#6) were
GATCCCCGTCTGTCCTTGGATTCCTTTTCAAGAGAAAGGAATCCAAGGACA
GACTTTTA, GATCCCCTTTCAACCACGTGGTACAGTTCAAGAGACTGTACCACGTGGTT
GAAATTTTA, and GATCCCCCTCAGGTGATGCTGTGTAATTCAAGAGATTACACAGCAT
CACCTGAGTTTTA, respectively.
For generation of infectious virus, HEK 293-T cells were seeded into collagen coated
T-25 cm2 flasks at 1.5 x 106 cells per flask on day one.  On day two, HEK 293-T cells were
transfected by calcium phosphate precipitation (pVPack-Gag/Pol 3 µg, pVPack-Ampho 3
µg, pSUPER.retro-puro ICMT shRNA), in Hank’s buffered saline (0.9 ml) and 1.25 M
CaCl2 0.1 ml. After 10 min incubation to allow DNA to precipitate, DNA was added to 4 mls
of media containing 25 µM chloroquine and then added to the cells.  Cells were incubated
with DNA for 6 h and then fed with 4 mls of growth media.  On day three target cells (i.e.
HBECs or A549 cells) were seeded at 1 x 105 cells per T-25 cm2 flask.  Cells are allowed to
recover for 24 h and then selection with growth media supplemented with puromycin is
initiated.   Mass populations of drug-resistance colonies were then pooled to establish stable
cell populations for analyses.
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Cell culture and transformation assays.  RIE-1 rat intestinal epithelial cells were obtained
from Robert Coffey (Vanderbilt) and maintained in Dulbecco’s minimum essential medium
(DMEM; Sigma-Aldrich, St. Louis MO) supplemented with 5% fetal calf serum (FCS).  The
A549 NCI-H1703, NCI-H23, and NCI-H727 NSCLC cell lines was acquired from ATCC
and maintain in growth media as recommended by ATCC. COS-1 cells were cultured in
DMEM supplemented with 10% FCS. HBECs (human bronchial epithelial cells) were
grown in BEGM medium. HEK (Human Embryonic Kidney) 293-T cells used for retroviral
infections were grown in DMEM-H supplemented with 10% FCS.  Ras-induced focus
formation analyses were done as described previously (Oldham et al., 1996). The Icmt
inhibitor, cysmethynil, was received from Dr. Patrick Casey of Duke University and has
previously been shown to be a specific inhibitor of Icmt methyltransferase activity {Winter-
Vann, 2005 #164}.
To evaluate the consequences of genetic or pharmacologic inhibition of Icmt on the
anchorage-dependent growth of A549 cells, we utilized an assay based on the ability of
viable cells to stimulate cleavage of the tetrazolium salt WST-1 producing a soluble
formazan salt.  Five x 103 cells per well were grown in a 96-well tissue culture plate for 48 h
in 200 ul of growth medium supplemented with the indicated amount of pharmacologic
inhibitor.  Following the 48 h incubation with the inhibitor, cells were incubated with 20 ul
of WST-1 for approximately 4 h. After this incubation period, the formazan dye formed was
quantitated using a scanning multi-well spectrophotometer (ELISA reader). The absorbance
revealed directly correlated to the cell number.
To determine the consequences of genetic or pharmacologic inhibition of Icmt on the
anchorage-independent growth of NSCLCs, single cell suspensions were made in growth
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media supplemented with 0.4% agar and plated over a 0.6% agar bottom layer. A total of 104
cells per well were seeded in triplicate into 6-well plates.  Clusters of cells consisting of
greater than 10 cells was considered a colony for quantification and 5 independent fields
within each 6-well was used to calculate an average number of colonies per field.
For analyses of the consequences of Icmt suppression on A549 tumorigenicity, 106
A549 cells were injected subcutaneously into the flanks of 5 to 6 week old nude mice.
Tumor formation was monitored daily for up to 3 months. Mice were monitored for tumor
formation for up to 18 days, with tumor size determined on the indicated days by the
formula for volume (V) an ellipsoid V=4/3π(L/2)(W/2)(D/2), where L, W, and D are
diameter measurements of the length, width, and depth of the tumor.
Western blot analyses. Anti-GFP antibody (BD Living Colors JL-8) was obtained from
Clontech  (#632381; Mountain View, CA).  Anti-β-actin (clone AC-15) was obtained from
Sigma-Aldrich  (#A5441; St. Louis MO). SDS-polyacrylamide gel electrophoresis (PAGE)
was performed to separate proteins from cell lysates. Proteins separated by SDS-PAGE were
transferred electrophoretically onto nitrocellulose membranes. For antibody detection assays,
nitrocellulose membranes were incubated for 1 h at room temperature in blocking buffer
(Tris-buffered saline [TBS], pH 7.4, with 0.1% Tween-20 [TBST] containing 5% skim milk
powder), washed three times with TBST, and incubated at 40C overnight in TBST with 5%
BSA and indicated with antibody at a1:1000 dilution. After washing three times with TBST,
membranes were incubated for 1 h with horseradish peroxidase–conjugated secondary
antibody (anti-mouse IgG, 1:5,000 dilution or anti-rabbit IgG, 1:5,000 dilution [Amersham
Biosciences; Buckinghamshire, England]) in blocking buffer. Membranes were then washed
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three times with TBST. Bound antibodies were detected by enhanced chemiluminescence
(Amersham).
Transfection and Microscopy. For live cell microscopy, cells were plated, transfected, and
imaged in the same 35 mm culture dish that incorporated a No. 1.5 glass coverslip-sealed 15
mm cut-out on the bottom (MatTek, Ashland, MA). DNA transfections were performed with
LipofectAMINE Plus according to the manufacturer's instructions (Invitrogen, Carlsbad,
CA).  Three h after transfection, cells were washed and grown in phenol red-free DMEM/F-
12 supplemented with 10% calf serum.
For live cell imaging studies, cells were examined with an inverted laser scanning
confocal microscope (Zeiss 510 LSM; Zeiss) using an oil immersion 63x NA 1.4 objective.
Images were captured by scanning with the 488 nM spectral line of an argon-ion laser using
the BP 505-530 emission filter (for live cell imaging; GFP). Brightness and contrast of JPEG
images were adjusted using Adobe Photoshop CS2 software.
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D. Results
A K-Ras12V CAAX variant that does not undergo AAX proteolysis and carboxyl
methylation has impaired plasma membrane localization and growth transformation in
epithelial cells. We previously described the generation of a CAAX mutant of K-
Ras4B(12V), K-Ras(12V)-CVYM, that is farnesylated, but is impaired in Rce1- and Icmt-
mediated processing (Kato et al., 1992). When expressed in NIH 3T3 mouse fibroblasts, K-
Ras(12V)-CVYM exhibited 55% of the transforming activity of the K-Ras(12V) wild-type
CAAX protein and 50% impaired plasma membrane association.  This limited reduction in
K-Ras transforming potency prompted our conclusion that inhibition of Rce1 and Icmt will
not be an effective approach for blocking K-Ras oncogenic activity.  Since the time that those
studies were performed, it has become evident that Ras transformation exhibits significant
cell type differences, in particular, when evaluated in epithelial cells, the cell type from
which the majority of KRAS mutation positive cancers arise.  Therefore, we speculated that
the transforming ability of the K-Ras(12V)-CVYM mutant might be further reduced when
evaluated in epithelial cells. To evaluate this possibility, we evaluated the transforming
activity of K-Ras(12V)-CVYM in RIE-1 rat intestinal epithelial cells, a well-characterized
epithelial model cell system that we and others have utilized to demonstrate cell type
differences in Ras-mediated transformation.
First, we compared the subcellular location of K-Ras(12V) in mouse embryo
fibroblasts that are deficient in either Rce1 or Icmt activity.  Similar to previous observations,
we found that K-Ras(12V) plasma membrane association was partially impaired and similar
with both deficiencies, indicating that Icmt deficiency is the primary basis for the altered
properties of the K-Ras(12V)-CVYM mutant (data not shown, see chapter 3).  Second, we
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evaluated the membrane localization of K-Ras(12V) and K-Ras(12V)-CVYM in two
different epithelial cell types.  For comparison, we also included the analysis of a second
CAAX mutant, K-Ras(12V)-CVIR, that is impaired in farnesylation, as well as Rce1- and
Icmt-mediated processing. K-Ras(12V)-CVIR is completely impaired in transforming
activity when evaluated in NIH 3T3 cells.  Green fluorescent protein-tagged fusion proteins
of the three K-Ras(12V) proteins were transiently expressed in Cos-1 and human bronchial
epithelial cells (HBECs).  We observed that K-Ras(12V) displayed complete plasma
membrane association, whereas K-Ras(12V)-CVYM retained partial membrane localization,
and K-Ras(12V)-CVIR was completely mislocalized (Figure 1). Thus, similar to fibroblasts,
the lack of the Icmt-catalyzed modification causes significant, but incomplete, impairment of
K-Ras plasma membrane association.
Third, we established mass populations of RIE-1 cells stably expressing K-Ras(12V),
K-Ras (12V)-CVIR,  and K-Ras(12V)-CVYM.  As expected, whereas K-Ras(12V) showed
potent focus-forming activity, K-Ras(12V)-CVIR was completely inactive.  Surprisingly, K-
Ras(12V)-CVYM showed a near-complete loss of transforming activity when evaluated in
RIE-1 rat intestinal epithelial cells compared to the 55% relative transforming activity
previously seen in mouse fibroblasts with this same K-Ras(12V)-CAAX mutant (Figure 2).
These results suggest that blocking Icmt activity will greatly impair Ras transforming activity
in some cell types, in particular epithelial cells.
Genetic inhibition of Icmt blocks transformation of K-Ras mutation positive NSCLC cells.
While the use of conditional deletion of Icmt in mouse embryo fibroblasts has provided a
powerful cell system to evaluate the importance of carboxyl methylation in K-Ras-mediated
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Figure 2.  Reduced transforming activity of K-Ras(12V) mutant proteins impaired in
CAAX-signaled posttranslational modifications. (A) An AAX cleavage and carboxyl
methylation-deficient mutant of K-Ras4B(12V) shows impaired transforming activity.
Primary focus formation assay of RIE-1 cells transfected with empty vector, K-Ras(12V)
wild-type CAAX (CVIM), or variant CAAX (CVYM or CVIR).  Subconfluent cultures of
RIE-1 cells were transfected with the empty pZIP-NeoSV(x)1 retrovirus expression vector
DNA, or encoding the indicated K-Ras4B(12V) protein.  After 14 days, the cultures were
fixed and stained with crystal violet to allow better visualization of transformed foci.  (B)
Quantitation of data shown in panel A.  The average number of transformed foci formed per
duplicate dishes.  Data shown are representative of three independent experiments. (Courtesy
of Jim Madigan)
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transformation (Bergo et al., 2004), the further analyses of the consequences of Icmt
inhibition in human epithelial cell-derived cancer cells that harbor RAS mutations is a critical
step for further validation of Icmt as a drug target.  To accomplish this, we have taken an
interfering RNA approach to suppress Icmt expression in NSCLC tumor cells.
For these analyses, we first generated retrovirus vectors for expression of short hairpin
interfering RNA (shRNA) for specific silencing of endogenous human Icmt.  We identified
three distinct sequences for shRNA design and introduced these sequences into the
pSUPER.retro.puro retrovirus expression vector.  Since there are no commercially available
antibodies to detect endogenous Icmt protein expression, we utilized two approaches to
validate the effectiveness of shRNA suppression of Icmt expression. First, we evaluated the
ability of each pSUPER-Icmt shRNA construct to suppress expression from a co-transfected
plasmid vector encoding GFP-Icmt.  We found that cotransfection analysis in HEK 293T
cells showed that all three shRNA Icmt constructs significantly blocked exogenous
expression of GFP-Icmt in a dose-dependent manner, with Icmt shRNA-3 and Icmt shRNA-5
showing the strongest suppression (Figure 3).
Next, to validate the effectiveness of shRNA for suppression of endogenous Icmt
expression, we utilized the A549 NSCLC cell line.  We established mass populations of
A549 cells stable-infected with each of the three shRNAs as well as a pSUPER.retro vector
encoding shRNA targeting GFP as a negative control.  Cell lysates for the four resulting
A549 cell lines were then directly measured for endogenous Icmt catalytic activity using
BFC as the prenylcysteine substrate and measuring the incorporation of [3H] from
[3H]AdoMet (the biological methyl donor) (Winter-Vann et al., 2005).  This analysis showed
that Icmt shRNA-3 caused the most significant (64% reduction) stable suppression of Icmt
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catalytic activity (Figure 4).  Therefore, we utilized Icmt shRNA-3 for all subsequent
analyses.
We next determined whether suppression of Icmt activity altered the ability of A549
cells to proliferate in an anchorage-independent environment.  We compare the colony
forming activity of A549 cells with Icmt ShRNA-3 or with GFP shRNA when suspended in
soft agar.  Icmt suppression resulted in a 64% reduction in soft agar colony formation (p =
4.8 x 10-11)  (Figure 5A). In addition to a quantitative reduction in colony number, Icmt
suppression also reduced colony size (Figure 5B).
To further evaluate the importance of Icmt activity for A549 growth we compared the
ability of the Icmt shRNA-3 or GFP shRNA expressing A549 cell lines to form tumors when
inoculated subcutaneously into athymic nude mice.  One mouse of the eight total in the Icmt
shRNA cohort reached one cm3 three weeks before any other mice in either cohort.
Calculation of a z-score to measure the deviation from the mean tumor volume within the
Icmt shRNA cohort revealed that this tumor was greater than 2.25 standard deviations from
the mean.  In addition, this tumor was greater than three times larger than the next biggest
tumor in the cohort. Therefore, this mouse was deemed an outlier and was not included in
the final analysis.  Stable suppression of Icmt resulted in a 50% reduction in tumor volume
(p = 0.07) (Figure 6). Thus, while there was a trend for reduced tumor volume it was not
statistically significant.
Pharmacologic inhibition of Icmt impairs K-Ras-dependent growth of NSCLC.  Recently,
we described the identification of a novel indole-based cell permeable inhibitor of Icmt,
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Figure 3. Transient shRNA suppression of ectopically expressed GFP-Icmt. HEK293
cells were transiently co-transfected with pEGFP plasmid DNA encoding GFP-Icmt and the
indicated amount of empty pSUPER.retro.puro control or expressing shRNA targeting three
different Icmt sequences.  A pSUPER.retro.puro plasmid expressing shRNA targeting the
mutant K-Ras12V sequence was used as a negative control.  After 24 h, the cells were lysed
and used for immunoblot analyses with anti-GFP to monitor suppression of GFP-Icmt
expression.  Blot analysis with anti-β-actin was done to verify loading of equivalent total
protein.  Data shown are representative of 2 independent experiments.
Figure 4. Icmt shRNA stably-suppresses ICMT carboxyl methylation activity in A549
lung carcinoma cells. Mass populations of A549 cells stably expressing each of the three
Icmt shRNA constructs were harvested and cell membranes containing Icmt were collected
following cell lysis. Cells stably transfected with the GFP-shRNA was used as a negative
control to represent full methylation activity. Icmt activity was measured as the incorporation
of [3H] from[3H]AdoMet into the Icmt substrate BFC.  Data shown are representative of 3
independent experiments.  (Courtesy of Ian Cushman)
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Figure 5. Suppression of Icmt activity reduces the anchorage-independent growth of
A549 cells. A549 cells stably expressing GFP shRNA or Icmt shRNA were suspended in
growth medium supplemented with 0.6% agar at a density of 5 x 103 cells per well in 6-well
plates.  (A) Colonies were grown for six weeks and then the number of colonies formed was
counted.  Data shown are the average of triplicate wells. (B) Representative images of
colonies are shown to indicate the consequences of shRNA suppression of Icmt activity on
the number and size of soft agar colonies.  Data shown are representative of 3 independent
experiments.
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Figure 6. A549 tumor formation in athymic nude mice.  One x 106 A549 cells stably-
infected with pSUPER.retro.puro retrovirus vectors expressing the negative control GFP
shRNA (n = 8) and Icmt shRNA (n = 7) were injected subcutaneously into the flank region of
athymic nude mice. Mice were monitored for tumor formation for up to 18 days, with tumor
size determined on the indicated days by the formula for volume (V) an ellipsoid
V=4/3!(L/2)(W/2)(D/2), where L, W, and D are diameter measurements of the length, width,
and depth of the tumor.  Data shown represents the average tumor volume per cohort of mice
for each cell line.
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designated cysmethynil (Winter-Vann et al., 2005).  Our previous evaluation of cysmethynil
found that it inhibited cell growth in an Icmt-dependent fashion and impaired Ras membrane
association in mouse and canine cells.  To extend these analyses to NSCLCs, we performed
an initial dose response curve to evaluate the ability of cysmethynil treatment to impair the
anchorage-dependent growth of A549 cells.  After 48 h of treatment, all concentrations of
cysmethynil tested resulted in a statistically significant reduction in anchorage-dependent
growth as measured by the WST-1 assay, a colorimetric based assay that measures
mitochondrial respiration (Figure 7A).  At 30 µM, cysmethynil treatment reduced anchorage-
dependent growth by approximately 50%.  This result is similar to what we observed
previously, where treatment with 30 µM cysmethynil disrupted the membrane association of
K-Ras, but not of the Yes tyrosine kinase, suggesting that selective inhibition of Icmt is
achieved at this concentration.
We next evaluated the ability of cysmethynil treatment to impair the anchorage-
independent growth of A549 and two additional K-Ras mutation positive NSCLC cell lines
(NCI-H23 and NCI-H727) as well as one K-Ras wild-type cell line (NCI-H1703), Treatment
with cysmethynil significantly reduced soft agar colony formation in dose-dependent fashion
(Figure 7B). At the highest concentration (30 µM), cysmethynil completely abolished colony
formation of the A549, NCI-H23, and NCI-H1703 cell lines and greatly reduced the colony
formation of the NCI-H727 cell line.  These results suggest that NSCLC cells are dependent
on full Icmt activity for anchorage-independent growth.
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Figure 7. Cysmethynil inhibits anchorage-dependent and independent growth of
NSCLC cells.   (A) A549 cells were seeded into 96-well plates at a density of 5 x 103 cells
per well and treated with the indicated concentration of cysmethynil.  Following 48 h of
treatment cell viability was measured using the colorimetric WST-1 assay. (B) NSCLC cell
lines with (A549, H727, H23) and without (H1703) endogenous activating K-Ras mutations
were seeded at a density of 1.0-1.5 x 103 cells per well in growth medium supplemented with
0.6% agar and treated with the indicated concentration of cysmethynil or DMSO (Vehicle).
Colony formation was monitored for six weeks and then the number of colonies formed was
quantitated.
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E. Discussion
One approach to inhibit Ras-mediated oncogenesis has been to develop inhibitors that disrupt
the CAAX tetrapeptide-signaled posttranslational modifications that target Ras to the proper
subcellular compartment (Basso et al., 2006; Rowinsky, 2006).  While there is substantial
evidence that prenylation is critical for Ras localization and function, efforts to develop
inhibitors that block this modification have been met with unforeseen difficulties. Therefore,
recent attention has focused on the other CAAX signaled posttranslational modifications as
possible targets for novel anti-Ras therapies (Winter-Vann and Casey, 2005).  However
unlike prenylation, the functional consequence of impaired carboxyl methylation on Ras-
mediated oncogenesis is unclear. Previous studies are limited by their use of imperfect model
systems and nonspecific compounds with pleiotropic effects (Winter-Vann and Casey, 2005).
Therefore, we determined the therapeutic value of targeting Icmt-mediated methylation for
NSCLC treatment. Using shRNA to suppress Icmt expression in the A549 NSCLC cell line
blocked anchorage independent growth and led to reduced tumor volume in mouse
xenografts. Furthermore, treatment of NSCLC cell lines with cysmethynil, a novel Icmt-
specific small molecule inhibitor, significantly blocked anchorage independent growth.
These results indicate that Icmt function is critical for NSCLC growth and support further
development of Icmt inhibitors for the treatment of NSCLC.
As mentioned, previous studies evaluating the importance of Icmt function for
oncogenesis have been limited by the use of ectopic expression of mutant K-Ras in mouse
fibroblasts (Kato et al., 1992); (Bergo et al., 2004).  Using the same K-Ras(12V)-CVYM
mutant that does not undergo Rce1- and Icmt-mediated posttranslational modifications and
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has previously been shown to retain 55% transforming ability in NIH 3T3 mouse fibroblasts,
we found this mutant to have a much greater reduction in transforming ability in epithelial
cells. Thus in the more stringent epithelial model system full Ras processing is required for
oncogenic transformation. This provides further evidence of the vast differences between
fibroblast and epithelial model systems and highlights the need for more critical evaluation of
the importance of Icmt function for Ras mediated oncogenesis in more relevant model
systems. Additionally, this finding suggests that carboxyl methylation of K-Ras(12V) is
critical for Ras function which is somewhat surprising in light of the fact that our localization
analysis of the K-Ras(12V) CAAX mutants in Cos-1 and HBEC cells (two epithelial cell
systems) revealed the same degree of mislocalization as previously reported in NIH 3T3
mouse fibroblasts and Icmt -/- MEFs. One explanation for the discordance between the
impact on localization and function could be that methylation is important for functions other
than localization such as mediating protein-protein interactions (Chen et al., 2000; Fukada et
al., 1994; Maske et al., 2003; Parish et al., 1995).
Our initial studies evaluating the K-Ras(12V) CAAX mutants addressed the
consequence of impaired CAAX processing on Ras specifically.   To address the global
effect of impaired Icmt function in NSCLC we used stable expression of Icmt shRNA in the
A549 K-Ras mutation positive NSCLC cell line.  Although we only achieved a partial
reduction in Icmt activity as measured by the BFC assay, this correlated with a comparable
reduction in anchorage independent growth.  Furthermore, while we found a significant
effect on soft agar colony formation, results from the xenograft experiment were not
statistically significant although there was a trend towards reduced tumor volume in the Icmt
shRNA cohort.  It is possible that the remaining level of Icmt activity was sufficient for
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proper processing of CAAX-terminating proteins such as Ras.
Angiogenesis, the formation of new blood vessels, is a key event in the growth and
progression of cancer and several novel angiogenesis inhibitors have recently gained FDA
approval for the treatment of a variety of solid tumors, including NSCLC.  Our Icmt shRNA
data provides evidence that Icmt function is critical for the growth of the cancer cell itself but
does not address the importance of Icmt function for angiogenesis. There are several studies
where inhibition of Icmt activity had dramatic effects on endothelial cells such as altering
monolayer permeability, changing the organization of intracellular junctions, and increasing
apoptosis (Kramer et al., 2003; Lu et al., 2004; Wang et al., 1997).  Thus, while our analysis
is focused specifically on the cancer cell, findings of the importance of Icmt function on
endothelial cells suggest that novel therapeutics developed against Icmt may block cancer
progression by inhibiting the growth of the cancer cell and by blocking endothelial cell
function needed for angiogenesis. So while our xenograft analysis shows a trend towards
reduced tumor volume we feel that inhibition of Icmt by a small molecule inhibitor is likely
to have a more robust reduction in tumorgenesis.
Until recently, attempts to develop Icmt inhibitors have led to the development of two
classes of compounds both of which are competitive inhibitors of Icmt that mimic either Icmt
substrates or products (Winter-Vann and Casey, 2005).  Their use of these inhibitors has
strengthened the believe that Icmt function is critical for oncogenesis however this has been
tempered by the fact that the S-adenosylhomocysteine (AdoHcy) class blocks most cellular
methyltransferases and thus is not specific for Icmt.  In addition, derivatives of
prenylcysteine have been developed to competitively inhibit Icmt substrates but they too
have been shown to have other effects besides inhibiting Icmt function.  Recently,
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cysmethynil, a specific small molecule inhibitor of Icmt was described (Winter-Vann et al.,
2005).  Characterization of this compound has revealed that it is specific for Icmt as it did not
inhibit SssI DNA methyltransferase or PCMT1 proteins methyltransferase.  In addition,
inhibition of anchorage independent growth in cells treated with cysmethynil was rescued by
overexpression of Icmt providing further evidence of its specificity.  In the current analysis
we determined the ability of cysmethynil to block anchorage independent growth of 3
NSCLC cell lines with K-Ras mutations (A549, NCI-H727, NCI-H23) and 1 wild-type K-
Ras NSCLC cell line (NCI-H1703).  Based on the K-Ras mutation status, we hypothesized
that the NCI-H1703 cell line would be less susceptible to cysmethynil treatment.
Surprisingly we found that all 4 cells lines had relatively similar sensitivities to Icmt
inhibition. One explanation for this finding is that Icmt function is critical for other proteins
involved in NSCLC growth. In support of this, we have shown (see Chapter 3) that the
subcellular localization and function of many of the Rho family GTPases, for which there is
considerable evidence for their involvement in oncogenesis, are exquisitely sensitive to loss
of Icmt function. In addition, previous reports have shown that genetic loss of Icmt results in
altered protein stability of the Icmt substrates such as RhoA and Ras. Therefore, it is possible
that cysmethynil treatment may also have this effect on other CAAX-terminating proteins.
Thus while cysmethynil has been shown to specifically inhibit Icmt, the exact mechanism of
its growth inhibitory properties is not fully appreciated.
In summary, we have validated Icmt as a novel target for the treatment of NCSLC
and have shown that cysmethynil is a novel Icmt inhibitor that warrants further development.
While these results are promising, further studies are needed to determine the mechanism of
cysmethynil induced growth inhibition.  Additionally, cysmethynil should be evaluated in
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more sophisticated model systems such as the K-Ras driven genetically engineered mouse
(Johnson et al., 2001), where the effect of cysmethynil treatment on tumor growth,
metastasis, and angiogenesis can be determined.
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Chapter 3
Rho family GTPases exhibit highly divergent requirements for ispoprenylation,
proteolysis and carboxyl methylation to promote membrane association and function.
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A. Abstract
Rho GTPases (20 human members) comprise a major branch of the Ras superfamily of
small GTPases, and aberrant Rho GTPase function has been implicated in oncogenesis and other
human diseases.  Much of our current concepts of Rho GTPases are based on the three classical,
best-studied members (RhoA, Rac1 and Cdc42).  However, recent studies have revealed the
diversity of biological functions mediated by related isoforms of the classical Rho GTPases, as
well as of atypical Rho GTPases.  A key basis for the functional diversity of Rho GTPases is
their association with distinct subcellular compartments and membranes, which is dictated in part
by three posttranslational modifications signaled by their carboxyl-terminal CAAX (C =
cysteine, A = aliphatic, X = terminal amino acid) motifs, which are prenyltransferase-catalyzed
addition of either farnesyl or geranylgeranyl isoprenoid lipids, Rce1-catalyzed endoproteolytic
cleavage of the AAX amino acids and Icmt-catalyzed carboxyl methylation of the
isoprenylcysteine. We utilized pharmacologic and genetic approaches to determine the sequence
requirements and roles of CAAX-signal modifications in dictating the subcellular locations and
functions of the Rho GTPase family.  Whereas the classical Rho GTPases are modified by
geranylgeranylation, we found that a majority of the other Rho GTPases are substrates instead
for farnesyltransferase (FTase).  We found that the membrane association and/or function of Rho
GTPases are differentially dependent on Rce1- and Icmt-mediated modifications.  Our results
further delineate the sequence requirements for prenyltransferase specificity and functional roles
for protein prenylation in Rho GTPase function.  Additionally, we demonstrate that a majority of
Rho GTPases will be key targets for pharmacologic inhibitors of FTase, Rce1 and Icmt.
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B. Introduction
Rho proteins belong to the Ras superfamily of small GTPases and function as GDP/GTP-
regulated switches (Colicelli, 2004; Wennerberg et al., 2005).  Much of our current
understanding of the biochemistry and biology of the Rho family, which is comprised of 20
human members, has come from studies focused on the three classical members, RhoA, Rac1,
and Cdc42 (Wennerberg and Der, 2004).  Like most members of the Ras superfamily, Rho
GDP/GTP cycling is regulated by two main classes of regulatory proteins. Guanine nucleotide
exchange factors promote the formation of the active GTP-bound form Schmidt, 2002 #208}and
GTPase-activating proteins catalyze the intrinsic GTPase activity and promote the formation of
inactive GTP-bound Rho (Bernards and Settleman, 2004).  Active, GTP-bound Rho GTPases
bind preferentially to downstream effectors, stimulating diverse cytoplasmic signaling cascades
that regulate actin reorganization and a diversity of other cellular processes (Etienne-Manneville
and Hall, 2002).  As recent studies have begun to focus on the study of other members of the
family, it has become clear that there is considerably greater biochemical and biological diversity
among Rho GTPases than originally believed.
Like Ras family proteins, the majority of Rho family GTPases undergo a series of post-
translational modifications that promote proper subcellular localization and biological function.
This series of modifications is initiated by the recognition of the C-terminal CAAX tetrapeptide
motif (C = cysteine, A = aliphatic, X = any amino acid), which is found on 16 of 20 Rho
GTPases.  The first step is mediated by farnesyltransferase (FTase) or geranylgeranyltransferase
I (GGTase-I) and results in the covalent addition of a farnesyl or geranylgeranyl isoprenoid lipid
to the cysteine residue of the CAAX sequence. Subsequently, the AAX peptide is cleaved from
the carboxyl-terminus by the Ras converting enzyme 1 (Rce1) endoprotease. Finally,
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isoprenylcysteine-O-carboxyl methyltransferase (Icmt) catalyzes the addition of a methyl group
to the farnesylated cysteine residue (Sebti and Der, 2003). Together, these modifications increase
lipophilicity and facilitate membrane targeting.  Where studied, mutation of the cysteine residue
of the CAAX motif, which prevents all three modifications, renders Rho GTPases cytosolic and
inactive.  This suggests that pharmacological inhibition of such modifications would also
interfere with Rho GTPase activity.
Although the CAAX-signaled posttranslational modifications are necessary for Ras and
Rho GTPase membrane association and function, these three modifications alone are not
sufficient to promote full membrane association and the necessary subcellular localization
required for protein function (Cox and Der, 1992).  Instead, at least two distinct sequence
elements positioned immediately upstream of the CAAX motif are able to serve as a second
signal that is also required to promote efficient membrane association and function.  One element
is comprised of polybasic stretches that provide a charge that facilitates association with acidic
membrane-associated lipids.  Polybasic residues comprise the second signal for K-Ras4B.  The
second sequence element is a cysteine residue(s) that undergoes posttranslational modification
by a palmitate fatty acid.  Palmitoylated cysteines comprise the second targeting signal for H-Ras
and N-Ras proteins, as well as for some Rho family GTPases (RhoB and TC10).  Mutant Ras
proteins that retain CAAX-signaled modifications, but lack either the polybasic or palmitoylated
cysteine, are mislocalized to Golgi membranes and are partially cytosolic, and are also
significantly compromised in biological activity.  Finally, additional sequences flanking these
elements form a third signal that also contributes to dictating the precise subcellular localization
of Ras and Rho GTPases (Willumsen et al., 1996) (Parton and Hancock, 2004; Quatela and
Philips, 2006).  These locations can vary significantly: whereas some Rho GTPases are found
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largely at the plasma membrane (e.g., Rac1), some are associated mainly with Golgi membranes
(e.g., Cdc42), and still others are associated with endosomes (e.g., RhoD).
Because of the importance of CAAX-signaled modifications to small GTPase localization
and function, farnesyltransferase inhibitors (FTIs) were developed initially as anti-Ras therapies
for cancer treatment.  Unfortunately, K-Ras and N-Ras (the two Ras isoforms most commonly
mutated in cancer) undergo alternative prenylation by GGTase-I when in the presence of FTIs
(Rowell et al., 1997; Whyte et al., 1997).   However, while FTIs have not been found to show
anti-tumor activity when administered to patients with Ras mutation-positive tumors (e.g.,
pancreatic cancers) (Macdonald et al., 2005; Martin et al., 2004; Van Cutsem et al., 2004), they
continue to show promise as novel therapeutics in ongoing clinical trials, despite the fact that
their true target or targets remain unknown. Controversially, among the farnesylated proteins
known to date, RhoB has been proposed as a key target of FTIs (Prendergast, 2000).  We will
show here that other Rho GTPases may also be targets of FTIs.
The observations that K-Ras and N-Ras undergo alternative prenylation in response to
FTI treatment have also stimulated interest in the development of inhibitors that block other
enzymes that facilitate Ras membrane association.  First, geranylgeranyltransferase I inhibitors
(GGTIs) to block the function of the alternatively prenylated Ras proteins (Sebti and Hamilton,
2000).  Additionally, with increasing evidence for the involvement of normally
geranylgeranylated proteins in cancer (e.g., Ral and Rho GTPases) (Ridley, 2004; Sahai and
Marshall, 2002), there is now greater interest in the development of GGTIs for cancer treatment.
Second, efforts to develop inhibitors of Rce1 and Icmt as novel anti-cancer agents recently
intensified (Winter-Vann and Casey, 2005).  However, since Ras proteins that fail to undergo
these two modifications do retain partial function, and since both FTase and GGTase-I substrates
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are substrates for these two enzymes, another concern is that such inhibitors will suffer from
significant off-target activities and cause significant normal cell toxicity.  Support for this latter
concern is provided by the embryonic lethality seen in mice deficient in either Rce1 or Icmt.
Whether similar toxicity would be seen in adult cells or animals is an important area of
investigation.
In light of the important roles of Rho family GTPases in normal cell physiology, and their
aberrant activation in oncogenesis (Ridley, 2004; Sahai and Marshall, 2002), establishing the
sensitivity of Rho GTPases to FTI and GGTI inhibitors, and the contribution of Rce1- and Icmt-
catalyzed modifications to their cellular functions, will be critical to the successful development
of inhibitors of CAAX-signaled modifications.  Therefore, we have utilized pharmacologic and
genetic approaches to establish the importance of CAAX-signaled modifications for the
functions of the less-studied Rho GTPases.  We found that, in contrast to the perception based on
the study of the classical Rho GTPases, farnesylation is a lipid modification that is equally
important as geranylgeranylation for Rho GTPase function.  Furthermore, we conclude that the
rules governing the CAAX tetrapeptide and prenyltransferase specificity derived from structural
studies are clearly imprecise and that experimental analyses is still required to establish the
prenylation status of a particular CAAX-terminating protein.  Finally, our evaluation of Rho
GTPase subcellular localization and/or function in Rce1- and Icmt-deficient cells clearly
supports the value of developing inhibitors of these two enzymes for therapeutic strategies to
block Rho GTPase function.
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C. Materials and Methods
Expression constructs and Cell Culture.   pEGFP mammalian expression vectors encoding
green fluorescent protein (GFP) fusion proteins of H-Ras, K-Ras, RhoA, RhoB, Rnd2, and Rnd3
were either described by us previously (Berzat et al., 2005b; Chenette et al., 2005), or obtained
from Pontus Aspenstrom, LICR Uppsala (RhoD, RhoH, TCL, Rnd1) (Aspenstrom et al., 2004),
or from Mark Philips, NYU (Cdc42p, TC10) (Michaelson et al., 2001), or constructed for the
present study (Rif, Cdc42b).
HEK 293T cells were maintained in Dulbecco’s modified minimum essential medium
(DMEM) supplemented with 10% fetal calf serum (Sigma-Aldrich, St. Louis MO), 100 U/ml
penicillin and 100 µg/ml streptomycin.  NIH 3T3 cells were maintained in DMEM supplemented
with 10% calf serum (Sigma-Aldrich, St. Louis MO), and 100 U/ml penicillin and 100 µg/ml
streptomycin. Spontaneously immortalized mouse embryonic fibroblasts (MEFs) were originally
prepared from Icmt–/– and Rce1–/– mouse embryos, along with control fibroblasts (Icmt+/+ and
Rce1+/+) from littermate embryos (Bergo et al., 2001) and were kindly provided by Stephen G.
Young (University of California at Los Angeles). MEF cultures were maintained in DMEM
supplemented with 15% calf serum (Colorado Serum, Denver, CO), nonessential amino acids,
and L-glutamine.
Transfection, Immunostaining, and Microscopy.  For live cell microscopy, cells were plated,
transfected, and imaged in the same 35 mm culture dish that incorporated a No. 1.5 glass
coverslip-sealed 15 mm cut-out on the bottom (MatTek, Ashland, MA). Uncoated dishes were
used for NIH 3T3 cells, and poly-D-lysine coated dishes were used for all experiments using
wild-type and knockout MEFs. DNA transfections were performed with LipofectAMINE Plus
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according to the manufacturer's instructions (Invitrogen, Carlsbad, CA).  Three h after
transfection, cells were washed and grown in phenol red-free DMEM/F-12 supplemented with
10% calf serum.
For immunostaining, cells transiently-transfected with plasmid DNAs encoding GFP-
fusion constructs of Rac proteins were fixed 24 h after transfection with 4% paraformaldehyde,
permeabilized with Triton X-100, stained with Alexa 594-phalloidin (Molecular Probes), and
mounted with FluorSave (Calbiochem).
For both live cell imaging and immunofluorescence studies, cells were examined with an
inverted laser scanning confocal microscope (Zeiss 510 LSM; Zeiss) using an oil immersion 63x
NA 1.4 objective.  Images were captured by scanning with the 488 nM spectral line of an argon-
ion laser using the BP 505-530 emission filter (for live cell imaging; GFP), or sequential
scanning with the 488 nM argon laser and the 543 nM HeNe1 laser and the BP 505-530 (for
GFP) or LP 585 (for Alexa 594) emission filters.  Brightness and contrast of JPEG images were
adjusted using Adobe Photoshop CS2 software.
Transformation assays. For soft agar colony formation analyses of anchorage-independent
growth, NIH 3T3 cells stably expressing activated Rac or Rac C178S mutants were seeded at a
density of approximately 105 cells per 60 mm dish in a solution of complete media containing
0.4% bacto-agar over a layer of complete media containing 0.6% bacto-agar.  Colonies were
allowed to form for 12-18 days after which representative fields were photographed under the 4x
objective and viable colonies were stained with the MTT (3,[4,5-dimethylthiazol-2-yl]-2,5-
diphenyltetrazolium bromide) tetrazolium salt.  For secondary focus formation, NIH 3T3 cells
stably expressing Rac or Rac C178S mutants were plated at 105 cells per 60 mm dish and
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allowed to grow for 20-25 days with fresh medium added to the plates every few days.
Representative fields were photographed under the 4x objective.  Results for transformation
assays are representative of at least three experiments from independently generated sets of
stable cell lines.
1-Biotinamido-4-[4′-(maleimidomethyl) Cyclohexanecarboxamido] Butane (Biotin-BMCC)
Labeling.  Direct analyses of protein palmitoylation were done as described in (Drisdel and
Green, 2004; Shutes et al., 2006). Briefly, 293T cells were transfected with 7 µg of the indicated
pEGFP construct using a calcium phosphate transfection technique. Forty-eight h after
transfection, cells were lysed and incubated with 5 µg of anti-GFP monoclonal antibody (JL-8;
Clontech) at 4°C for 1 h, at which point 20 µg of protein G (Invitrogen) was added to the lysates
and incubated at 4°C for 1 h. Bound protein was washed and incubated with lysis buffer
containing 50 mM N-ethylmaleimide (Sigma-Aldrich) for 48 h at 4°C. Bound protein was then
washed and treated with 1 M hydroxylamine, pH 7.4, to cleave thioester bonds for 1 h at 25°C,
washed again, and treated with biotin-BMCC (Pierce Chemical, Rockford, IL), which recognizes
free sulfhydryl groups, for 2 h at 25°C. Bound protein was washed again, resuspended in 50 µl of
2x sample loading buffer, and resolved by 12% SDS-PAGE and transferred to polyvinylidene
difluoride membrane. Labeled protein was detected by incubating with streptavidin-horseradish
peroxidase (HRP; Pierce Chemical), and the membrane was washed and exposed to x-ray film.
Twenty ug of lysate was resolved by SDS-PAGE, transferred, incubated with anti-GFP primary
antibody and anti-mouse IgG-HRP secondary antibody, and exposed to x-ray film to verify the
presence of all GFP-tagged proteins.
120
In vitro prenylation analyses.  Rnd proteins were expressed as fusion proteins containing six
histidine residues at the amino terminus. The coding regions of human Rnd proteins were
amplified from appropriate cell lines by polymerase chain reaction and subcloned into QE
bacterial expression vector. The identity of all plasmids was confirmed by restriction mapping
and DNA sequencing of the polymerase chain reaction-amplified fragments.  Six-histidine-
tagged Rnd1, Rnd2 and Rnd3 were expressed and purified from E. coli by bacterial cells by
nickel-affinity chromatography as we have described previously (Yohe et al., 2007).  Expression
and purification of recombinant human FTase and GGTase-I from SF9 insect cells was done as
described elsewhere (Zhang et al., 1997).  FTase and GGTase-I activity on Rnd proteins was
determined by measuring the transfer of [3H]farnesyl or [3H]geranylgeranyl to the Rnd
substrates.
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D. Results
Farnesylation is a common modification of Rho GTPases - Substrate specificity of FTase
and GGTase-I towards small GTPases is determined primarily by the sequence of the CAAX
motif.  Biochemical and structural studies of CAAX peptides in complex with FTase and
GGTase-I have defined rules that govern substrate selectivity (Reid et al., 2004).  While the
specific isoprenoid modification of the classical Rho GTPases, and related isoforms, has been
confirmed in vivo, the precise isoprenoid modification of a majority of Rho family GTPases has
not been tested.  Where studied, the prenylation of Ras and Rho small GTPases is essential for
proper subcellular localization.  Therefore, to determine the specific prenylation status of Rho
GTPases, we ectopically expressed them as GFP-fusion proteins to visualize their subcellular
localization in live cells, and determined the ability of potent and highly selective FTI (FTI-
2153) and/or GGTI (GGTI-2417) treatment to alter their subcellular location (Berzat et al.,
2005a).  The use of GFP fusion proteins has been used extensively to evaluate the subcellular
localization of small GTPases and has been validated to accurately reflect the subcellular
location of endogenous protein (Choy et al., 1999; Heo and Meyer, 2003; Michaelson et al.,
2001).
First, we verified inhibitor specificity by determining their ability to disrupt the
membrane association and subcellular location of small GTPases that are well-validated
substrates of FTase and/or GGTase-I (Figure 1).  In the absence of lipid modification, GFP-
tagged small GTPases relocalize to the cytoplasm and nucleus, similar to the distribution of the
GFP protein alone (data not shown; (Choy et al., 1999; Heo and Meyer, 2003; Michaelson et al.,
2001)).   H-Ras has been shown previously to be solely farnesylated, and treatment with FTI-
2153 but not GGTI-2417 caused relocalization of H-Ras from plasma membrane to the
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Figure. 1. The specific isoprenoid modifications of Ras and Rho GTPases are accurately
defined using specific FTase and GGTase inhibitors.  NIH 3T3 cells were transfected with
expression constructs for the GFP-tagged fusion proteins of the indicated Ras or Rho GTPases
and treated with FTI-2153, GGTI-2417 or both (10 µM each) or DMSO (Vehicle).  Cells were
visualized alive using confocal microscopy.  Images shown are representative of three
independent experiments with > 80 cells examined per assay.  Scale bar, 10 µm.
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cytoplasm and nuclear accumulation.  RhoA is a substrate for the enzyme GGTase-I but not
FTase (Katayama et al., 1991) and, as expected, treatment with GGTI-2417 but not FTI-2153
caused accumulation of GFP-tagged RhoA to the nucleus.  K-Ras4B is farnesylated normally,
but can be alternatively modified by GGTase-I in vivo when cells are challenged with FTI
(Rowell et al., 1997; Whyte et al., 1997).  Consistent with these observations, we found that only
concurrent treatment with FTI-2153 and GGTI-2417 caused relocalization of K-Ras from the
plasma membrane to the cytoplasm and nucleus. These results verify that treatment with FTI-
2153 and GGTI-2417 can accurately determine the specific isoprenylation status of Rho
GTPases in vivo.
Unlike the classical Rho GTPases, Rnd3/RhoE and the related Rnd1 and Rnd2 isoforms
are predicted to be substrates for FTase, with Rnd3 demonstrated to be farnesylated in vivo
(Foster et al., 1996).  However, Rnd proteins contain a carboxyl-terminus similar to that seen in
K-Ras4B, terminating with a CXXM motif and possessing upstream polybasic sequences that
dictate the prenyltransferase interactions of K-Ras4B (Fiordalisi et al., 2003 and {James, 1995
#216)}. Consequently, it has been speculated that Rnd proteins may also undergo FTI-induced
alternative prenylation (Sebti and Der, 2003).
To determine the prenylation specificity of Rnd proteins, we first evaluated the ability of
bacterially-expressed proteins to serve as substrates for FTase and GGTase-I activity as
determined by measuring the transfer of [3H]farnesyl or [3H]geranylgeranyl, respectively.  As
expected, Rnd proteins were efficient substrates for FTase.  Consistent with the possibility that
Rnd proteins may undergo alternative prenylation, Rnd proteins were also capable of serving as
minor substrates for GGTase-I in vitro (data not shown).  This result is similar to our previous
observations with K-Ras4B, where we found that K-Ras4B, but not H-Ras, was a substrate for
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GGTase-I in vitro, albeit with a 140-fold lower affinity than that for FTase (Zhang et al., 1997).
Consistent with previous observations, we found that Rnd1 and Rnd3 showed plasma and
endomembrane association, whereas Rnd2 was found in the cytoplasm and on endomembranes,
and that Rnd1 and Rnd3, but not Rnd2, caused cell rounding (Table 1) (Chardin, 2006).
Unexpectedly, we found that the localization of all Rnd proteins was disrupted by FTI-2153
treatment alone (Figure 2A).  FTI and not GGTI treatment resulted in the loss of membrane
localization accompanied by increased cytoplasmic and nuclear accumulation of all three Rnd
proteins.  Additionally, FTI treatment reversed the cell rounding phenotype caused by ectopic
Rnd1 and Rnd3 expression.  While treatment with GGTI-2147 had no effect on localization of
Rnd proteins, it induced an exaggerated rounding phenotype in cells expressing ectopic Rnd1,
probably due to RhoA inactivation secondary to loss of RhoA geranylgeranylation.  Thus, unlike
K-Ras4B, the weak GGTase-I activity seen may not be physiologically significant and Rnd
proteins do not undergo FTI treatment-induced alternative prenylation.
TC10 (CAAX = CLIT) and the closely related Rho GTPase, TCL (CAAX = CSII), are
predicted to be modified by F and GG, respectively (Reid et al., 2004).  However, we found that
treatment with FTI was sufficient to disrupt the plasma membrane and vesicular localization of
both GTPases, whereas GGTI treatment did not induce misclocalization of either GTPase. This
result was consistent with our analyses in vivo, where we found that TC10 is farnesylated (data
not shown).  However, treatment with FTI resulted in the appearance of alternatively GG-
modified TC10.  Nevertheless, we found that the cellular mislocalization of TCL and TC10 in
cells treated with both FTI and GGTI were similar to FTI treatment alone.  This suggests that
either GG-modified TC10 is not membrane-associated or, more likely, the fraction of TC10 that
undergoes GG modification is not significant and detectable by immunofluorescence.
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Figure. 2. Rnd, TC10, TCL, and RhoD are farnesylated in vivo.  NIH 3T3 cells were
transfected with expression constructs for GFP-tagged fusion proteins with the indicated Rho
GTPases and treated with FTI-2153, GGTI-2417 or both (10 µM each) or DMSO vehicle. Cells
were visualized alive using confocal microscopy.  Images shown are representative of three
independent experiments with > 80 cells examined per assay.  Scale bar, 10 µm.
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Like TC10, RhoD terminates with X = T, and we found that RhoD endosome association
was disrupted by treatment with FTI alone.  While we consistently observed an increase in
nuclear accumulation of RhoD upon FTI alone, the additional treatment with both inhibitors did
not disrupt this endosomal localization. Thus, this localization may be prenylation-independent.
In summary, in contrast to the classical Rho GTPases, we determined that the localization of six
other Rho GTPases (Rnd1, Rnd2, Rnd3, TC10, TCL and RhoD) can be effectively disrupted
with FTI treatment.
Some Rho GTPases are substrates for both FTase and GGTase-I - Alternative gene
splicing results in the expression of two 191 amino acid Cdc42 isoforms (Marks and
Kwiatkowski, 1996), the most commonly studied ubiquitous Cdc42p (CDC42Hs) isoform
isolated originally from placenta (Shinjo et al., 1990) and brain-specific Cdc42b (G25K) isoform
(Munemitsu et al., 1990). Cdc42p and Cdc42b proteins are identical between residues 1–181,
except for a conservative arginine to lysine substitution at residue 163. The carboxyl-terminal 10
amino acids (181–191) are completely different (Cdc42p: PKKSRRCVLL; Cdc42b:
TQPKRKCCIF), except for the Cys residue at 188 that is part of the CAAX motif.  However,
both lack upstream cysteine residues and instead possess polybasic residues that comprise a
related second signal for membrane targeting.  As described previously by ourselves and others,
we found here that Cdc42p is modified by geranylgeranylation.  Unexpectedly, however,
although a previous study determined that Cdc42 from brain is also geranylgeranylated (Yamane
et al., 1991), we found that Cdc42b subcellular location was sensitive to FTI and not GGTI
treatment (data not shown).  The alternate prenylation of Cdc42 isoforms may distinguish the
function of these otherwise highly related proteins.
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RhoH terminates with a CKIF CAAX motif, and similar to TC21/R-Ras2 (CVIF), is
predicted to be modified by both F and GG (Carboni et al., 1995).  In agreement with this
prediction, we found that treatment with either FTI or GGTI alone had no effect on RhoH
subcellular localization (Figure 3).  Instead, dual treatment with FTI and GGTI resulted in
complete relocalization of RhoH to the cytoplasm and nucleus, indicating that RhoH is
alternatively prenylated when challenged by FTI treatment.  Alternatively, RhoH, like TC21,
exists as both F- and GG-modified forms in vivo.
Rif terminates with a CLLL motif and is predicted to be modified exclusively by GG.
Consistent with this possibility, we found that treatment with GGTI caused nuclear accumulation
of Rif.  Unexpectedly, FTI treatment alone caused a partial relocalization of Rif to the cytoplasm
and nucleus (Figure 3). Interestingly, Rif-induced filopodia seen in untreated cells was not
compromised by FTI treatment. While single treatment with either FTI or GGTI impaired Rif
localization, dual treatment had a synergistic effect on Rif mislocalization as judged by increased
cytoplasmic and nuclear fluorescence. Collectively, these results indicate that Rif is naturally
prenylated by both FTase and GGTase and exists in independent F- and GG-modified pools.
These results also indicate that, of the sixteen Rho GTPases that possess carboxyl-terminal
CAAX motifs, nine can serve as substrates for FTase.
Not all cysteines upstream of CAAX motifs are sites of palmitoylation  - Ras (H-Ras and
N-Ras) and Rho (RhoB and TC10) GTPases with cysteine residues upstream of the CAAX motif
undergo posttranslational modification by palmitoylation that is critical for proper subcellular
localization  (Hancock et al., 1990; Michaelson et al., 2001).  The three Rac isoforms (Rac1, 2
and 3) contain an invariant cysteine residue at position 178 in the hypervariable domain, several
residues N-terminal to the cysteine of the CAAX motif.  Furthermore, this cysteine residue and
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Figure 3.  RhoH and Rif are farnesylated and/or geranylgeranylated in vivo. NIH 3T3 cells
were transfected with expression constructs for the indicated GFP-tagged Rho GTPase and
treated with FTI-2153, GGTI-2417 or both (10 µM each) or DMSO vehicle. RhoH and Rif can
be farnesylated and geranylgeranylated in vivo.  Cells were visualized alive using confocal
microscopy.  Images shown are representative of three independent experiments with > 80 cells
examined per assay.  Scale bar, 10 µm.
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flanking sequences are conserved in evolution, and are found in Rac1 orthologs in Drosophila,
Danio and Xenopus (Table 2).  TCL also possesses two C-terminal, putative palmitoylation sites
similar to TC10 that may serve as additional signals to control proper subcellular localization.
Since there are no known consensus motifs, aside from the cysteine residue, to indicate whether
these sites within Rac1, Rac2, Rac3 and TCL are targeted for palmitoylation (Linder and
Deschenes, 2003), we determined whether these proteins were palmitoylated in vivo.
To evaluate the palmitoylation status of the Rac proteins and TCL, we used biotin-BMCC
labeling to directly analyze protein palmitoylation. This assay involves hydrolyzing the thioester
bond that links palmitate groups to cysteines and treating with a biotinylated compound that
recognizes and binds to the free sulfhydryl group generated upon cleavage of the thioester bond
(Drisdel and Green, 2004). Using this technique, we found efficient labeling of TC10, which is
consistent with the previous observation that TC10 undergoes palmitoylation (Figure 4)
(Michaelson et al., 2001).  Surprisingly, none of the Rac proteins was labeled, indicating that Rac
isoforms are not palmitoylated (Figure 4).  In addition, mutation of C178 to S did not affect
subcellular localization, membrane ruffling, or transforming activities of Rac1, Rac2, or Rac3 in
NIH 3T3 cells (data not shown).  Thus, despite the strong conservation, it is unlikely that this
cysteine residue is posttranslationally lipid-modified or important for Rac subcellular localization
or function.  More surprisingly, we also found that TCL did not exhibit significant labeling,
despite the presence of a cysteine residue immediately adjacent to the CAAX motif, a topology
found in the palmitoylated TC10 and RhoB proteins.  These results highlight the complex and
highly unpredictable nature of sequences that dictate palmitoylation of prenylated proteins.
The membrane association and/or function of farnesylated RhoGTPases are dependent
on Rce1-mediated proteolysis – Since the majority of Rho GTPases (16 of 20) terminate with
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Figure 4. Conserved cysteines in Rac1, Rac2, Rac3 and TCL are not palmitoylated. 293T
cells were transiently transfected with expression constructs for GFP-tagged activated Rac1 61L,
Rac2 12V, and Rac3 61L with and without an additional C178S mutation; TC10, TCL or empty
vector and subjected to the biotin BMCC labeling assay.  Levels of biotin-labeled GTPases were
measured by western blotting with streptavidin-HRP (top panel).  Expression of GFP-tagged
constructs was confirmed by immunoblotting with anti-GFP antibodies (bottom panel).
(Courtesy of Emily Chenette)
IP: anti-GFP
Biotin-BMCC Labeling
WB: anti-GFP
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Table 2.  Evolutionary conservation of the Rac1 carboxyl-terminal cysteine
Protein Species Carboxyl-terminal sequencea
Rac1 Homo sapiens VKYLECSALTQRGLKTVFDEAIRAVLCPPPVKKRKRKCLLL
Rac1 Homo sapiens VKYLECSALTQRGLKTVFDEAIRAVLCPQPTRQQKRACSLL
Rac3 Homo sapiens VKYLECSALTQRGLKTVFDEAIRAVLCPPPVKKPGKKCTVF
Rac1 Mus musculus VKYLECSALTQRGLKTVFDEAIRAVLCPPPVKKRKRKCLLL
Rac1 Rattus norvegicus VKYLECSALTQRGLKTVFDEAIRAVLCPPPVKKRKRKCLLL
Rac1 Borus taurus VKYLECSALTQRGLKTVFDEAIRAVLCPPPVKKRKRKCLLL
Rac1 Canis familiaris VKYLECSALTQRGLKTVFDEAIRAVLCPPPVKKRKRKCLLL
Rac1 Gallus gallus VKYLECSALTQRGLKTVFDEAIRAVLCPPPVKKRKRKCLLL
Rac1 Xenopus laevis VKYLECSALTQRGLKTVFDEAIRAVLCPPPVKKRRRKCLLL
Rac1 Danio rerio VKYLECSALTQRGLKTVFDEAIRAVLCPPPVKRRRRRCLLL
Rac1 Drosophila VKYLECSALTQKGLKTVFDEAIRSVLCPVLQPKSKRKCALL
Sequence conservationb ***********:***********:****    : :*:* *
aConserved cysteine residue is shaded; CAAX motif is underlined.  bSequence conservation: *,
identical; :, conserved.
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CAAX motifs, they are also likely substrates for Rce1-catalyzed removal of the AAX residues
and carboxyl methylation of the prenylated cysteine.  A recent study found that the membrane
association and function of farnesylated Ras proteins, but not geranylgeranylated Rho GTPases
was impaired in the absence of Rce1 or Icmt expression (Michaelson et al., 2005).  However,
other studies using pharmacologic inhibitors suggest that geranylgeranylated protein function
also depends on these modifications (Lu et al., 2004; Papaharalambus et al., 2005).  Therefore, to
further evaluate whether the specific isoprenoid modification of a Rho GTPase dictates
dependence on Rce1-mediated AAX cleavage, we evaluated the subcellular localization of Rho
GTPases in Rce1-/- MEFs.
For these analyses we transiently transfected wild type and Rce1-/- MEFs with expression
constructs for GFP-tagged K-Ras or Rho GTPases.  Plasma membrane localization of K-Ras has
been demonstrated to be partially dependent on Rce1-mediated AAX cleavage (Bergo et al.,
2002; Michaelson et al., 2005).  In agreement with earlier studies, we found that GFP-K-Ras was
partially re-localized to the cytoplasm in Rce1-/- cells.  Furthermore, we found that RhoA
localization, shown previously to be independent of Rce1-mediated cleavage (Michaelson et al.,
2005), remained unchanged.
Although RhoA and RhoB share significant sequence (83%) and biochemical identity,
RhoB can be modified by both F and GG.  In contrast to RhoA, we found that loss of Rce1
expression resulted in a loss of RhoB plasma membrane localization and increased cytoplasmic
and nuclear accumulation (Figure 5). In addition to changes in localization, blebbing of plasma
membrane can be seen in Rce1 knockout MEFs that expressed RhoB.  This morphologic
phenotype appears to be specific to RhoB as it was not seen with any other Rho GTPases
evaluated in this study. Since RhoB exists in both F and GG-modified forms, these results
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Figure 5.  Rce1-mediated –AAX proteolysis is differentially required for subcellular
localization of Rho-family proteins. Wild-type or Rce1 -/- MEFs were transiently transfected
with expression constructs for GFP-tagged fusion proteins of the indicated Rho GTPase.  Cells
were visualized alive using confocal microscopy.  Images shown are representative of three
independent experiments with >80 cells examined per assay.  Scale bar, 10 µm.
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suggest that the membrane association and function of both prenylated forms are dependent on
Rce1-mediated modification. Our observations contrast with previous analyses that found that
RhoB localization was not dependent on Rce1 expression (Michaelson, 2005).
When expressed in Rce1 -/- cells, Rnd1 and Rnd3 showed decreased membrane and
increased cytoplasmic and nuclear localization. In addition, Rnd1 became enriched within the
endomembranes. Cytoplasm-localized Rnd2 showed increased endomembrane localization and
an increased negative staining of internal organelles resembling GFP protein localization in
Rce1-/- cells.  Therefore, we concluded that all three Rnd proteins require Rce1-mediated AAX
proteolysis for proper localization.
The closely related farnesylated TC10 and TCL GTPases showed reduced plasma
membrane association while maintaining their vesicular localization in Rce1 -/- cells. The
farnesylated RhoD and RhoH displayed subtle changes in their distribution. Expression of RhoD
in Rce1 -/- MEFs resulted in reduced plasma membrane association and increased association
with vesicles that were smaller in size. While loss of Rce1 function did not impair RhoH plasma
membrane association, it did result in a loss of RhoH endomembrane association and in
increased association with vesicles in the cell body. Lastly, Rce1 deficiency did not result in any
detectable alteration in Rif localization, yet still resulted in a complete loss of Rif-induced
filopodia.  Thus, the Rho GTPases that can be farnesylated all showed Rce1-dependent
membrane association and/or function.
Dependence of Rho family subcellular localization on Icmt-mediated carboxyl
methylation – Rce1-mediated proteolysis is a prerequisite step required for Icmt-mediated
carboxyl methylation of the prenylated cysteine. Since we have found that many Rho family
members can be farnesylated and are dependent on Rce1-mediated proteolysis, we predicted that
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Icmt-stimulated carboxyl methylation would also be critical for localization of these proteins. To
test the importance of the Icmt-mediated methylation alone, we utilized Icmt-deficient MEFs
established from Icmt -/- embryos.  A similar phenotype in both Rce1- and Icmt- cells would
suggest that carboxyl methylation is the critical modification lost  in Rce1 deficiency.  However,
a more severe effect in Rce1 -/- cells when compared to Icmt -/- cells would support an
important role for the –AAX cleavage step alone. As expected, Icmt deficiency resulted in
increased cytoplasmic localization of K-Ras4B similar to that seen in Rce1 -/- cells (Figure 6A)
(Bergo et al., 2002).  Surprisingly, and in contrast to the loss of Rce1, loss of carboxyl
methylation resulted in mislocalization of RhoA and not RhoB.  While RhoA demonstrated
markedly increased nuclear accumulation and loss of endomembrane association, RhoB
maintained plasma membrane association. However, RhoB plasma membrane integrity was
disrupted similar to that seen in Rce1 -/- MEFs.
The Rnd proteins displayed greater sensitivity to loss of Icmt-mediated methylation than
was seen with loss of Rce1. Rnd proteins exhibited a complete loss of plasma and
endomembrane localization accompanied by increased cytoplasmic expression.  In addition,
Rnd1 and Rnd2, but not Rnd3, showed nuclear accumulation, similar to that of the GFP control
(data not shown).  In contrast to Rnd proteins, the extent of mislocalization of RhoD and RhoH
was similar to that seen in Rce1-deficient cells. RhoD exhibited reduced plasma membrane
association, but retained an endomembrane and vesicular localization.   In Icmt -/- cells, RhoH
displayed a loss of endomembrane association and was found on vesicles throughout the
cytoplasm. Expression of Rif in Icmt -/- cells did not cause mislocalization of Rif as determined
by increased cytoplasmic or nuclear localization.  However, loss of Icmt resulted in a spatial
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redistribution of Rif-induced filopodia from the cell periphery to the dorsal side of the cell
(Figure 6B).
 Finally, the highly related TC10 and TCL proteins exhibited differential requirements for
Rce1 proteolysis or carboxyl methylation for proper subcellular localization (Figure 7).  Whereas
the loss of Rce1 activity reduced plasma membrane association of TCL, the loss of Icmt induced
complete mislocalization of TCL to the cytoplasm and nucleus. In contrast to TCL, TC10
demonstrated a mild loss of membrane association with no nuclear accumulation. Thus, the loss
of AAX cleavage may be more critical for TC10 membrane association.
Our results suggest that TC10 and not TCL can be palmitoylated. Therefore, we
hypothesized that the increased membrane affinity of TC10 due to palmitoylation results in
insensitivity to the loss of Icmt.  To test this hypothesis we treated cells expressing TC10 and
TCL with 2-BP (2-bromo-palmitate), a well-characterized inhibitor of palmitoylation in vivo, and
determined the impact on subcellular localization. As expected, treatment with 2-BP had no
effect on subcellular localization of TCL in either wild-type or Icmt -/- MEFs (Figure 7).  Plasma
membrane localization of TC10 was insensitive to 2-BP treatment in wild-type MEFs,
suggesting that loss of palmitoylation is not sufficient to mislocalize TC10.  However, plasma
membrane association was lost in Icmt -/- MEFs treated with 2-BP, resulting in an increase in
cytoplasmic and nuclear accumulation.  Thus, carboxyl methylation and palmitoylation may be
partially redundant and cooperative modifications targeting TC10 to the plasma membrane.
These results further suggest that, although prior farnesylation is required for palmitoylation to
occur, full CAAX-mediated processing including carboxyl methylation is not.
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Figure 6. ICMT-mediated methylation is differentially required for subcellular localization
of Rho family proteins.  Wild-type or ICMT -/- MEFs were transiently-transfected with
expression constructs for the indicated GFP-tagged GTPase. Cells were visualized alive using
confocal microscopy. (A) Ras and Rho proteins have differential requirements for ICMT-
mediated processing for proper subcellular localization. Images shown are representative of three
independent experiments with >80 cells examined per assay. Scale bar, 10 µm. (B) ICMT-
mediated processing of Rif is not required for membrane association but contributes to
subcellular membrane distribution.  GFP-Rif localization was examined by Z-sectioning.  The
bottom and top stacks of each cell were examined for the presence of filopodia and images
shown are representative of three independent experiments with >50 cells examined per assay.
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Figure 7. Methylation and palmitoylation act as redundant membrane targeting signals for
TC10 localization. Wild-type or ICMT-/- MEFs were transiently-transfected with expression
constructs for the indicated GFP-tagged Rho GTPase. Cells expressing GFP-TCL and GFP-
TC10 were treated with 100 µM 2-BP and imaged alive.  Images shown are representative of
three independent experiments with >80 cells examined per assay.
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E. DISCUSSION
Due to the critical role of Rho family small GTPases in oncogenesis and their dependence
on CAAX processing for proper localization and function, Rho proteins are tantalizing targets for
pharmacological inhibitors of the CAAX processing enzymes FTase, GGTase-I, Rce1, and Icmt.
In the current study, we utilized pharmacologic and genetic approaches to determine the
sequence requirements and roles of CAAX-signaled modifications in dictating the subcellular
location and function of the Rho GTPase family.  Our results demonstrate the complexity of
sequence requirements dictating prenyltransferase specificity and functional roles for protein
prenylation and post-prenyl processing in Rho GTPase function.  Additionally, we demonstrate
that most Rho GTPases will be key targets for pharmacologic inhibitors of FTase, Rce1 and Icmt
(Table 3).
Rules governing substrate selectivity for CAAX prenyltransferases were originally
defined based on the ability of these enzymes to transfer prenyl groups onto bacterially-
expressed peptides or proteins in in vitro prenylation assays (Kinsella et al., 1991; Moores et al.,
1991), and these studies suggested that selectivity depended largely on the terminal X amino acid
of a given prenylatable CAAX motif. Recent crystallographic analyses of FTase and GGTase-I
complexed with eight validated CAAX-containing prenyltransferase substrate peptides have
been used to outline a newer series of rules that govern substrate peptide selectivity (Reid et al.,
2004).  These rules were then used to generate a list, derived from presumably prenylated
CAAX-terminating proteins encoded in the human genome, of hypothetical substrates for FTase
and GGTase-I.  Since both FTase and GGTase can accept any amino acid at the A1 residue of the
CA1A2X motif, it appears that both the A2 and X residues dictate substrate selectivity. In contrast
to the classical Rho family members that are known to be prenylated by GGTase-I, these rules
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predict that many of the Rho family members are farnesylated in vivo.  In general agreement
with these predictions, we found that a majority of the noncanonical Rho GTPases are substrates
for FTase in vivo.  While the rules for predicting substrate selectivity of FTase and GGTase were
not 100% accurate, we found that they correctly predicted a majority of the Rho family members
evaluated in this study (6 out of 9). Of the three predictions that were missed,  two were partially
correct.
One of the Rho GTPases whose prenylation status was not accurately predicted from the
structural analyses was Rif.  Rif possesses a Leu at both the A2 and X residues, which suggests
that it is a substrate for GGTase-I.  Surprisingly, we found that Rif appears to exist in
independent F- and GG-modified pools. As predicted, we found that treatment with GGTI
caused complete nuclear accumulation of Rif and loss of Rif-induced filopodia.  Unexpectedly,
FTI treatment alone also caused a partial, but significant, relocalization of Rif to the cytoplasm
and nucleus.  However, the formation of Rif-induced filopodia was not compromised by FTI
treatment. Dual treatment had an intermediate effect that did not cause complete nuclear
accumulation.  While there are few examples of FTase substrates with a Leu at the X position,
modeling of the FTase binding pocket has revealed an alternative binding site that can
theoretically bind atypical X residues such as Leu. In agreement with this and in support of our
data, RhoB (CAAX = CKVL) is known to be a substrate for both FTase and GGTaseI (Adamson
et al., 1992).  Presently, we do not have a clear explanation for the effects of FTI treatment on
Rif localization, since it seemed to be completely disrupted by GGTI treatment.  While this
suggests that a pool of Rif may be farnesylated, an alternative explanation may be that Rif is
exclusively GG-modified, but that its subcellular localization is dependent, in part, on interaction
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with a farnesylated protein.  Metabolic labeling analyses of the prenylation status of Rif in FTI-
and GGTI-treated cells will be needed to clarify the precise nature of Rif prenylation.
K-Ras4B is normally farnesylated exclusively in vivo, but can undergo alternative
prenylation when FTase activity is blocked by FTI treatment.  Our analyses identified additional
farnesylated proteins that could also undergo alternative prenylation in response to FTI
treatment, and still others that can be normally prenylated by either enzyme.   For example, we
found that RhoH, a third GTPase terminating with A2 = Ile and X = Phe, can be a substrate for
both FTase and GGTase-I.  Finally, TCL (CAAX = CSII) was found to be a substrate for FTase
and not GGTase-I.   Ile is a common amino acid at the A2 position of FTase substrates, and while
it has not previously been observed at the X position there are no reasons why the FTase binding
pocket would exclude proteins terminating in Ile. Thus, out of the three Rho proteins not
correctly predicted by the rules defined by Reid et al., two were partially correct and the third is
easily explained.
Alternative gene splicing results in the expression of two 191 amino acid Cdc42 isoforms
(Marks and Kwiatkowski, 1996), the most commonly studied ubiquitous Cdc42p (CDC42Hs)
isoform isolated originally from placenta (Shinjo et al., 1990)and brain-specific Cdc42b (G25K)
isoform (Munemitsu et al., 1990). Cdc42p and Cdc42b proteins are identical between residues
1–181, except for a conservative Arg to Lys substitution at residue 163. The C-terminal 10
amino acids (181–191) are completely different (Cdc42p: PKKSRRCVLL; Cdc42b:
TQPKRKCCIF), except for the Cys residue at 188 that is part of the CAAX motif.  However,
both lack upstream cysteine residues and instead possess polybasic residues that comprise a
related second signal for membrane targeting.  Both isoforms are expressed in brain, although
spatial gene expression in neural tissue is not identical (Olenik et al., 1999).  As described
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previously, we found that Cdc42p is modified by geranylgeranylation.  Unexpectedly, although a
previous study determined that Cdc42 from brain is also geranylgeranylated, we found that
Cdc42b subcellular location was disrupted by FTI and not GGTI treatment.  This is consistent
with a study (Kho et al., 2004)that used substrate tagging technology to search for farnesylated
proteins. Although the authors concluded that the identification of Cdc42 represented a flaw in
their technology based on the previous understanding of Cdc42 as a geranylgeranylated protein,
it now seems likely that the Cdc42 that they detected was the brain-specific isoform. The fact
that the two isoforms appear to be targets of distinct prenyltransferases could have important
implications.  Thus, while no clear functional differences in Cdc42p and Cdc42b have been
described to date, the alternate prenylation of Cdc42 may distinguish the regulation of these
otherwise highly related proteins.  Finally, this result suggests that normal cell toxicity of GGTIs,
due to Cdc42 inhibition, may not be an issue with neurological tissue.
Based on its CAAX motif, we had predicted that Cdc42b would be a substrate for both
FTase and GGTase-I.  Approximately 40% of all known FTase and GGTase substrates contain
an Ile at the A2 position supporting the prediction that Cdc42b would be a dual substrate.  Similar
to TC21 (CAAX = CVIF), a dual FTase and GGTase-I substrate, the brain-specific Cdc42
isoform possesses a Phe at the X position.  Since the primary binding pocket of FTase is too
small to accommodate Phe at the X position and it is only in the alternative pocket that the Phe
can fit, one might have expected that if it was not a dual substrate it would be a GGTase-I
substrate. Therefore it is interesting that this GTPase showed selectivity for FTase and not
GGTase-I, and raises the possibility that the brain-specific Cdc42 isoform also possesses other
unique properties in addition to the A2 and X residues that govern its prenyltransferase
specificity.
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In addition to defining the natural prenylation of the Rho family members, we were also
interested in determining whether they would be alternatively prenylated when challenged with
prenyltransferase inhibitors. Of the nine Rho family members evaluated, only RhoH showed the
potential to be alternatively prenylated.  Surprisingly, the Rnd proteins, which have been
speculated to undergo FTI-induced alternative prenylation (Sebti and Der, 2003)were exquisitely
sensitive to FTI treatment alone and did not undergo alternative prenylation by GGTase-I.
Together, this suggests that alternative prenylation of Rho proteins is a rare event and that most
Rho targets of FTase inhibitors will likely be sensitive to FTase inhibition alone.  Finally, we
have determined that Rnd3 expression is upregulated in human melanomas (Shields et al., 2007),
and in pancreatic and other human cancers, via activation of the ERK mitogen-activated protein
kinase cascade (unpublished).  Perhaps Rnd3 may represent an important target for the anti-
tumor activity seen with FTIs.
Efforts to develop inhibitors for the post-prenyl processing steps regulated by Rce1 and
Icmt have intensified since K-Ras was determined to be alternatively prenylated when treated
with FTI (Winter-Vann and Casey, 2005).  The possibility that pharmacologic inhibitors of these
two enzymes may exhibit anti-Ras activity is supported by recent studies with Rce1- or Icmt-
deficient MEFs (Bergo et al., 2002).  These studies showed that K-Ras and H-Ras-mediated
transformation is indeed impaired by a deficiency in either enzyme.  However, in light of the
significant number of CAAX-terminating proteins encoded in the human genome, including
many proteins with established roles in normal cell proliferation and survival, the significant
“off-target” normal cell toxicity of such inhibitors is an obvious concern.  A recent limited study
of RhoA, Rac1 and Cdc42 suggested that these final two modifications are not required for those
proteins that are GG-modified (Michaelson et al., 2005).  However, in general, we found that
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most Rho family members were dependent on both Rce1 and Icmt function for proper
subcellular localization and/or function.  In contrast to this previous report, we observed that
localization of RhoA was sensitive to loss of Icmt expression.  In the previous study, an activated
RhoA(L63) construct was used to evaluate the dependence of Icmt function on RhoA
localization, whereas in the current study we used wild-type RhoA.  To determine whether there
was a differential dependence on Icmt function between wild-type and activated RhoA, we also
evaluated the localization of activated RhoA in Icmt -/- cells and found that its localization was
not affected (data not shown).  This differential dependence may reflect a role for carboxyl
methylation in the interaction of Rho proteins with RhoGDIs.  Regardless of the mechanism,
however, since there are no known RhoA activating mutations that naturally occur in cancer, we
conclude that RhoA is a promising target of Icmt inhibitors.  In support of this conclusion, loss
of Icmt has been shown to alter the stability of RhoA within the cell (Backlund, 1997; Bergo et
al., 2004).  In addition, inhibition of carboxyl methylation has been shown to increase
permeability of the endothelial cell monolayer as well as increase endothelial cell apoptosis
through a RhoA-dependent mechanism (Lu et al., 2004).
In addition to RhoA, we also found that RhoB was sensitive to loss of Rce1 and partially
sensitive to loss of Icmt function.  This result also differed from those of Philips and colleagues,
who concluded that RhoB function was not dependent on the activity of either enzyme
(Michaelson et al., 2005).  Since we both utilized enzyme-deficient MEFs for our studies, the
basis for our different results is not clear.  While only loss of Rce1 resulted in complete
mislocalization, loss of either post-prenylation processing step resulted in a disruption of the
integrity of the cell membrane that we termed “blebbing.” Since RhoB exists in both farnesylated
and geranylgeranylated pools, our observations provide further evidence that the function of
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geranylgeranylated as well as farnesylated proteins may depend on these two modifications.
Although not directly evaluated, the membrane blebbing in the Rce1 -/- or Icmt -/- cells did not
appear to be undergoing apoptosis as evidenced by the maintenance of proper nuclear
morphology and lack of cell rounding. In addition, we believe this phenotype is a result of
impaired RhoB effector interactions since it appears to maintain membrane localization in the
Icmt -/- cells.
Rce1-mediated proteolysis is a prerequisite processing step essential for Icmt-mediated
carboxyl methylation.  As such, it is expected that loss of Rce1 function would have more drastic
consequences than loss of Icmt.  However, whereas Rce1-deficient mice died during late
gestation or soon after birth, Icmt-deficient mice showed a more severe phenotype, with virtually
all of the knockout embryos (Icmt-/-) dying by mid-gestation (Bergo et al., 2001).  This greater
severity had been explained by the fact that there are additional Icmt substrates that are not Rce1
substrates and it is the mislocalization of these proteins that results in the more severe phenotypic
changes.  In addition, conditional deletion of Icmt in mouse fibroblasts has been shown to cause
a more dramatic reduction in Ras-induced transformation compared to conditional deletion of
Rce1. Interestingly, we found that many of the Rho family members evaluated have differential
sensitivity to loss of Rce1 and Icmt. As mentioned, RhoB appeared to be more sensitive to loss
of Rce1, whereas RhoA is more dependent on Icmt.  In addition, we found that the Rnd proteins
were sensitive to loss of both processing steps, although the loss of Icmt was much more
dramatic.  Finally, loss of Rce1 blocked Rif-induced filopodia but did not impair localization,
while loss of Icmt altered the spatial orientation of Rif, yet filopodia formation was maintained.
One explanation for the differential consequences of the loss of Rce1 and Icmt is that Rho
GTPases may be less affected by the presence of the AAX extension than they are by the
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presence of the carboxylate anion (Silvius and l'Heureux, 1994).  In accordance with this
hypothesis, protein stability as measured by cellular half-life is significantly altered by both
pharmacological and genetic disruption of Icmt (Backlund, 1997; Bergo et al., 2004).  The
mechanism of these changes in protein stability is unknown, although it could be the result of
altered recognition by the degradative enzymes within the cell.
In summary, our analyses of the Rho GTPase family reveal that the function of a majority
of Rho GTPases will be sensitive to FTI treatment, as well as to inhibitors of Rce-1 and Icmt.
Our observations also reveal the complex and varied requirements of Rho GTPases for CAAX-
mediated posttranslational modifications.  FTIs are currently in phase II/III clinical trials and our
studies identify additional targets that may contribute to their anti-tumor activities.  Recent
preclinical studies in mouse models suggest that GGTIs will also exhibit anti-tumor activities (El
Oualid et al., 2006; Sjogren et al., 2007; Sun et al., 2003), and that Rho GTPases may also be
important targets for these activities (Sjogren et al., 2007).  Finally, although the development of
Rce1 or Icmt inhibitors has been limited, our findings provide further validation for these two
enzymes as important drug targets and support a therapeutic value for such inhibitors.
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Chapter 4
K-Ras mutations are associated with activation of the Raf-MEK-ERK mitogen-
activated protein kinase cascade and disease recurrence: implications for rational
clinical trial design for the treatment of non-small cell lung cancer
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A. Abstract
Lung cancer is the leading cause of cancer related death in the United States.
Non-small cell lung cancer (NSCLC) accounts for 85% of all lung cancer cases and
although great efforts have been made to improve the clinical outcomes of this disease,
the five-year survival remains at 10-15%.  Activation of the K-Ras proto-oncogene is one
of the most frequent alterations found in these tumors, occurring in approximately 30% of
NSCLC cases.  The prevalence of this mutation, along with extensive evidence
supporting its role in lung cancer oncogenesis makes it an important target for the
development of novel anti-cancer drugs for NSCLC treatment.  Presently, much of this
effort is focused on small molecule inhibitors of the Raf-MEK-ERK mitogen-activated
protein kinase (MAPK) cascade. However, since there is evidence for both Raf-
dependent and Raf-independent mechanisms of Ras-mediated oncogenesis, it is unknown
whether therapies targeting the Raf-MEK-ERK pathway will be effective in the treatment
of K-Ras mutation-positive NSCLCs. In addition, while the most obvious candidates
likely to benefit from ERK/MAPK-targeted therapies are NSCLC patients with
constitutive activation of the Ras signaling pathway, studies of pancreatic and other
cancers suggest that Ras mutational status alone will not accurately predict patient
response to these agents.  Using a cell-based model system we found that NSCLC growth
is dependent on ERK signaling.  In addition, we used a tissue microarray (TMA) of 169
NSCLC patients to define the subset of patients likely to respond to inhibitors of the Raf-
MEK-ERK pathway. We found that smoking status and Ras mutation were associated
with elevated ERK activation and represent two patient characteristics that may be used
to select patients likely to benefit from ERK-targeted therapies.
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B. Introduction
Lung cancer is the leading cause of cancer death in the United States.  The American
Cancer Society estimates over 172,000 new cases and 163,000 lung cancer deaths in 2005
(Jemal et al., 2005).  Non-small cell lung cancer (NSCLC) comprises approximately 80% of
these cases.  The most important prognostic variable for survival in NSCLC is tumor stage,
primarily because early stage disease is amenable to complete surgical resection. Patients
who undergo curative surgery have a higher survival rate compared to patients who are not
surgical candidates (Flehinger et al., 1992). However, surgically-resected patients have a
significant risk of relapse, likely secondary to micrometastatic spread of disease.
Additionally, tumor behavior can vary widely even within the same stage and subtype.  Some
small tumors detected at an early stage behave very aggressively and rapidly progress to
widespread, fatal disease, while others never recur.  This implies that there are other
important stage-independent genetic or biochemical predictors of prognosis.  Elucidating
these tumor characteristics would allow clinicians to make better decisions regarding patient
treatment and care.
For example, adjuvant therapies have proven effective in some patients with early stage
lung cancer (Arriagada et al., 2004; Strauss et al., 2004; Winton et al., 2004).  Knowledge of
tumor aggressiveness would enable physicians to select those patients who might benefit
most from adjuvant therapy.  The same is true for molecular markers that predict sites of
distant spread, particularly of brain and bone metastases.  At least 50-60% of metastases to
the brain arise from primary tumors of the lung (Patchell, 2003; Wen and Loeffler, 2000).
Furthermore, brain metastases constitute the most common site of failure in surgically staged
IIIa NSCLC patients (Mamon et al., 2005). If it were possible to predict which patients
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would experience disease recurrence in the brain, cancer care may be improved with
prophylactic cranial irradiation. Biomarkers that predict brain metastases or other sites of
disease recurrence may also serve as targets for future drug development.
Target-based therapies are the future of cancer treatment, and as detailed in Chapter
1, the Raf-MEK-ERK mitogen-activated protein kinase (MAPK) signaling pathway and its
upstream activators have received considerable interest as possible candidates for novel drug
development (Sebolt-Leopold and Herrera, 2004). The ERK MAPK signaling cascade
promotes cell proliferation, cell survival, and metastasis.  These functions, along with the
overwhelming frequency with which this pathway is aberrantly activated in cancer, in
particular by upstream activation by the epidermal growth factor receptor (EGFR) and the
Ras small GTPase, support efforts to identify approaches to inhibit this pathway.
While up to 30% of NSCLCs have activating mutations in K-Ras, the significance of
this mutation remains in debate.  A plethora of studies employing a variety of methods to
detect mutational activation and to measure protein expression of K-Ras in NSCLC patient
samples have reported widely inconsistent results.  However, in a more recent meta-analysis,
the presence of a K-Ras mutation was associated with a worse overall survival (Mascaux et
al., 2005).  In this evaluation it was found that studies employing PCR-based K-Ras
mutational analysis were able to detect an association with overall survival while studies
using immunohistochemistry (IHC) to measure K-Ras protein expression were unable to
detect a relationship between K-Ras and survival. This finding is consistent with the fact that
K-Ras is not known to be activated through overexpression, and thus it is not expected that
protein levels would vary in tumors with K-Ras activation.
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Ras proteins (H-, K- and N-Ras) function as GDP/GTP-regulated switches. GDP/GTP
cycling is regulated by guanine nucleotide exchange factors (RasGEFs; e.g., Sos) that
promote formation of active Ras-GTP, whereas GTPase activating proteins (GAPs; e.g.,
NF1, neurofibromin) stimulate GTP hydrolysis and formation of inactive Ras-GDP (Mitin et
al., 2005). In normal quiescent cells, Ras is GDP-bound and inactive. Extracellular stimuli
(e.g., EGF) cause transient formation of the active, GTP-bound form of Ras. The mutant Ras
genes in human cancer encode proteins that harbor single amino acid substitutions primarily
at residues G12 or Q61. These mutations result in the synthesis of Ras proteins, which are
GAP-insensitive, constitutively GTP-bound and activated. Constitutive activation of Ras
results in stimulus-independent, persistent activation of downstream effectors such as the
Raf-MEK-ERK cascade.
In 1993 the Raf-1 serine/threonine kinase was identified as a downstream effector of
Ras, and Ras was believed to promote tumorigenesis simply by facilitating the activation of
Raf (Repasky et al., 2004).  We now know that Ras signals through many different
catalytically diverse effectors and there is considerable evidence for both Raf-dependent and
Raf-independent oncogenic signaling. Constitutively activated Raf and MEK have been
shown to transform rodent fibroblasts. Furthermore, MEK and ERK have been shown to be
required for Ras-mediated transformation of NIH 3T3 mouse fibroblasts (Shields et al.,
2000). More recently, mutationally activated B-Raf has been identified in a variety of human
cancers and the finding that mutationally activated Ras and Raf occur in a non-overlapping
manner in melanomas, colorectal carcinomas, papillary thyroid carcinomas, serous ovarian
carcinomas, and lung cancers suggests that these mutations are functionally equivalent
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(Davies et al., 2006; Mercer and Pritchard, 2003; Rajagopalan et al., 2002; Sieben et al.,
2004; Singer et al., 2003; Vos et al., 2003).
With all the data pointing at Raf as “the” critical Ras effector, it would seem that
further validation of this pathway as a target for drug development is not needed. However,
there is considerable evidence supporting the theory that oncogenesis mediated by Raf
activation also requires activation of other Ras effectors and that Ras-mediated oncogenesis
can even be completely independent of Raf (Repasky et al., 2004). While 70% of melanomas
harbor B-Raf mutations, the PTEN tumor suppressor is commonly lost in these tumors
leading to activation of PI3K>AKT (another Ras effector pathway), suggesting that Raf
activation alone is not enough to promote tumorigenesis (Tsao et al., 2004). Other studies
using rodent fibroblasts found mutated B-Raf alone to have significantly lower transforming
potency (35-fold lower) when compared to mutant Ras (Davies et al., 2002).  As mentioned
above, certain cancers can harbor Ras or Raf mutations, but there are other cancers that
harbor only Ras mutations and have not been reported to have Raf mutations, suggesting that
activation of B-Raf alone is not sufficient for these cancer types (pancreatic, follicular
thyroid, mucinous ovarian and others cancers) (Repasky et al., 2004).  Finally, despite the
strong evidence for a causal role for Ras mutations in pancreatic cancers (Yeh and Der,
2007), studies using both pancreatic cancer cell lines as well as patient tumors found a lack
of relationship between Ras mutation status and elevated ERK activity (Lim et al., 2005; Lim
et al., 2006; Yip-Schneider et al., 1999).
Further evidence supporting the lack of a consistent functional linkage between Ras
mutational activation and ERK activation comes from mouse model studies in which
endogenous K-Ras drives tumorigenicity.  Expression of endogenously activated K-Ras in
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mouse embryo fibroblasts caused a proliferative response, but ERK was not found to be
activated (Tuveson et al., 2004).  More recently, a genetically engineered mouse model has
been reported where expression of mutant K-Ras results in the formation of adenocarcinoma
of the lung (Johnson et al., 2001). Gene array analysis of tumors from these mice has been
shown to recapitulate the gene expression of human lung tumors harboring Ras mutations
(Sweet-Cordero et al., 2005). While these tumors appear to more faithfully mimic human
lung cancer, ERK activation was not seen, raising the question of whether this pathway is
important for Ras-mediated NSCLC.   Recently, it was shown that loss of PI3K activation
alone was sufficient to cause a near-complete inhibition of K-Ras-induced lung tumors in the
same mouse model (Gupta et al., 2007).  This result also argues that Raf activation alone will
not be sufficient to cause lung tumorigenesis.
Since the identification of Raf, a multitude of additional catalytically-distinct Ras
effectors have been discovered and there is evidence that at least four other classes of
effectors, such as RalGEFs (Hamad et al., 2002; Lim et al., 2005), also contribute to Ras-
mediated oncogenesis. There is considerable interest to develop small molecule inhibitors of
Ras signal transduction, particularly inhibitors of Raf signaling.  One potential complication
that may diminish the effectiveness of Raf inhibitors for the treatment of lung cancer is that
Ras utilizes different downstream effectors in a tissue and tumor type specific fashion and
that validation of Raf as the most critical effector in NSCLC has yet to be confirmed.
Therefore, a critical step in the development of Raf and MEK inhibitors for the treatment of
NSCLC will be to define the importance of the Raf-MEK-ERK pathway in NSCLCs with
activating mutations in the K-Ras proto-oncogene.  To address these questions we have
developed a tissue microarray (TMA) of approximately 169 NSCLC patients in order to
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characterize the clinicopathologic features, including K-Ras mutations, which are associated
with elevated ERK activation. To complement and validate these studies we utilized genetic
and pharmacological approaches to directly evaluate the importance of the K-Ras-Raf-MEK-
ERK pathway in cell culture studies with NSCLC cell lines.  Our observations support a
clinical value for therapeutic approaches that target the ERK pathway for NSCLC treatment.
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C. Materials and Methods
Patient specimens and characteristics.  All patients were surgically resected at the
University of North Carolina Hospital in Chapel Hill, NC between 1991 and 2005.  Paraffin-
embedded tissue specimens from 169 patients were obtained according to institutional
review board approved protocols.  All tissue specimens were obtained from surgical
specimens from patients who underwent surgical resection of their tumors.
Clinicopathologic characteristics captured included age, sex, race, histology, stage, and
grade of differentiation, as well as EGFR and K-Ras mutation status. Using retrospective
chart review, outcomes data including survival and disease recurrence were collected.
Western blot analyses and immunohistochemistry.  MEK1 and MEK2 activate ERK1 and
ERK2 by phosphorylation at tandem residues Thr202 and Tyr204.  To monitor activation of
the ERK MAPK pathway, an anti-phospho-ERK1/2 (pERK) antibody was used. Anti-
pERK1/2 (Thr202/Tyr204) and anti-ERK1/2 antibodies were obtained from Cell Signaling
(#9101S and #9102; Beverly, MA).   For western blot analyses, antibodies were used at a
dilution of 1:1000 and samples were incubated overnight at 4oC.
For immunohistochemical analyses, we constructed a tissue microarray (TMA) of the
paraffin-embedded surgical specimens.  Three cores from each specimen were placed on the
TMA and haematoxylin and eosin staining were performed to verify the cellularity of each
core.  The TMA was cut and slides were prepared using methods previously described
(Reisman et al., 2005). Anti-pERK1/2 was used at a dilution of 1:100 (determined after
preliminary serial dilution studies using A549 cells fixed in 10% buffered formalin).
Samples were incubated overnight at 4˚C with the primary antibody and stained using the
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automated Vision Biosystems BOND instrument. Dr. William Funkhouser, a trained
pathologist, without knowledge of the clinicopathologic features independently reviewed the
staining results. The abundance of positively stained tumor cells (0-100%) was calculated for
each antibody and the median percentage of positively stained cells was determined. The
average scoring of all three cores from each patient sample was used for statistical analyses.
The median value of pERK staining was used as the cutoff point; values greater than the
median were considered positive and all values below the median were considered negative
for constitutive activation of pERK.
DNA extraction and mutational analysis.  To determine K-Ras and EGFR mutational status
of each specimen, tumor DNA was extracted from formalin-fixed, paraffin-embedded
(FFPE) tissue blocks corresponding to each sample on the TMA, using Turbo DNase
(Ambion, Austin, TX).  Mutation scanning was performed using high-resolution fluorescent
melting curve analysis {Lewis, 2005 #210}. After amplification on the LightCycler, sample
cuvettes were transferred into a beta HR-1 instrument and slowly heated at 0.2 °C/second
from 60 °C to 90 °C with continuous fluorescence acquisition. Fluorescence versus
temperature plots were analyzed using custom software as described elsewhere.  K-Ras was
evaluated for codon 12, 13 and 61 mutations and EGFR was analyzed for mutations in exons
19 and 21.
Retrovirus expression and interfering RNA vectors. Using the OligoEngine RNAi design
software program, we generated a retrovirus-based (pSUPER.retro.puro; OligoEngine)
short-hairpin interfering RNA (shRNA)-expressing vector that recognizes the K-Ras
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sequence beginning at position 384, which by BLAST analysis should not interfere with the
expression of any other genes.  A similar pSUPER.retro.puro-based construct encoding a
pan-B-Raf shRNA expression construct was obtained from David A. Tuveson (Hingorani et
al. 2003). For generation of infectious virus, HEK 293-T cells were seeded into collagen-
coated T-25 cm2 flasks at 1.5 x 106 cells per flask on day one.  On day two, HEK 293-T cells
were transfected by calcium phosphate precipitation (pVPack-Gag/Pol 3 µg, pVPack-
Ampho 3 µg, pSUPER.retro-puro-K-ras or –B-raf shRNA), in Hank’s buffered saline (0.9
ml) and 1.25 M CaCl2 0.1 ml. After 10 min incubation to allow the DNA to precipitate,
DNA was added to 4 ml of medium supplemented with 25 µM chloroquine and then added
to the cells.  Cells were incubated with DNA for 6 h and then fed with 4 ml of growth
medium.  On day three the NSCLC target cells (i.e. A549 cells) were seeded at 1 x 105 cells
per T-25 cm2 flask.  Cells were allowed to recover for 24 h and then selection with growth
medium supplemented with puromycin was initiated.  Mass populations of puromycin drug-
resistant colonies were then pooled together to establish mass populations of stably-infected
cell populations for analyses.
Cell culture and transformation assays.  The A549 cell line was acquired from the ATCC
and maintained in growth medium as recommended by the ATCC.  HEK (Human
Embryonic Kidney) 293-T cells used for retroviral infections were grown in Dulbecco’s
minimum essential medium (DMEM-H) supplemented with 10% fetal calf serum (FCS).
To determine the consequences of pharmacologic inhibition of ERK-MAPK
signaling on the anchorage-dependent growth of A549 cells, we utilized an assay based on
the ability of viable cells to stimulate cleavage of the tetrazolium salt WST-1 producing a
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soluble formazan salt.  Five x 103 cells per well were grown in a 96-well tissue culture plate
for 48 h in 200 µl of growth medium supplemented with the indicated amount of
pharmacologic inhibitor.  Following a 48 h incubation with the inhibitor, cells were
incubated with 20 µl of WST-1 for approximately 4 h. After this incubation period, the
formazan dye formed was quantitated using a scanning multi-well spectrophotometer
(ELISA reader). The absorbance revealed directly correlates to the number of viable cells.
To determine the consequences of genetic or pharmacologic inhibition of K-Ras, B-
Raf and ERK signaling on the anchorage-independent growth of NSCLCs, single cell
suspensions were made in growth medium supplemented with 0.4% agar and plated over a
0.6% agar bottom layer. A total of 104 cells per well were seeded in triplicate into 6-well
plates.  Clusters consisting of greater than 10 cells were considered colonies for
quantification and five independent fields within each 6-well were used to calculate an
average number of colonies per field.
Statistical analysis. All statistical methods were carried out using the statistical package
SPSS Data Analysis Program and Microsoft Excel.  The methods used included Student’s t-
test, calculation of odds ratio, ANOVA, and the Cox regression test for univariate analysis. In
all cases, p < 0.05 was considered statistically significant.
166
D. Results
Smoking status is associated with elevated ERK activation in NSCLC patients. Based on
evidence that signaling molecules other than Ras can lead to ERK activation, coupled with
evidence that Ras can utilize multiple effector pathways, we hypothesized that K-Ras
mutational status alone would not be likely to predict activation of the Raf/MEK/ERK
pathway.  If this were true, other predictive characteristics would be needed to determine
which patients have constitutive activation of ERK. Previous observations during the
development of EGFR-directed therapies have repeatedly shown that smoking status, gender
and race are reliable predictors of response in clinical practice (Lynch et al., 2004; Pham et
al., 2006).  To determine if similar patient characteristics are associated with increased ERK
activation as well as to determine if pERK correlates with more aggressive disease we
developed a tissue microarray (TMA) of 169 patients with histologically proven NSCLC.
The characteristics of these patients are summarized in Table I.
Normal lung tissue, such as bronchiolar epithelial cells, endothelial cells, and type I/II
pneumocytes, present throughout the biopsy specimens was negative for activated ERK.
Immunohistochemical staining for pERK in tumors revealed an unequal distribution of the
percent positive cells in each tumor.  For statistical purposes we determined that the median
percent of cells stained positive for cytoplasmic pERK was 14%, and we used this value as
the cut-off for positive staining.  Patients with at least 14% tumor cells stained positive for
pERK were considered to have elevated pERK whereas patients with < 14% were considered
negative. Overall 70.5% of tumor samples were negative and 29.5% were positive.  There
was no statistical correlation between cytoplasmic pERK staining and gender, race,
histology, grade, or stage (data not shown), and univariate analysis of ERK
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Table 1.  Patient characteristics: NSCLC tumor tissue microarray
Patients (n=169) % Total Patients (n=169) % Total
Age T
  Median 65   1 72 43
  Range 34-88   2 80 47
Gender   3 11 7
  Female 75 44   4 3 2
  Male 94 56   X 3 2
Race Grade
  AA 35 21   WD 23 14
  Ca 134 79   MD 82 49
Smoking 0   PD 53 31
  Avg PPY 52 31   NA 11 7
  Current 58 34 N
  Never 9 5   0 111 66
  Former 70 41   1 35 21
  UNK 32 19   2 19 11
Histology   3 0 0
  Adeno 89 51   X 4 2
  Squamous 63 37 Stage
  BAC 4 2   I 100 59
  Mixed 9 5   II 36 21
  NSCLC 6 4   III 26 15
  Other 1 1   IV 1 1
  UNK 6 4
AA, African American; Ca, Caucasian; Avg PPY, Average Packs Per Year; UNK,  unknown;
Adeno, adenocarcinoma; Squamous, squamous cell carcinoma; BAC, bronchioalveolar
carcinoma; WD, well differentiated; MD, moderately differentiated; PD, poorly
differentiated; NA, not available
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activation failed to correlate with survival (p = 0.125; Figure 1). It was surprising that none
of these clinicopathologic features was associated with ERK activation.  In particular, it was
expected that histology may have correlated with pERK staining since mutational patterns of
oncogenes thought to utilize MAPK signaling such as K-Ras and EGFR are known to occur
more frequently in adenocarcinomas and bronchioalveolar carcinomas (BAC), respectively.
Smoking is the greatest risk factor for developing lung cancer.  In clinical practice we
estimate a person’s risk based on his or her pack year history, which is calculated as the
number of packs smoked per day multiplied by the number of years that the person has
smoked (i.e. two packs per day x 20 years = 40 pack years).  In general, the threshold for
increased risk begins at 10 pack years.  To determine the correlation between smoking and
elevated pERK, we separated patients into two groups based on their pack year history: (A)
those patients with greater than 10 pack years and (B) those patients with less than a 10 pack
year history.  We found that smoking was significantly associated with increased ERK
activation (p = 0.05; Figure 2).  This finding was intriguing in light of the fact that cigarette
carcinogens are known to be the causal agents in K-Ras mutational activation in NSCLC
(Husgafvel-Pursiainen et al., 1993; Slebos et al., 1991).  In addition, smoking status has been
shown to be a useful clinical predictor of anti-EGFR sensitivity, where non-smokers have
been shown to have the greatest benefit.
K-Ras mutation-positive tumors demonstrate elevated pERK and have a higher rate of
disease recurrence. To evaluate whether the presence of Ras mutations in patient samples
was associated with elevated ERK activation we used the original tissue blocks from which
the TMA was created to extract tumor DNA and determine the K-Ras and EGFR mutation
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Figure 1.   ERK activation is not associated with worse overall survival.  Kaplan-Meier
survival plot by cytoplasmic pERK staining (14% cutoff).
                 
Figure 2.  Smokers have increased ERK activation.  Patients were divided into two groups
based on the number of pack years they smoked and a cutoff of 10 pack years.  The mean
percent of cells stained positive for pERK staining was calculated for each group and
compared using Student’s t-test.
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status of these patients.  Due to the varying number of tumor cells present in the paraffin
embedded tissue samples, we were able to determine the mutational status of 47 patients.  Of
these, we identified 13 (28%) K-Ras mutations and 11 (23%) EGFR mutations.  Using this
information, we divided the patients into three groups based on their mutational status and
calculated the mean pERK level for each group (Figure 3).  K-Ras mutation-positive tumors
had a mean percentage of 20% cells stained positive for pERK, whereas EGFR mutants and
K-Ras/EGFR wild-type tumors displayed means of 7.3% and 12.8% positive cells,
respectively.  Thus, only the K-Ras tumors had a mean value greater than the cut-off value of
14% as a group. While there was a trend toward higher ERK activation in patients with K-
Ras mutations, this was not statistically significant using ANOVA to compare the difference
between all three means (p = 0.31).  This is the first report that K-Ras mutation positive
NSCLCs have increased ERK activation.  This result contrasts with observations with
pancreatic cancers, where K-Ras mutation status did not correlate with ERK activation (Lim
et al., 2005; Lim et al., 2006; Yip-Schneider et al., 1999).
Stage is the best prognostic indicator used in clinical practice, mainly because early
stage disease can be treated with potentially curative surgery.  Despite the increased chance
of cure, approximately 40% of surgical patients still have disease recurrence.  In the current
cohort of patients 36% had either local or distant recurrence following surgery.  In contrast,
53% of patients with K-Ras mutations experienced disease recurrence (OR 2.04; CI 0.65-
6.46) (Figure 4).  Together, results from these studies suggests that, in cell culture and in
human tumors, constitutive activation of K-Ras results in increased ERK signaling as
measured by detection of ERK phosphorylation. In addition, we have identified K-Ras
mutations as a predictor of increased ERK activation and risk of relapse following surgical
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Figure 3.  K-Ras mutation-positive tumors demonstrate increased ERK activation.
Patients were divided into three groups based on their K-Ras and EGFR mutation status. The
mean percent of tumor cells stained positive for pERK staining was then determined for each
group. (p = 0.31)
                              
Figure 4. Patients with K-Ras mutations are at increased risk of disease recurrence
following surgical resection of their tumor.  Of the 169 tumor specimens evaluated we
were able to collect disease recurrence data on 134 patients.  K-Ras mutation status was then
compared in patients who were found to have local or distant disease recurrence following
surgical resection.  (Odds ratio 2.04; confidence interval 0.65-6.46)
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resection.  Thus in addition to extending these analysis to a larger cohort of patients, it will
be important to determine if inhibition of ERK activation can reduce NSCLC recurrence
following surgical resection.
The Raf>MEK>ERK pathway is critical for K-Ras-mediated NSCLC growth and
proliferation. Although we observed a correlative association between K-Ras mutation and
elevated ERK activation, these analyses do not establish whether ERK activation is
mechanistically important for maintenance of tumor growth.  To provide more direct
evidence for a causal role for the ERK signaling pathway in Ras-mediated NSCLC, we
utilized genetic and pharmacologic approaches to block ERK signaling in K-Ras mutant
NSCLC.
For these analyses, we generated or obtained retrovirus vectors that express short
hairpin interfering RNA (shRNA) to silence endogenous K-Ras or B-Raf expression,
respectively.  We infected and established A549 NSCLC adenocarcinoma cells with stable
suppression of K-Ras and B-Raf. Stable expression of jellyfish green fluorescent protein
(GFP)-targeted shRNA was used as a negative control for the nonspecific effects of shRNA-
stimulation of endogenous activities associated with cellular processing of RNAi.
Knockdown of endogenous K-Ras and B-Raf protein expression was confirmed by western
blot analysis (Figure 5A), which revealed nearly complete loss of protein expression for both
genes.  Although A549 cells are known to possess the common K-Ras12V mutation, it had
not been demonstrated that expression of this mutant allele is required for continued growth
and proliferation of this cell line.  As can be seen in Figure 5B, stable suppression of mutant
K-Ras greatly impaired anchorage-independent growth of the A549 cell line.   These results
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Figure 5. Raf is a critical effector of Ras-mediated NSCLC.   (A) Stable expression of
shRNA greatly reduced K-Ras and B-Raf expression measured by western blot analysis of
K-Ras and B-Raf.   GFP shRNA was used as a negative control.  (B) Stable suppression of
K-Ras and B-Raf impaired A549 NSCLC cell anchorage-independent growth. A549 cells
stably expressing GFP, K-Ras or B-Raf shRNA were seeded at a density of 5000 cells per
well into 0.6% agar. Soft agar cultures were maintained for six weeks and then the number of
proliferating multi-cellular colonies formed was quantitated.  Data shown are representative
of three independent experiments.   
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are similar to those described previously in a different tumor type, where shRNA suppression
of mutant Ras impaired the growth of pancreatic carcinoma cells (Brummelkamp et al.,
2002).
In addition to blocking mutant K-Ras, we also found that stable suppression of B-Raf
also resulted in a significant reduction in anchorage-independent growth.  These observations
are similar to those made in human melanomas, where shRNA silencing of mutant B-Raf
greatly suppressed growth in soft agar (Hingorani et al., 2003; Sharma et al., 2005;
Sumimoto et al., 2004).  These data indicate that B-Raf activation by mutant K-Ras is
required for continued tumor growth and that pharmacologic inhibition of the ERK pathway
will be an effective therapeutic strategy for K-Ras mutation positive NSCLCs.
To complement our genetic analysis and provide further evidence for the importance
of the Raf-MEK-ERK pathway in K-Ras-mediated NSCLC, we used pharmacologic
inhibitors to determine if inhibition of ERK activation would impair the anchorage-
dependent and anchorage-independent growth of A549 cells. To perform this analysis we
utilized three distinct pharmacologic inhibitors of the ERK pathway. We used the well-
characterized U0126 MEK1 and MEK2 kinase inhibitor, the sorafenib (BAY 43-9006;
Nexavar) multi-kinase inhibitor, which acts in part by inhibiting Raf kinase, and MCP110, a
small molecule inhibitor of Ras-Raf protein-protein interaction (Davies et al., 2000; Kato-
Stankiewicz et al., 2002; Lyons et al., 2001).  The advantage of using all three of these
inhibitors is that they each work by blocking different stages of ERK signaling, starting at the
beginning of the pathway where Ras activates Raf and ending where MEK activates ERK.
Since there can be cross-talk with other signaling pathways at each level of this pathway, this
approach will critically evaluate methods that block the Raf-MEK-ERK signaling cascade at
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distinct points in the pathway.  Another advantage of using different inhibitors is that each is
known or likely to have off-target activities that may contribute to their perceived efficacy.
Treatment with all three compounds completely abolished ERK phosphorylation in
A549 cells as measured by western blot analysis (Figure 6A), indicating that they all
effectively inhibited ERK signaling.   To determine the impact of impaired ERK signaling on
the transformed growth properties of these cells, we first evaluated the consequences of
inhibitor treatment on anchorage-dependent growth.  We observed that inhibition of Ras-Raf
interaction (MCP110) or Raf kinase activity (sorafenib) greatly impaired their ability to
proliferate in an anchorage-dependent manner, but surprisingly, inhibition of MEK (UO126)
had no effect (Figure 6B).  In contrast, we found that all three inhibitors were capable of
blocking growth in soft agar (Figure 6C), a measure of anchorage-independent growth and a
gold standard in cell-based models for preclinical oncology drug development.  Together,
these results demonstrate the importance of the Raf-MEK-ERK pathway for K-Ras-mediated
NSCLC and validate the further development of ERK cascade inhibitors for NSCLC
treatment.
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Figure 6. The Raf-MEK-ERK signaling pathway is critical for Ras-mediated NSCLC.
A549 cells were treated with 10 µM UO126, 20 µM MCP110, and 10 µM sorafenib/BAY
43-9006 and the degree of inhibition of ERK activation, anchorage-dependent and
anchorage-independent growth was compared to vehicle-treated control cultures.  (A)
Inhibitor treatment suppresses ERK activation.  A549 cells were treated with the indicated
inhibitor for 24 h and then ERK activation was measured by western blot analysis for pERK.
Total ERK levels were determined to verify equivalent loading of total protein.  (B) Inhibitor
treatment reduces anchorage-dependent growth.  A549 cells were seeded into 96-well plates
at a density of 5 x 103 cells per well and treated with the indicated inhibitors.  Following 48 h
of treatment, cell viability was measured using the WST-1 colorimetric assay.  (C)  Inhibitor
treatment impairs anchorage-independent growth.  A549 cells were seeded at a density of 5 x
103 cells per well into complete growth medium supplemented with 0.6% agar and
supplemented with the indicated inhibitors. Colonies were grown for six weeks and then the
number of colonies formed was counted.  Data shown are representative of three independent
experiments.
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E. Discussion
Although the overall 5-year survival for NSCLC is only 15%, recent advances in our
understanding of cancer genetics and biology will undoubtedly lead to vast improvements in
our ability to effectively treat this disease. Proof of these advancements is evidenced by the
recent incorporation of novel target-based therapies into our treatment paradigms, such as of
bevacizumab (Avastin) and erlotinib (Tarceva) (Sebolt-Leopold and English, 2006). Another
recent advancement has been the validation that adjuvant chemotherapy increases overall
survival of patients following surgical resection (Arriagada et al., 2004; Douillard et al.,
2006; Kato et al., 2004; Strauss et al., 2004; Winton et al., 2005).  Previously, up to 60% of
surgically resected stage IB-IIIA patients relapsed and died following surgical resection
(Johnson and Rabin, 2005).  While it is clear that certain patients receive great benefit from
adjuvant chemotherapy, the overall impact on the entire patient population is relatively small,
with an overall risk reduction of approximately 10%.  Thus in the current state of the art
many patients receive adjuvant chemotherapy while only a few receive benefit. The other
patients are exposed to the toxicities of chemotherapy without a positive impact on survival
either because they were the patients who would not have relapsed or because the adjuvant
chemotherapy regimen was not effective for their disease.  Since it is currently not possible
to select patients likely to relapse or likely to benefit from adjuvant therapy, it is imperative
that clinical and molecular markers be identified in order to select those patients who should
receive adjuvant chemotherapy.   In this study, we evaluated the importance of the ERK
protein kinase cascade as a clinical correlate and as a drug target for NSCLC treatment.  Our
results support the importance of ERK-targeted therapies for NSCLC treatment.
 Signal transduction targeted-based therapies are widely considered the future of
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cancer treatment, and efforts to develop inhibitors of mutant Ras and the Raf-MEK-ERK
signaling pathway has garnered considerable interest (Roberts and Der, 2007).  To identify
patients most likely to benefit from adjuvant therapy targeting the ERK signaling pathway,
we retrospectively evaluated the clinicopathologic features associated with aberrant ERK
activation in a cohort of 169 early staged NSCLC patients previously treated with surgical
resection.  Elevated pERK expression has been shown to be associated with more advanced
NSCLC tumors (stage III and I) (Vicent et al., 2004).  In addition, while univariate analysis
showed increased cytoplasmic staining was associated with worse overall survival,
multivariate regression modeling was unable to validate pERK as a negative prognostic
marker (Vicent et al., 2004).  In the current study, the patient population was comprised of
predominantly early stage NSCLC patients with 80% being stage I-II.  In all, the median
percentage of pERK stained cells was 14%, and using this as the positive cutoff we found
30% of all tumor specimens showed activation of ERK.  This pattern of pERK staining was
similar to the previously reported 15% and 34% respectively (Vicent et al., 2004).  Despite
the similar pattern of ERK activation we did not find the same association with grade of
differentiation, stage or survival.  The most likely explanation for these differences is due to
the different stage composition in each of the two patient cohorts.
Interestingly, we found that elevated ERK activation was positively associated with
smoking status. Using pack-year history to calculate smoking exposure we found that
patients with greater than a 10 pack-year history had higher levels of pERK.  Although
EGFR mutations and gene amplification are good markers for predicting response to EGFR-
directed small molecule inhibitors, these tests are not commonly performed in clinical
practice. Thus the most reliable clinical marker to predict EGFR sensitivity has become
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smoking status (Pham et al., 2006).  In the current treatment paradigm, non-smokers are
offered erlotinib in addition to the traditional chemotherapy while smokers are limited to
only the traditional treatment options.  Although our findings need to be further validated,
they suggest that smokers may be more likely to benefit from ERK-directed therapies than
non-smokers.   In support of this we found that patients with EGFR mutations had the lowest
levels of ERK activation suggesting that mutant EGFR does not signal through the ERK
pathway in NSCLC.  This result is consistent with previous in vitro analysis where EGFR
mutants were found to have a shift in the signaling pathways that they utilize, leading to
reduced ERK activation and increased EGFR-mediated AKT serine/threonine kinase and
STAT transcription factor activation (Sordella et al., 2004).  Thus, if our results are
confirmed in prospective studies, future treatment paradigms may use smoking status to
select non-smokers for EGFR therapies and smokers for ERK-targeted therapies.
In addition to EGFR mutations, K-Ras mutations are another common genetic
alteration in NSCLC carcinogenesis. Early cell culture studies utilizing ectopic
overexpression of activated Ras in mouse fibroblast model cell systems showed that
activation of the K-Ras oncogene clearly causes activation of the Raf-MEK-ERK pathway.
However, Ras utilizes different downstream effectors in a tissue and tumor type specific
fashion, and validation of Raf as the critical effector in NSCLC has yet to be confirmed
(Repasky et al., 2004).  Furthermore, it has become clear that our previous model cell system
studies may be compromised by issues such as overexpression artifacts and cell type and
species differences in Ras-mediated signaling.  Hence, there is a strong need to re-assess the
relationship between Ras mutational activation and stimulation of the ERK cascade in more
physiologically-relevant human cell systems.  To address this question we compared the
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level of ERK activation in patients with EGFR mutations, K-Ras mutations, and who were
wild-type for these molecular alterations. We found that only the group of patients with K-
Ras mutations had a median percentage of pERK positive cells greater than the cutoff of
14%.  These data suggest that, in contrast to pancreatic cancers (Lim et al., 2005; Lim et al.,
2006; Yip-Schneider et al., 1999), K-Ras does utilize the ERK signaling pathway in NSCLC.
Since these data show a correlative, but not causal, association between K-Ras and
pERK, we used a cell culture-based approach to determine if Raf-MEK-ERK signaling was
required.  Results from these experiments demonstrate that mutant K-Ras is required for
tumor maintenance and that the Raf-MEK-ERK signaling cascade is a critical effector
pathway of Ras in NSCLC.  In addition these data suggest that ERK-targeted therapies will
be an effective treatment strategy in patients with K-Ras mutation positive NSCLC.  In
particular, our results support the evaluation of these therapies in the setting of adjuvant
therapy.  As stated above there is a great need for improved patient selection in the adjuvant
setting and our results showing that K-Ras mutations lead to increased risk of relapse,
suggest that K-Ras mutation status is an important molecular marker to predict disease
recurrence following surgery. Since several Raf and MEK inhibitors are currently in clinical
trials, we are hopeful that they may be useful agents in an adjuvant setting (Roberts and Der,
2007).
These findings have implications for other treatment settings of NSCLC as well. K-
Ras mutation-positive NSCLCs have been shown repeatedly to be resistant to small molecule
inhibitors of EGFR in patients with advanced disease (Eberhard et al., 2005; Pao et al.,
2005).  Our finding that the ERK signaling cascade is critical for K-Ras-mediated NSCLC
growth, when coupled with previous observations that ERK activation is associated with
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advanced NSCLC tumors, suggest that Raf and MEK inhibitors will be effective treatment
options for stage III and IV advanced NSCLC tumors with K-Ras mutations (Vicent et al.,
2004).  Although discontinued due to poor pharmaceutical properties, the MEK inhibitor, CI-
1040, revealed an association between baseline pERK and response in phase II trials, further
highlighting the importance of identifying the subset of patients with elevated ERK
activation (Rinehart et al., 2004).   In addition, in vitro analysis has shown that the ERK
pathway may promote resistance to chemotherapy, and that the use of small molecule
inhibitors of MEK can act in synergy with commonly used NSCLC chemotherapeutic agents
such as paclitaxel (Brognard and Dennis, 2002; MacKeigan et al., 2000; Skobeleva et al.,
2007).  Thus, this may represent the beginning of individualized therapies where Ras
mutation status or IHC staining for ERK activation will be used to select patients for
treatment with either ERK pathway or EGFR inhibitors, or other targeted agents that block
other signaling pathways involved in NSCLC growth.
In conclusion, we have identified K-Ras mutations as a potential marker for both
elevated ERK activation and increased risk of disease recurrence following surgical
resection. In addition we have shown that K-Ras-mediated NSCLCs are dependent on the
ERK MAPK pathway.  Together these results support the continued evaluation of Raf and
MEK inhibitors for NSCLC treatment, particularly in the setting of adjuvant therapy.  To
advance our current understanding of the role of ERK signaling in NSCLC, we are currently
constructing two additional TMAs enriched with patients with known metastatic disease as
well as with patients who have been treated with standard platinum-based chemotherapy.
This will allow us to evaluate whether ERK activation can be used to predict site-specific
metastasis and determine whether ERK mediates chemotherapy resistance in patients with
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advanced NSCLC.
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Chapter V
Conclusions and Future Directions
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A. Overview
Our studies presented here were aimed at evaluating two distinct approaches to
inhibit Ras-mediated growth transformation of non-small cell lung cancer cells
(NSCLCs).  The first examined the requirement of isoprenylcysteine-O-carboxyl
methyltransferase (Icmt) catalyzed methylation of the carboxyl-terminal cysteine of K-
Ras for proper localization and function. These studies addressed both the potential
therapeutic value and the potential normal cell toxicity limitations of Icmt inhibitors.
While efforts to exploit the requirement of CAAX-signaled post-translational
modifications for anti-cancer drug development have focused primarily on Ras, it is
recognized that other CAAX-terminating proteins may also be inhibited by these
approaches (Winter-Vann and Casey, 2005). Therefore, in addition to examining the
impact of inhibiting Icmt on K-Ras, we also examined the impact of inhibiting this and
other modifications on the localization and function of Rho family proteins.  Like Ras,
Rho family GTPases are potential targets of Icmt inhibitors and key mediators of many
normal cellular processes (e.g., cell cycle progression, cell survival), and their aberrant
function is associated with human cancer development (Etienne-Manneville and Hall,
2002; Sahai and Marshall, 2002).  Additionally, as elaborated below, Rho function is
necessary for Ras mediated oncogenesis (Bar-Sagi and Hall, 2000; Khosravi-Far et al.,
1995; Lambert et al., 2002; Malliri et al., 2002; Murphy et al., 1999; Qiu et al., 1997;
Qiu et al., 1995a; Qiu et al., 1995b; Roux et al., 1997).   Therefore their response to Icmt
inhibition may influence the outcome of Icmt inhibitor treatment both on Ras-mediated
growth transformation and also on normal cell toxicity.
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Another approach to inhibiting Ras in NSCLC has been to inhibit downstream
effector signaling pathways critical for Ras-mediated oncogenesis.  The Raf-MEK-ERK
protein kinase pathway has garnered considerable interest as the key signaling cascade
utilized by Ras in oncogenesis.  However, since Ras can utilize at least four distinct non-
Raf effector pathways to promote oncogenesis (e.g., the PI3K-AKT and RalGEF-Ral
pathways), whether inhibition of the Raf-MEK-ERK pathway alone will be effective for
blocking the Ras-mediated growth of NSCLC has not been addressed.  Therefore we
examined the importance of this pathway in Ras mutation-positive NSCLC cell lines and
additionally characterized Ras mutation and ERK activation in patient tumor specimens.
In the latter study, an important issue that we addressed was whether Ras mutation status
provided a reliable genetic correlation with elevated ERK activity, and presumably with
ERK dependency, in NSCLCs.  The remainder of this chapter summarizes the results of
these studies and identifies some key unanswered questions for future investigation.
B. Icmt is critical for Ras-mediated NSCLC anchorage-independent growth and
tumorigenicity.  What is the mechanism of this growth inhibition?
In search of novel approaches to inhibit Ras-mediated oncogenesis, efforts to
develop inhibitors of Icmt have recently intensified despite previous results that indicated
only a mild disruption of Ras function when carboxyl methylation was impaired (Kato et
al., 1992).  Fueled by recent observations that K-Ras mediated transformation is greatly
reduced in mouse embryonic fibroblasts (MEFs) deficient in Icmt function, we used
genetic and pharmacologic approaches to inhibit Icmt function in NSCLC cells harboring
endogenous K-Ras mutations (Bergo et al., 2004a).  While these approaches blocked
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NSCLC anchorage-independent growth and tumorigenicity, the exact mechanism of this
inhibition remains unknown.  In multiple studies it has been demonstrated that the loss of
Icmt leads to only a partial disruption of K-Ras membrane association (Bergo et al.,
2004a; Kato et al., 1992; Winter-Vann et al., 2005), and in agreement with these
observations we found a similar partial degree of K-Ras mislocalization in Icmt -/- MEFs
(chapter 3).  In addition, we were unable to detect a change in localization of GFP-tagged
mutant and wild-type K-Ras in NIH 3T3 cells treated for 24 hr with cysmethynil, an Icmt
inhibitor (data not shown).  Together these findings raise questions about the mechanism
of Icmt inhibition and whether perturbation of Ras association with the plasma membrane
alone is sufficient for the anti-tumor activities of Icmt inhibition.
There are several possible explanations for these observations. First, there are
reports that methylation of Ras is critical for protein-protein interactions between Ras and
its downstream effectors, independent of its effects on localization (Chen et al., 2000b;
Chiu et al., 2004).  If so, one possible explanation for the ability of Icmt loss to impair
Ras oncogenicity may be that lack of carboxyl methylation of Ras impairs association of
Ras with downstream effectors or regulatory proteins required for full transformation. In
its initial characterization the Icmt inhibitor, cysmethynil, was shown to inhibit EGF
stimulated ERK activation (Winter-Vann et al., 2005).  Whether this inhibition was due
to mislocalized Ras or to impaired effector binding is unknown, but this finding further
raises questions surrounding the role of methylation in Ras transformation.  In another
report, in vitro proteolysis of the AAX amino acids from the carboxyl-terminal domain of
K-Ras was shown to inhibit binding of K-Ras to microtubules.  In vitro methylation of
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these cleaved products restored microtubule binding, thus demonstrating that carboxyl
methylation was required for this interaction (Chen et al., 2000b).
Additionally, other CAAX-terminating proteins have been shown to require
carboxyl methylation for proper function independent of the role in localization, thus
further supporting the hypothesis that carboxyl methylation is an important regulator of
protein-protein interactions (Fukada et al., 1994; Maske et al., 2003; Parish et al., 1995).
For instance, G protein γ subunits are farnesylated and methylated.  In the case of the
photoreceptor G protein transducin (Tαβγ), methylation has been shown to facilitate Tα
and Tβγ subunit interactions independent of its role in G protein localization (Fukada et
al., 1994).   In addition to increasing subunit interactions, methylation is also important
for mediating G protein interactions with their downstream effectors.  Specifically,
demethylated γ-subunits were shown to have a ten-fold lower ability to activate the
downstream effectors phospholipase C and phosphoinositol 3-kinase (Parish et al., 1995).
Further evidence that methylation is critical for functions other than localization comes
from studies that have shown methylation is needed for protein-protein interactions
between lamin B and an unidentified protein on the inner surface of the nuclear envelope
(Maske et al., 2003).   
Collectively, these findings suggest that, despite its weak effects on localization,
inhibition of Icmt may drastically impair Ras function by altering protein-protein
interactions.  Therefore, an important future direction for the characterization of Icmt
inhibitors will be to determine whether Ras interaction with and activation of key
downstream effectors is impaired sufficiently to contribute to the loss of Ras
oncogenicity.  To test this, GFP-K-Ras(12V) stably expressed in Icmt -/- or +/+ MEFs
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could be co-immunoprecipitated with its endogenous effectors, to determine if Ras
effector binding is impaired in the absence of Icmt.  Although Ras localization is not
completely abolished in these cells, it is possible that the partial mislocalization may
result in decreased effector binding. To account for this possibility we will also evaluate
the Ras-effector interactions of myristoylated Ras, which as described below has been
validated to localize to the plasma membrane independent of the three CAAX-signaled
processing modifications (Buss et al., 1989).
A second possible mechanism whereby inhibition of Icmt blocks Ras function
despite only causing partial mislocalization of Ras itself is that it might block the function
of other CAAX-terminating proteins that are critical for Ras-dependent NSCLC growth.
For example, one critical Ras effector pathway involves Ral guanine nucleotide exchange
factor (RalGEF) activation of the RalA and RalB small GTPases.  Ral GTPases terminate
in CAAX motifs and are modified by geranylgeranylation, and there is considerable
evidence that Ral GTPase function is critical for Ras-mediated oncogenesis (Repasky et
al., 2004), in particular, in pancreatic cancers (Lim et al., 2006).  Whether Ral GTPases
are also important for Ras-mediated oncogenesis in NSCLCs, and whether Ral GTPase
function is critically dependent on Icmt carboxyl methylation, will be important issues to
be addressed in future studies. Finally, another Icmt substrate, the Rab5 small GTPase,
functions downstream of the Rin proteins, another class of Ras effectors (Tall et al.,
2001).  Rab5 regulates endocytosis, a process that may be important for facilitating cell
surface epidermal growth factor receptor (EGFR) tyrosine kinase function (Barbieri et
al., 2004).  Ral proteins are also intimately involved in endocytic processes, thus there are
multiple Ras effectors necessary for proper functioning of this key pathway whose
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activity is likely to depend on Icmt function.  Whether the Rin-Rab5 signaling cascade is
involved in Ras-mediated oncogenesis in NSCLC needs to be addressed.
A third possible mechanism of Icmt inhibitor blockade of Ras function that does
not involve mislocalization of Ras may instead involve a requirement for Icmt-mediated
carboxyl methylation of Rho family GTPases downstream of Ras.  As mentioned above,
there is considerable evidence that Ras-mediated transformation of rodent fibroblasts is
dependent on RhoA, Rac1 and Cdc42 (Bar-Sagi and Hall, 2000; Khosravi-Far et al.,
1995; Qiu et al., 1997; Qiu et al., 1995a; Qiu et al., 1995b; Roux et al., 1997).  Another
key Ras effector pathway involves the Tiam1 guanine nucleotide exchange factor, which
activates Rac small GTPases (Lambert et al., 2002; Malliri et al., 2002).  Rnd3 gene and
protein expression is upregulated by Ras activation of the ERK signaling pathway
(Shields et al., 2007), and our lab has found upregulated Rnd3 in a wide variety of Ras-
transformed cells (Singh and Der, unpublished).  In our evaluation of Rho family proteins
described in Chapter III, we found that Rnd proteins were exquisitely sensitive to loss of
Icmt, much more so than Ras.  Interestingly, two recent reports have shown that
Rnd3/RhoE is upregulated in NSCLC tumor specimens and is associated with worse
overall survival (Cuiyan et al., 2007; Zhang et al., 2007).  Therefore, it is possible that
Rnd3 may be critical for Ras-mediated NSCLC.  Additionally, since we found that Rnd
proteins were exquisitely sensitive to loss of methylation, blockade of Rnd3 localization
and function may explain the growth inhibitory effects of Icmt inhibition reported in
chapter 2.
We plan to determine whether a myristoylated-fusion protein of K-Ras can rescue
the growth inhibition of K-Ras mediated NSCLC resulting from Icmt inhibition. This will
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further our understanding of whether Ras carboxyl methylation is important solely for
plasma membrane localization or whether it is required for Ras-effector interactions.
These experiments will also give us additional insight into whether the growth inhibitory
activity of Icmt blockade is a result of incomplete Ras posttranslational processing or
whether it is due to the incomplete posttranslational processing of other CAAX proteins.
Our lab showed previously that the addition of an N-terminal myristate fatty acid signal
sequence to Ras [designated Myr-Ras(61L)] results in a variant protein that retains potent
transforming activity, yet no longer depends on CAAX-signaled modifications for
function (Buss et al., 1989).  Furthermore, our lab showed that Myr-H-Ras(61L) was
insensitive to inhibition by FTase inhibitor (FTI) treatment (Cox et al., 1994).  Therefore,
if Myr-K-Ras(12V) renders NSCLC cells resistant to Icmt inhibition, it would suggest
that mutant K-Ras(12V) is the key target that accounts for the inhibitory activities of
these compounds and that methylation is critical for localization. However, it is possible
that Myr-K-Ras(12V) may still not rescue the cell from the growth inhibitory effects
resulting from loss of Icmt despite being membrane-targeted.  Other critical targets of
Icmt may also need to be restored in order to rescue the growth inhibitory effects. If the
Myr-K-Ras(12V) is not able to rescue cells from Icmt inhibition, data from the co-
immunoprecipitation experiments described above will guide us in determining whether
this construct failed to rescue because of impaired effector interactions or because the
function of other critical CAAX proteins was still blocked.  Therefore, further analysis is
needed to validate which proteins, or which protein-protein interactions, may contribute
to Icmt-mediated growth inhibition.
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C. What is the impact of impaired Icmt activity in animal models: additional
mechanisms of anti-tumor activity or severe toxicity?
As detailed in chapter 4, K-Ras mutation-positive tumors are associated with a
worse overall survival, increased risk of disease relapse following surgery, and resistance
to EGFR-directed small molecule inhibitors (Eberhard et al., 2005; Mascaux et al., 2005;
Pao  et al., 2005). Thus, while questions remain regarding the mechanism of Icmt
inhibitors, the fact that we found Icmt function to be critical for K-Ras-mediated NSCLC
supports further validation of this novel target for the treatment of K-Ras-mediated
NSCLC.
An important approach to further validating Icmt as a target in K-Ras-mediated
NSCLC would be to evaluate the consequences of Icmt blockade in an appropriate mouse
model of lung cancer. Recent characterization of a K-Ras-driven genetically engineered
mouse model (GEMM) of lung cancer (Johnson et al., 2001; Sweet-Cordero et al., 2005)
has shown that it more faithfully recapitulates human adenocarcinoma than previous lung
cancer models where H-Ras and N-Ras were expressed using traditional transgenic
approaches resulting in direct expression of the oncogenic allele in every cell of the
targeted tissue (Adams and Cory, 1991).  In the current model, mice harbor latent
oncogenic alleles of K-Ras that are spontaneously activated in vivo in a subset of lung
epithelial cells rather than the uniform expression seen in previous models. (Johnson et
al., 2001).  The application of genetically engineered mouse models, which are thought to
more precisely mimic the genetic and biological evolution of human cancers, is expected
to greatly improve our success in developing effective therapeutics (Sharpless and
Depinho, 2006). These models offer advantages over traditional xenograft models, in
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particular, by more accurately replicating the tumor cell-host tissue interactions seen in
human cancers.  Since host stromal interactions may critically dictate tumor growth and
drug response, it is widely believed, although not yet proven, that GEMMs will provide
more accurate models for target-based anti-cancer drug discovery.  Using shRNA
suppression of Icmt, we found that loss of Icmt function partially reduced tumorigenicity
in a NSCLC xenograft model.  In this model, inhibition of Icmt was limited only to the
NSCLC cells stably expressing the shRNA.  We speculate that systemic treatment with
Icmt-targeted small molecule inhibitors, such as cysmethynil, will demonstrate a more
profound anti-tumor effect in animal models than observed in our Icmt shRNA xenograft
experiments, possibly through an anti-angiogenic mechanism.  This speculation is
supported by evidence that endothelial cell function is critically dependent on Icmt
function (Kramer et al., 2003; Lu et al., 2004; Zhang et al., 1997).
Our hypothesis can be tested using the GEMM model to evaluate blood vessel
growth within the tumor.  Therefore, future directions may include testing the
effectiveness of cysmethynil in treating NSCLC using the K-Ras driven NSCLC GEMM
mice. In these studies the primary endpoints will be tumor response as measured by
tumor size and survival.  In addition, secondary endpoints important for the development
of these inhibitors include measuring Icmt activity within the tumor to validate that the
target is sufficiently blocked, as well as to evaluate the effects of Icmt blockade on
angiogenesis to determine if Icmt function is necessary for new blood vessel formation.
Also, as addressed below, if loss of Icmt function is tolerated by lung epithelial cells,
development of mice with conditional loss of Icmt in adult lung tissue, which can then be
crossed with the K-Ras lung tumor model, would be another excellent approach to
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determine if Icmt loss will be effective for blocking Ras-mediated tumor formation.
Finally, another concern for normal cell toxicity is the existence of Ras family proteins
that undergo CAAX-signal posttranslational modifications, but that, unlike Ras, appear to
function as tumor suppressors.  These include the farnesylated Ras family proteins Di-
Ras/Rig and NOEY2/ARHI, proteins whose expression is lost in human cancers (Ellis et
al., 2002; Yu et al., 1999).  Therefore, in some settings, Icmt inhibitors may actually
promote oncogenesis.
While the efficacy of cysmethynil may benefit from the fact that there are several
hundred potential targets of Icmt mediated methylation, one concern is that inhibition of
these alternative targets may lead to unacceptable toxicity.  Previously, it has been shown
that Icmt function is critical during development, as Icmt knockout mice die during early
embryogenesis (Bergo et al., 2001).  However, since viable, proliferating fibroblasts that
are deficient in Icmt function can be maintained in cell culture, it is possible that adult
tissue may not be as critically dependent on Icmt function.  Whether this will be the case
for other normal tissues, in particular epithelial and hematopoietic cells, remains to be
determined.  Addressing this issue will help determine whether Icmt inhibition will cause
significant normal cell toxicity, an important question that will be critical to the continued
progress of this approach to anti-cancer drug development.  Again, the use of the K-Ras
driven NSCLC GEMMs will allow us to evaluate not only the effectiveness of Icmt
inhibitors, but will also help us predict the toxicity profile that we may expect in patients.
D. Rho proteins in Cancer: novel targets or sources of toxicity?   
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In the classical review entitled “Hallmarks of Cancer”, Hanahan and Weinberg
describe six essential alterations in cell biology that lead to development of cancer
(Hanahan and Weinberg, 2000). These alterations include self-sufficiency in growth
signals, insensitivity to anti-growth signals, evading programmed cell death, limitless
replicative potential, sustained angiogenesis, and tissue invasion and metastasis.  Rho
family members are known for their ability to control actin reorganization and regulate
cell polarity, cell motility, cell shape, cell adhesion, and membrane trafficking.  As such,
it is thought that Rho proteins contribute to cancer progression by influencing the cell’s
ability to migrate and thus invade and metastasize.  In addition to these alterations in
cellular function, aberrant activation of Rho proteins have also been shown to contribute
to other “hallmarks of cancer” such as cell growth, proliferation, survival, and
angiogenesis (Ridley, 2004).   Therefore, defining pharmacologic approaches for
inhibition of Rho GTPase function may represent an important direction for target-based
anti-cancer drug discovery.
To date much of the evidence linking Rho proteins to cancer has centered on the
three canonical Rho members, RhoA, Rac1, and Cdc42.  However mounting evidence
implicating the importance of other Rho members in cancer has begun to accumulate.
For example, studies evaluating the expression of Rnd3 (RhoE) have shown it to be
overexpressed in NSCLC and associated with worse overall survival (Cuiyan et al., 2007;
Zhang et al., 2007). The hematopoietic cell-specific RhoH has been shown to be involved
in lymphoma and multiple myeloma (Preudhomme et al., 2000) and RhoC has been
found to be a critical mediator of metastasis in melanoma, lung and gastric cancer (Clark
et al., 2000; Hakem et al., 2005; Ikoma et al., 2004; Kondo et al., 2004).  In addition,
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Rac1b, Rac2, Rac3, Rnd1 and RhoG have all been found to be overexpressed in cancer
(Gomez del Pulgar et al., 2005).   
In chapter 3, we identified several Rho proteins as potential targets of FTase
inhibition, a finding that should aid in the future development of FTIs.  Additionally, we
showed Rho family localization is also exquisitely dependent on Rce1 and Icmt,
indicating that Rce1 and Icmt are promising targets to block aberrant Rho signaling in
cancer.  The critical question that remains is whether inhibition of these proteins will
result in a favorable therapeutic index where the anti-tumor efficacy outweighs normal
cell toxicity. Further research is needed to identify the role of the noncanonical Rho
family members in cancer and the impact of blocking their CAAX-signaled post-
translational modifications on normal cell physiology.
While target-based drug discovery is thought to be the future of cancer therapy,
early experiences have shown that rational drug design against select targets is not as
simple as we had hoped.  Using the epidermal growth factor receptor (EGFR) as an
example illustrates this point precisely.  EGFR is known to be overexpressed in 50-80%
of NSCLC, yet phase II-III clinical trials found EGFR inhibitors are only effective in
approximately 10% of patients (Fukuoka et al., 2003; Gatzemeier et al., 2007; Giaccone
et al., 2004; Herbst et al., 2004; Herbst et al., 2005; Kris et al., 2003).  The reason for this
discordance has since been explained by the fact that approximately 10% of NSCLC
contain EGFR activating mutations and it is mostly these patients that are sensitive to
EGFR inhibition (Eberhard et al., 2005; Lynch et al., 2004; Pao et al., 2005).  With this
experience in mind, we should be cautious in our interpretation of previous FTI clinical
trial results in solid tumors.  While FTIs were initially developed as anti-Ras drugs, it is
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possible that they may be effective in a smaller subset of patients whose tumors are
dependent on one or more non-Ras FTase substrates.  As mentioned above, in chapter 3
we found that in contrast to the canonical Rho members, localization of many of the
noncanonical Rho proteins is dependent on FTase function. Identification of the subset of
patients whose tumors are dependent on specific Rho proteins may provide a place for
FTIs in our armamentarium against cancer.  Similarly, identification of the role of
specific Rho proteins in cancer and identification of which tumors depend on the function
of these proteins will aid in the design and execution of clinical trials evaluating FTase,
GGTase, Rce1, and Icmt inhibitors.
Preclinical and clinical experience with FTase and GGTase inhibitors (FTIs and
GGTIs, respectively) has surprisingly shown these agents are relatively well tolerated
despite the fact that FTase and GGTase are each thought to modify approximately 50-60
substrates (Appels et al., 2005; Philips and Cox, 2007; Winter-Vann and Casey, 2005).
Whether this will be the same for Rce1 and Icmt inhibitors is unknown. Similar to FTase,
genetic disruption of Rce1 and Icmt results in embryonic lethality (Bergo et al., 2002;
Bergo et al., 2001; Mijimolle et al., 2005). Studies using conditional deletion of FTase
subsequently showed that FTase function is dispensable in adult tissue (Mijimolle et al.,
2005), a finding that has been confirmed in clinical trials where FTI treatment is well
tolerated (Basso et al., 2006; Philips and Cox, 2007). Whether FTase function is
dispensable because there are two other prenyltransferase enzymes or because its
substrates are not critical for normal cell physiology is not known (Basso et al., 2006).
However, unlike the prenyltransferases, there is thought to be only one endoprotease
(Rce1) and methyltransferase (Icmt) capable of completing the CAAX-signaled
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modifications.  This suggests that loss of either of these enzymes may have a more severe
effect on normal cell physiology than loss of any one of the prenyltransferases.
To date there is limited data regarding the requirement of Rce1 and Icmt function
for normal cell physiology.  In chapter 3, we show that both of these post-prenyl
processing steps are critical for the localization of most Rho family members. Since the
Rho family regulates a wide array of cellular functions it is essential that we determine
the impact of Rce1 or Icmt blockade in normal tissue.  One approach to address this
question is through the use of conditional knockout mouse models, where the animals are
allowed to complete development before the genes are silenced.  Targeted deletion of
Rce1 in either the heart or liver revealed that Rce1 is dispensable in the liver, while
deletion of Rce1 in the heart results in the accumulation of CAAX proteins in the cardiac
tissue and early death due to cardiomyopathies (Bergo et al., 2004b).  This is an
interesting finding and points to possible toxicities that may be expected with the use of
Rce1 inhibitors.  Similar studies of Rce1 in other tissues, as well as parallel experiments
evaluating Icmt are needed to fully appreciate the consequence of Rce1 and Icmt
inhibition on normal cell physiology.
While it is the global effect of impaired Rce1 and Icmt function on normal cell
physiology that we are concerned with, knockout studies of specific Rho proteins have
indirectly provided some insight into the potential ramifications of blocking Rho post-
prenyl processing.  To date studies evaluating the genetic deletion of Cdc42, Racs, RhoB,
RhoC, RhoG and RhoH have been completed. Knockout of Cdc42, Rac1 and RhoA
results in embryonic lethality (Chen et al., 2000a; Sugihara et al., 1998; Wang and
Zheng, 2007), whereas deletion of RhoB, RhoC, Rac2, Rac3, RhoG, or RhoH results in
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no evident developmental abnormalities (Cho et al., 2005; Corbetta et al., 2005; Gu et al.,
2006; Hakem et al., 2005; Liu et al., 2001; Roberts et al., 1999; Vigorito et al., 2004).
Conditional deletion of Cdc42 and Rac proteins in adult tissues has revealed tissue
specific roles for these Rho members such as hair loss (Cdc42 and Rac1), impaired
inflammatory recruitment (Rac1), hematopoietic abnormalities (Rac1 and Rac2) and
neuronal defects (Cdc42 and Rac3) (Benvenuti et al., 2004; Cancelas et al., 2005;
Cappello et al., 2006; Chen et al., 2006; Cho et al., 2005; Corbetta et al., 2005; Glogauer
et al., 2003; Roberts et al., 1999; Walmsley et al., 2003; Wu et al., 2006).  In addition,
deletion of RhoG and RhoH appear to disrupt normal B- and T-cell function (Roberts et
al., 1999; Vigorito et al., 2004).  While these results provide a glimpse of potential
toxicities that may be encountered from Rce1 or Icmt inhibition, they really highlight the
complexity of Rho function in normal cell physiology.  Rho proteins regulate diverse
cellular functions and there appear to be great tissue specific differences in the role of
Rho proteins.  In particular, there is tissue-specific expression of certain Rho members
(i.e., Rac2, Rac3, RhoH) as well as tissue-specific functions of specific Rho proteins
(Cho et al., 2005; Gu et al., 2005; Roberts et al., 1999).  To add to this complexity,
studies of the three Rac isoforms have shown they have both unique and redundant
functions.  These characteristics make it hard to predict whether inhibiting Rho post-
prenyl processing will be an effective treatment approach to cancer or whether it will be
too detrimental to normal cells. Furthermore, much of our knowledge of Rho function
comes from studies of the canonical Rho members.  Therefore, with little knowledge of
the function of the other Rho members it is hard to predict the consequence of global
Rce1 or Icmt activity on the entire Rho family.  Therefore, to complement conditional
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deletion studies of Rce1 and Icmt, additional deletion studies of the noncanonical Rho
proteins will be useful in characterizing their function and requirement in adult tissue.
E.  Defining the roles of ERK activation in NSCLC: incorporating Raf and MEK
inhibitors into NSCLC treatment paradigms.   
Because a key effector arm of Ras signaling in transformation includes the Raf-
MEK-ERK pathway, another potential approach to successful targeting of Ras-mediated
NSCLC may be downstream blockade of Raf or MEK.  Efforts to develop pharmacologic
inhibitors of the Raf-MEK-ERK pathway have been validated by the extensive evidence
from model cell culture models that ERK MAPK signaling is aberrantly activated in
cancer and can promote cell proliferation, cell survival and metastasis (Roberts and Der,
2007; Sebolt-Leopold and Herrera, 2004).  Despite the vast amount of information
regarding the presence of activated ERK in human tumors, little is known about the exact
role that ERK plays in vivo.  Based on these preclinical studies, it seems likely that
specific Raf and MEK inhibitors will gain FDA approval and join our armory in the fight
against NSCLC.  However, current cell culture analyses of these inhibitors suggest that
compensatory mechanisms may offset their inhibitory actions.
Since the Raf-MEK-ERK pathway can be regulated by a multitude of
mechanisms, at every level of the pathway, there is an emerging belief that effective
inhibition of this pathway will require concurrent inhibition of the cascade at multiple
points.  Another hurdle that we will have to be overcome is how to best use these agents.
Specifically, determining what genetic mutations will be useful for identifying those
patients who will be responsive to Raf and MEK inhibitor treatment has not been a
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straightforward issue.  Also, will ERK inhibition be the best biomarker for drug activity?
To answer these questions we will have to understand which tumors are dependent on
ERK activation and what role activated ERK plays in mediating tumor initiation, growth,
metastasis and chemotherapeutic response. Finally, another important development will
be the need to evaluate more specific and potent anti-Raf inhibitors.  Sorafenib, although
described as a Raf inhibitor, may elicit its clinical benefit primarily from its inhibition of
receptor tyrosine kinases involved in endothelial cell biology and tumor angiogenesis
(Wilhelm et al., 2004).  The recent initiation of clinical studies with the Raf-specific
PLX4032 kinase inhibitor will aid in this endeavor (Roberts and Der, 2007).
To address the questions of which tumors are dependent on ERK activation and
what role activated ERK plays in mediating tumor initiation, growth, and metastasis, we
used a tissue microarray comprised of 169 NSCLC tumors from patients surgically
resected at the University of North Carolina Hospital to evaluate the clinicopathologic
features associated with ERK activation.  Our results, described in chapter 4, indicate that
the presence of a K-Ras mutation may be associated with both increased risk of disease
recurrence following surgical resection and elevated ERK activation.  These results
suggest that K-Ras mutant NSCLCs are more aggressive compared to other NSCLCs and
that inhibition of ERK signaling may be an effective treatment option for these tumors.
Since these results only show an association between K-Ras mutation and ERK, we used
a cell-based approach to verify that the Raf-MEK-ERK cascade is critical for K-Ras-
mediated NSCLC.
Since all of our patients on the TMA were surgically treated as their primary
treatment modality, most of them never received chemotherapy.  Therefore, our TMA
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was not amenable to addressing the consequence of ERK activation on chemotherapeutic
response. Chemotherapy is the primary treatment modality for late stage disease and
recent advances have demonstrated a role for chemotherapeutic intervention following
surgical resection to reduce disease recurrence.  Where Raf and MEK inhibitors will fit
into the current treatment paradigm is unknown.  ERK activation has been shown to be
associated with advanced disease and a worse overall survival by univariate analysis
(Vicent et al., 2004), suggesting that Raf and MEK inhibitors may offer great benefit to
patients whose tumors are dependent on ERK signaling.  In addition, ERK has been
shown to promote resistance to chemotherapy, and the combination of small molecule
inhibitors of Raf and MEK with chemotherapeutic agents such as paclitaxel have been
shown to have synergistic effects in inhibiting oncogenesis  (Brognard and Dennis, 2002;
MacKeigan et al., 2000; Skobeleva et al., 2007).  To further explore the interaction
between ERK activation and response to platinum-based chemotherapeutic regimens, the
standard of care for advanced NSCLC, we plan to construct a new TMA enriched with
patients who received platinum based chemotherapy as their primary treatment modality.
This will allow us to evaluate the role of ERK activation in chemoresistance as well as to
further characterize the clinicopathologic features associated with ERK activation.
In our evaluation of ERK activation in NSCLC described in chapter 4, we did not
identify ERK activation as a prognostic marker of poor survival.  Previous analysis found
ERK activation to be associated with late stage disease and a marker of poor survival in
univariate analysis(Vicent et al., 2004). One logical explanation for this discrepancy is
that our patient population was comprised of significantly more patients with early stage
disease. We did identify smoking status and mutant K-Ras as two potential
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clinicopathologic features that may be useful in selecting patients for treatment with Raf
or MEK inhibitors.  In addition, as mentioned above, we found that K-Ras mutations
were associated with an increased risk of disease recurrence following surgery.  The fact
that ERK activation itself was not associated with disease recurrence in vivo suggests that
pERK may be critical but not sufficient for the more aggressive phenotype seen in
patients who experience disease relapse. Indeed we see other tumors without mutational
activation of Ras that have elevated ERK activation.  Thus it may be in the setting of Ras
mutations, where additional effector signaling is also aberrantly activated, that ERK
activation becomes important for disease relapse.  Obviously, determining whether this is
true will greatly impact our ability to select the patients most likely to benefit from Raf
and MEK inhibitors.
The K-Ras driven NSCLC GEMM model mentioned above  (Johnson et al., 2001;
Sweet-Cordero et al., 2005) could be used to answer some of the key questions raised
here.  First we could use this model to determine if treatment with Raf and MEK
inhibitors can reduce disease recurrence following surgical resection of lung tumors by
applying a previously described pneumonectomy model to these mice (Brown et al.,
1999).  Results from this analysis may help validate or disprove the association between
K-Ras, activated ERK, and relapse.  If ERK activation is critical for K-Ras-mediated
disease recurrence, these studies will contribute to the validation of Raf and MEK
inhibitors as adjuvant therapies.   In addition to defining the importance of ERK signaling
in early stage disease, we could also use this model to test the effectiveness of Raf and
MEK inhibitors in mice with late stage disease. In this setting, we will determine whether
these inhibitors are effective as single agents or if they need to be administered in
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combination with traditional chemotherapeutic agents.  This analysis will also allow us to
evaluate different dosing strategies and combinations before going to the clinic to
promote more rational trial design and eliminate the trial-by-error approach that clinical
research has historically relied upon.  However, a key issue related to the results seen
with GEMMs is whether they indeed will provide more accurate models than tumor
xenograft mouse models for predicting patient response.  As is evident from a wealth of
cell culture and mouse model studies, while mouse models remain our best hope for
accurate preclinical determination of drug action and efficacy, it is also clear that “mice
are not simply small people” (Rangarajan and Weinberg, 2003).   Thus, another goal of
studies of Raf and MEK inhibitor analyses will be further critical evaluation of GEMMs
as models for anti-cancer drug discovery.
F. Summary.
Using a cell-based model coupled with genetic and pharmacologic approaches,
we have added to the validation of Icmt and the Raf-MEK-ERK cascade as two potential
targets for anti-Ras therapy and for the treatment of NSCLC. The ultimate success of
these approaches is dependent on our ability to further define the role of these proteins
that are important for Ras function in mediating oncogenesis. One key step will be to
expand our analysis to GEMMs of NSCLC, which hopefully will more faithfully mimic
the human disease and enable us to more accurately unravel the complexities surrounding
the use of Icmt and Raf/MEK inhibitors for cancer treatment.
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